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Attention Deficit Hyperactivity Disorder (ADHD) is the most common neurobehavioral 
disorder diagnosed in children and adolescents, affecting approximately 11% of children in the 
United States in 2011. Children are often diagnosed with ADHD before seven years of age. Yet, 
there is very little information about the diagnoses, treatments, healthcare utilization, and costs 
associated with ADHD in preschool children.  
The American Academy of Pediatrics recommends behavioral therapy as the first-line 
therapy for preschoolers, with a recommendation to prescribe medications only if behavioral 
therapy is unsuccessful in alleviating ADHD-related symptoms. For children in elementary 
school, combination therapy is recommended. Thus, the goal of the current study was to assess 
the epidemiology (i.e., prevalence and incidence), treatment patterns (i.e., adherence, persistence, 
augmentation, and switching), healthcare utilization, and costs in preschoolers diagnosed with 
ADHD using the Texas Medicaid dataset.  
Patients < 6 years of age diagnosed with ADHD (ICD-9 codes 314.00, 314.01) with 
continuous enrollment for a 6-month pre-index period and a 12-month post-index period between 
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2008 and 2013 were identified from the Texas Medicaid dataset. Epidemiology estimates were 
calculated for all the patients < 6 years of age diagnosed with ADHD. Treatment patterns, 
healthcare utilization, and costs were estimated for patients between 2 – 6 years of age. Based on 
the study inclusion criteria, we identified 10,877 patients in the overall cohort. A subsample from 
the overall cohort was selected for inclusion in the treatment pattern cohort (n = 8,833). The 
index date for the overall cohort was the ADHD diagnosis date. The index date for the treatment 
pattern cohort was the date of the first ADHD prescription. Prevalence and incidence estimates 
were calculated for all the patients < 6 years of age. Time-to-initiation, healthcare utilization, and 
costs were analyzed using the overall cohort. Treatment pattern outcomes (i.e., adherence, 
persistence, augmentation, and switching) were evaluated using the treatment pattern cohort. The 
study sample was further subcategorized into pharmacotherapy only, psychotherapy only, and 
combination therapy groups. The study covariates included patient demographic (i.e., age, 
gender, race/ethnicity, and urban/rural status), clinical (i.e., other psychotropics, other mental 
health diagnosis, medication duration of action, and medication class), and prior utilization (i.e., 
pre-index total costs, pre-index psychiatric visits, and pre-index non-psychiatric visits) 
characteristics. Bivariate and multivariate analyses were used to analyze the data.  
The prevalence of ADHD in preschoolers was estimated to be between 2.1% and 8.5% 
from years 2008 to 2012. Incidence estimates were stable and were estimated to be between 
2.4% and 2.1% from years 2009 to 2012. Medication adherence, augmentation, and switching 
rates were higher in the combination therapy group as compared to the pharmacotherapy group. 
The combination therapy group had significantly higher healthcare utilization in all resource 
utilization categories except ADHD-related prescriptions, other mental health-related office-
based, and inpatient visits. Similarly, medical, prescription, and total healthcare costs were also 
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significantly higher in the combination therapy group as compared to the pharmacotherapy group 
except for the other mental health-related medical costs.  
In summary, the prevalence and incidence of ADHD in preschoolers is significant. Most 
of the patients received medication therapy followed by combination therapy and psychotherapy. 
A comparison of treatments revealed that combination therapy group had a higher healthcare 
burden as compared to the pharmacotherapy group. This study adds to the existing literature 
regarding ADHD in preschoolers, from a Medicaid perspective. Also, since Texas Medicaid 
provides coverage for nearly 50% of children in Texas these results have important implication 
for the state of Texas. The results of the current study will help identify the more important 
healthcare utilization and cost categories so as to develop a more targeted intervention approach 
for patients with ADHD. Further research is needed to understand the long-term effects of 
pharmacotherapy, psychotherapy, and combination therapy in preschoolers. More evidence is 
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CHAPTER 1: INTRODUCTION 
Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common 
neurodevelopmental disorders diagnosed in children. Although symptoms of ADHD decline with 
age, a vast majority of patients show developmental delays and associated mental health 
problems later in life. The Diagnostic and Statistical Manual Fifth Edition (DSM-V) emphasizes 
that the onset of impulsivity or inattentiveness can start manifesting in children earlier than 7 
years of age (i.e., during kindergarten and preschool years).1 Although there is a lack of more 
recent prevalence estimates of ADHD in preschoolers, previous studies during the 1990s and 
2000s have estimated the prevalence rate of ADHD in preschool children (< 6 years of age) to 
vary between 0.5% and 6.5%.2–6 These ADHD prevalence estimates are lower (11%) compared 
to those in children (6 – 12 years of age) and adolescents (13 – 17 years of age) and vary based 
on the referral source, diagnostic criteria, and diagnostic instruments used in the studies.2–6 
Preschoolers who are referred to psychiatrists and other healthcare professionals are more likely 
to have a higher healthcare burden, frequent behavioral issues, comorbidities, aggressive and 
disruptive behavior, inattentiveness and impulsivity compared to their peers. They are more 
likely to suffer from injuries, are developmentally more challenged, have problems in 
maintaining peer-to-peer relationships, are at higher risk of expulsion from school or daycare, 
and are at-risk for poor educational outcomes.7,8 In addition, children with developmental delays 
are more likely to continue on the same developmental trajectory leading to mental health 
problems as they grow older.    
Previous developmental theories have postulated two basic mechanisms of 
developmental delays characterized by “cardinal basic deficits” and a “specific developmental 
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trajectory” of ADHD.9–11  The temperamental precursors of ADHD emerge early on during 
childhood, which is related to basic deficits in the executive and motivational deviations that 
involve prefrontal (dorsolateral and orbitofrontal), cingular (dorsal anterior cingulate cortex), and 
striatal regions that are integrated predominantly by dopamine pathways. With an increase in 
age, the prefrontal structures and their connectivity attain maturity; however, the most rapid 
changes occur in the first five years of brain development. Garon et al. (2008) assimilated 
existing research on the developmental functions and distinguished two distinct developmental 
periods. The authors suggested that in the first developmental period (i.e., the first three years of 
a child’s life) skills such as holding a representation in mind, inhibiting a response using a rule 
held in mind, and consequently the capacity to suppress a motivationally-determined motor 
response develop in children. Between 22 and 33 months of age, most children master simple 
tasks like suppressing a response. Similarly, between three and five years of age, a child’s brain 
continues to develop in a non-linear fashion and more complex skills are acquired. Yet, a 
majority of the past research on ADHD has focused on school-aged children and adolescents. 
Understanding the pattern of disease development early on in life might help achieve better 
outcomes, as the child grows older. In addition, the problem is further compounded due to the 
lack of treatment options for ADHD in preschoolers. 
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CHAPTER 2: LITERATURE REVIEW 
Chapter overview 
The chapter provides a detailed overview of the literature pertaining to ADHD. It briefly 
discusses the historical evolution of ADHD as a condition, prevalence of ADHD in the general 
population as well as in preschoolers, diagnosis criteria for ADHD, age-of-onset and prognosis 
of ADHD, treatment options available for the management of ADHD, utilization of treatment 
options, and comorbidities in patients with ADHD. This chapter also provides a brief overview 
of the Texas Medicaid program. This chapter concludes with the study rationale and the 
objectives that were examined in the study. It also provides a list of hypotheses that were tested 
to answer the research questions.  
2.1 History of ADHD 
The symptoms of ADHD are described in their contemporary form in the Diagnostic and 
Statistical Manual Fifth Edition (DSM-V). However, a description of symptoms similar to 
ADHD was made more than two centuries ago in 1798 by Sir Alexander Crichton, a Scottish 
physician born in Edinburgh.12 His observations were compiled together into a book titled “An 
Inquiry into the Nature and Origin of Mental Derangement: Comprehending a Concise System 
of the Physiology and Pathology of the Human Mind and a History of the Passions and their 
Effects.” His work was one of the early studies where mental health conditions were formally 
discussed as medical conditions. In the second chapter of his book titled “On Attention and its 
Disease,” Crichton provided a detailed account of the challenges that a few young students 
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experience while focusing on daily school activities.12 These observations were similar to the 
characteristics of children diagnosed with inattentive type ADHD. 
Almost eight decades later in 1884, a German physician, Heinrich Hoffmann, provided a 
detailed description of symptoms that were also similar to ADHD in his storybook titled “Der 
Struwwelpete.”13 This pictorial storybook designed for his 3-year-old son discusses some of the 
characteristics of ADHD based on a popular character “Zappelphilipp” (Fidgety Philip). The 
descriptions provided in the book are starkly similar to the diagnosis of hyperactive subtype in 
children diagnosed with ADHD.  
Dr. George Still’s early discussions of abnormal defect of moral control in children are 
considered by scholars to be the clinical starting point of ADHD. The symptoms that were first 
observed by Dr. Still in 1902 were collectively labeled as “morbid defect of moral control.”14  He 
observed certain traits that were peculiar to individuals diagnosed with this disorder including 
over activity, inattention, and poor inhibitory regulation. In addition to these traits, he also 
observed that these behaviors were not easily modifiable through corrective measures. Since 
then, the term has gone through numerous modifications and was subsequently labeled as 
“postenchephalitic behavior disorder” (1922), “hyperactive child syndrome” (1950s), 
“hyperkinetic reaction of childhood” (1968), and “attention deficit disorder” (1980) before it was 
established as attention deficit hyperactivity disorder in the year 1987.14 These initial 
observations became the core characteristics for diagnosis of patients with ADHD almost eight 




2.2 Etiology and risk factors of ADHD  
The etiology of ADHD is very complex and research is still underway to determine the 
possible causes of ADHD. Nevertheless, environmental and genetic factors are widely accepted 
as probable causes of ADHD. Genetic predisposition and family history of ADHD have been 
identified as possible explanations for the occurrence of ADHD in certain populations. Previous 
clinical research has shown that reduction in the size of the prefrontal cortex, the caudate 
nucleus, and the globus pallidus results in lack of connectivity between the regions that moderate 
attention, stimulus processing, and impulsivity.15  
Genetic studies have identified and established the role of genetic influences on 
occurrence of ADHD. Previous studies based on observations in family, adoption, and twin 
populations have identified family history of ADHD as a predictor for ADHD occurrence in 
offspring and siblings.16,17 Previous studies have identified the role of “familiality trait” in the 
etiology of ADHD. A study by Faraone et al. (2000) showed that the risk of being diagnosed 
with ADHD is 6-to 8-fold higher in siblings exposed to similar familial risk factors.18 In order to 
control for similar environmental exposure within the same household, Biederman et al. (1990) 
conducted a study where they controlled for gender, intactness of family, and socioeconomic 
status.17 The results from these studies show that familiality is certainly associated with an 
increased likelihood of being diagnosed with this condition. However, since members of the 
same family are more likely to experience the same genetic and familial environmental 
influences, twin studies and adoption studies were needed to delineate the relative contributions 
of each factor.  
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Adoption studies have been conducted to address the confounders associated with the 
family studies. Adoption studies offer a unique perspective where environmental factors can be 
studied while controlling for biological effects. More specifically, biological relatives are 
genetically similar but are exposed to different environmental factors whereas adoptive relatives 
are exposed to the same environmental factors but are genetically dissimilar. Thus, examining 
the relative risk of ADHD in these two cohorts provided pointers towards probable causes of 
ADHD. Adoption studies showed that risk of ADHD occurrence in children of parents with a 
history of ADHD was higher in biological siblings than adopted siblings.20–22   
Faraone et al. (2005) conducted an extensive review of studies conducted on twins to 
identify and confirm the heritability trait of ADHD diagnosis.23 Twin studies are conducted in 
order to disentangle and identify the heritability parameter that might not be easily recognizable 
in population studies. The central idea of twin studies is that monozygotic twins (i.e., twins that 
are identical and share nearly 100% of the gene composition) will have a higher likelihood of 
being diagnosed with ADHD compared to dizygotic twins (i.e., non-identical or fraternal twins 
who share 50% of the gene composition). Both monozygotic and dizygotic twins will have a 
higher likelihood of inheriting the disease than the general population. The authors calculated the 
heritability factor at 76%, thus indicating that ADHD is a highly heritable disease.   
Previous studies have also discussed the role of molecular genetics in the etiology of 
ADHD. In individuals with ADHD, the prefrontal cortex, caudate nucleus and globus pallidus 
are typically smaller than in people without ADHD, which suggests a lack of connectivity 
between the brain regions that moderate attention, stimulus processing and impulsivity.15 A 
faulty dopamine receptor D4 (DRD4) gene and over expression of dopamine transporter-1 
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(DAT-1) could be a possible explanation for the lack of attention and impulsivity observed in 
ADHD patients.15 Additionally, individuals with the DRD4-7 dopamine risk allele show a 
greater chance of having the same severity of ADHD in adulthood.24  
Some environmental factors that have been implicated as secondary causes of ADHD are 
a high degree of social stress, maternal mental disorders, paternal criminality, low 
socioeconomic status, and being in foster care. In addition to this, some studies indicate that 














2.3 Diagnosis of ADHD  
ADHD is considered to be one of the most common mental health disorders diagnosed in 
children. A thorough evaluation of symptoms should be conducted prior to the initiation of 
treatment for a patient diagnosed with ADHD. Symptoms of ADHD are classified into three 
major categories: inattention, hyperactivity, and impulsivity, or a combination of these factors.28 
Inattention is characterized by loss of attention to detail and inability to follow or comprehend 
instructions. Hyperactivity is characterized by increased fidgeting, increased talking, or the 
constant need to be in motion. Impulsivity is characterized by impatience and constant 
interruption of activities.  
As expected, it is normal for young children to be inattentive, hyperactive, and impulsive; 
therefore, necessary precautions should be taken by the physician to avoid misdiagnosis. 
Although there is general agreement that ADHD is a real mental health condition, there are some 
challenges surrounding the diagnosis of ADHD. Three major sets of guidelines are used to assess 
and establish the diagnosis of ADHD in children. Diagnosis guidelines are published by the 
American Academy of Pediatrics (AAP), the American Academy of Child and Adolescent 
Psychiatry (AACAP), and the Diagnostic and Statistical Manual, which is considered to be the 
gold standard for diagnosis of ADHD. The AAP and AACAP diagnostic guidelines were 
published from a primary care physician’s perspective, owing to their increased involvement in 




2.3.1 AAP diagnostic evaluation guidelines 
The AAP diagnostic guidelines were published for establishing diagnosis of ADHD in 
children between six and twelve years of age. These guidelines were updated in 2011 to broaden 
the age range from 4 to 18 years.29 The AAP recommends that relevant diagnosis information be 
obtained using behavioral rating scales to establish a diagnosis of ADHD based on DSM-IV 
criteria (Table 2.1). The AAP asserts that broadening the age range from 4 to 18 years will result 
in early detection and therefore, increase the chances of better outcomes. The AAP has 
developed 4 key action statements for establishing a diagnosis of ADHD in children. First, the 
AAP recommends initiating evaluation of ADHD in any child between the ages of 4 and 18 
years who presents behavioral and academic problems along with a concurrent symptom of 
inattention, hyperactivity, or impulsivity. Second, to establish a diagnosis of ADHD, the AAP 
recommends that the primary care physician verify that the individual meets the diagnostic 
criteria specified in the DSM-IV. The DSM criteria should have been met in more than one 
setting and should be based on evidence obtained from caregivers, teachers, and other school and 
mental health clinicians involved in the child’s care. Third, the physician should also examine 
the patient for other comorbidities such as disruptive behavior disorder, mood disorder, and 
anxiety as well as learning disabilities that might be responsible for symptoms similar to ADHD. 
It is important to rule out other causes before establishing a diagnosis of ADHD. Fourth, use of 
other diagnostic tools such as blood lead levels, thyroid hormone levels, brain imaging, and 





Table 2.1: Behavior rating scales recommended by the AAP29,30 
Behavior Rating Scales 
Conner’s Parent Rating Scale 3 ADHD Index (DSM-IV) 
Conner’s Parent Rating Scale - 1997 Revised Version: Long Form, DSM-IV Symptoms Scale 
Barkley's Home and School Situations Questionnaire-Original Version 
ADHD – Attention Deficit Hyperactivity Disorder 
DSM-IV – Diagnostic and Statistical Manual Fourth Edition  
DSM-V – Diagnostic and Statistical Manual Fifth Edition 














2.3.2 AACAP diagnostic evaluation guidelines 
The diagnostic evaluation criteria adopted by the AACAP include recommendations that 
are similar to those of the AAP. The AACAP recommends that a thorough evaluation of 
developmental, medical, psychiatric, and family history should be undertaken, in addition to the 
systematic assessment of the DSM-IV symptoms.31 The AACAP recommendations are tailored 
for each age group (i.e., preschoolers 3-5 years of age; children 6-12 years of age; and 
adolescents 13-17 years of age).32  
The AACAP recommends that screening for ADHD should be conducted irrespective of 
the nature of the complaint associated with the visit. Evaluation should focus on the core 
parameters as outlined by the DSM-IV (i.e., inattention, hyperactivity, and impulsivity). A brief 
preliminary evaluation based on the rating scales and questionnaires listed in the DSM-IV should 
be conducted (Table 2.2). If the symptom requirements are met, then a detailed account of each 
of the 18 symptoms listed in the DSM-IV criteria must be obtained for that patient. The 
physician should ascertain the presence of symptoms, age-of-onset, frequency, and severity of 
the symptoms.32 The patient must report at least six of the nine symptoms listed in the inattention 
cluster or six of the nine symptoms listed in the hyperactivity/impulsivity cluster. The physician 
should also ascertain that the symptoms being observed are not transient in nature and were 
detected in early childhood.  
After the presenting symptoms have been assessed, evidence regarding the academic and 
intellectual functioning of patients in a daycare setting (for preschoolers) and in a school setting 
(for school-aged children and adolescents) should be obtained.32 DSM-IV requires that 
impairment should be present in more than one setting (either home, school, or job); however, 
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clinicians also agree that significant impairment in one setting can be an indicator for starting 
treatment. Assessment of the patient’s parents based on standardized behavior rating scales 
should also be conducted to confirm the diagnosis. Since DSM-IV criteria state that ADHD 
symptoms should be present in two settings, assessment of other caregivers can also be 
conducted to confirm the diagnosis of ADHD. 
Following functional impairment assessment, ADHD patients should be evaluated for 
other coexisting psychiatric disorders.32 Assessment of underlying psychiatric diagnoses should 
be conducted to rule out symptoms that are inconsistent with the ADHD diagnosis. Because 
ADHD is strongly associated with genetic inheritability, a detailed review of family history as 
well as the social history should be carried out. In addition, physicians should obtain information 
regarding the patient’s perinatal history, developmental milestones, medical history, and mental 
health history. The AACAP, however, does not recommend laboratory or neurological testing in 
cases where a discreet family history information cannot be ascertained.32 Additional 
psychological and neurological tests are recommended for situations where patients have low 
cognitive ability or achievement in language and mathematics compared to their overall 








Table 2.2: Behavior rating scales recommended by the AACAP 
Behavior Rating Scales  
Academic Performance Rating Scale (APRS) 
ADHD Rating Scale-IV 
Brown ADD Rating Scales for Children, Adolescents, and Adults  
Child Behavior Checklist (CBCL) 
Conner’s Parent Rating Scale-Revised (CPRS-R) 
Conner’s Teacher Rating Scale-Revised (CTRS-R) 
Conner’s Wells Adolescent Self-Report Scale 
Home Situations Questionnaire-Revised (HSQ-R), 
School Situations Questionnaire-Revised (SSQ-R) 
Inattention/Overactivity With Aggression (IOWA) Conners Teacher Rating Scale 
Swanson, Nolan, and Pelham (SNAP-IV), 
Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP) 
Vanderbilt ADHD Diagnostic Parent and Teacher Scales 
ADHD – Attention Deficit Hyperactivity Disorder; ADD – Attention Deficit Disorder; 











2.3.3 DSM-IV and the DSM-V diagnostic evaluation guidelines 
 According to the DSM-IV guidelines, diagnosis of ADHD is subjective and should be 
considered only if the symptoms of inattention, hyperactivity or impulsivity persist for more than 
6 months (Table 2.3).28 More recently, the diagnosis criteria for ADHD were updated to address 
the age group-related concerns raised by some of the experts in the clinical field. According to 
the assessment criteria specified in DSM-IV, ADHD diagnosis can be ascertained if the patient 
presenting these symptoms meets at least five of the criteria. The first criterion is that the patient 
should present at least 6 of the 9 symptoms in the inattention and/or hyperactivity domains for at 
least six months to an extent that it is developmentally maladaptive and inconsistent with the 
overall intellectual ability of the child (Table 2.3). Second, these symptoms must be manifested 
in the patient before 7 years of age. This criterion has been slightly relaxed in the DSM-V where 
a patient can be diagnosed with ADHD between 4 and 12 years of age. Third, functional 
impairment affecting behavior and development should be present in more than one setting (i.e., 
either school, home or both for school-aged children and home, daycare or both for 
preschoolers). Fourth, observed impairment should be substantial so that it hinders normal 
development or behavior in school, social, and work place settings. Fifth, the observed 
symptoms should not be attributable to other coexisting mental health conditions and should be 
clearly associated with ADHD. Evidence regarding functional impairment can be obtained from 
the clinical interviews of parents, teachers, and other caregivers in school. Although, behavioral 
rating scales provide much valuable information, they should be supplemented with other 




Table 2.3: List of symptoms for diagnosis of Attention Deficit Hyperactivity Disorder as defined 
in the Diagnostic and Statistical Manual Fourth Edition (DSM-IV) 
 Inattentive Symptoms Hyperactive/Impulsive Symptoms 
1. 
Often fails to give close attention to 
details or makes careless mistakes 
Often fidgets with hands or squirms in seat 
2. 
Often has difficulty sustaining attention in 
tasks or play activities 
Often leaves seat in classroom or in other 
situations in which remaining seated is 
expected 
3. 
Often does not seem to listen when 
spoken to directly 
Often runs about or climbs excessively in 
situations in which it is inappropriate 
4. 
Often does not follow through on 
instructions and fails to finish schoolwork, 
chores, or duties in the workplace 
Often has difficulty playing or engaging in 
leisure activities quietly 
5. 
Often has difficulty organizing tasks and 
activities 
Is often “on the go” or often acts as if 
“driven by a motor” 
6. 
Often avoids, dislikes, or is reluctant to 
engage in tasks that require sustained 
mental effort 
Often talks excessively 
7. 
Often loses things necessary for tasks or 
activities 
Often blurts out answers before questions 
have been completed 
8. 
Is often easily distracted by extraneous 
stimuli 
Often has difficulty awaiting turn 









Standardized rating scales, such as Conner’s Rating Scales for parents and teachers, may 
be utilized to document baseline symptom severity (Table 2.4).33 Other behavioral symptoms 
that are prevalent in preschool kids could be erroneously labeled as ADHD in this population. In 
such cases, precautions should be taken in establishing the diagnosis of ADHD in preschoolers 
because their ability to use and respond to language for moderating behavior may be limited. 
Similarly, behavioral interventions might not be as effective because of potential challenges in 
communicating the treatment. Young children might not notice the differences between 













Table 2.4: Behavior rating scales recommended by the Diagnostic and Statistical Manual Fourth 
Edition (DSM-IV) 
Behavior Rating Scales 
ADHD Rating Scale-IV (ADHD-RS) 
Swanson, Nolan, and Pelham-IV (SNAP-IV) 
Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) 
Connors Rating Scales (Long or Short Version)  
Vanderbilt ADHD Rating  Scales 
Strengths and Weaknesses of ADHD Symptoms and Normal Behavior Scale (SWAN)  
Inattention/Overactivity with Aggression Connors Teacher Rating Scale (IOWA)  
Brown Attention - Deficit Disorder Scales (BADDS)   













2.4 Prevalence of ADHD and other behavioral disorders in children and adolescents  
ADHD is a neurobehavioral disorder primarily characterized by impairment of executive 
functioning leading to developmentally inappropriate level of inattention, hyperactivity, and 
impulsivity.19,20 The proportion of children in the U.S. aged 4 to 17 years with a parent-reported 
ADHD diagnosis increased from 7.8% in 2003 to 9.5% in 2007. A more recent study (2011) 
using the National Health Interview Survey indicated that nearly 8.4% of parents reported that 
their children had a history of ADHD diagnosis.36 The prevalence rate was higher in males 
(13.2%) as compared to females (5.6%) and a higher proportion of patients were in the 15 to 17 
years age range. Compared to the national average, the prevalence of ADHD in children between 
4 and 17 years of age was lower in Texas and was estimated to be 10.1% in 2007.37  
Symptoms in ADHD often overlap with symptoms from other psychiatric disorders. 
Irrespective of the age when ADHD is diagnosed, ADHD exhibits a high rate of comorbidity and 
substantial role impairment. Previous studies assessing comorbidities in ADHD patients were 
conducted in clinical and community samples. Wilens et al. (2002) conducted a systematic 
review of all the clinical characteristics in preschool children (4-6 years of age) and in school-
aged children (7-9 years age).38 Psychiatric comorbidity was reported in 74% of the preschoolers 
and 79% of the school-aged children diagnosed with ADHD. Oppositional defiant disorder 
(ODD) and Major Depressive Disorder (MDD) were the most common comorbidities in the 
preschool group as well as the school age group.  
Recently, a large-scale study was conducted to determine the comorbidities commonly 
occurring in respondents diagnosed with ADHD. The study was conducted on a birth cohort of 
patients born between January 1, 1976 and December 31, 1982. The study cohort, before study 
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criteria were applied, consisted of 5,718 children (2,956 boys and 2,762 girls). After inclusion 
and exclusion criteria were applied, the final cohort consisted of 343 children with ADHD. 
Occurrences of psychiatric disorders were higher in the ADHD group as compared to the non-
ADHD group. Moreover, 62.1% of the children in the ADHD cohort were reported as having 
more than one psychiatric disorder while 34.4% were reported as having more than two 
psychiatric disorders.39 
Diagnosis of ADHD in patients with comorbid psychiatric disorders is difficult and the 
similarities of symptoms often obscure the diagnosis process. More recently, comorbid autism 
spectrum disorder (ASD) in ADHD patients has generated considerable debate. ASDs are a 
group of pervasive developmental disabilities characterized by impairments in socialization, 
communication, and the presence of restricted, repetitive behaviors or interests.40 Establishing 
diagnosis of ADHD in preschoolers is difficult and may be at times preceded by symptoms of 
ODD or conduct disorder (CD). ODD and CD are classified together as disruptive behavior 
disorder (DBD). Conversely, preschoolers might be labeled with a DBD diagnosis that may or 








2.5 Prevalence of ADHD and other behavioral disorders in preschoolers < 6 years of age 
Prevalence of ADHD in preschoolers has not been adequately reported in the literature. 
One of the early studies estimating the prevalence of ADHD and other psychiatric disorders in 
preschoolers was conducted in 1982. The study reported the prevalence of ADHD in preschool 
children to be around 2% for ADHD, 4% for oppositional defiant disorder (ODD), and 5% for 
anxiety.41 A study by Keenan et al. (1997) studied 104 mother-child dyads recruited from the 
Women, Infant and Children Program (WIC) of Allegheny County, Pennsylvania who were 
living in poverty. The authors reported that nearly 5.7% of the sample had ADHD, 8.0% of the 
participants were considered to be suffering from oppositional defiant disorder, 1.1% were 
estimated to be suffering from depression, and 2.3% from anxiety disorder.3  
Lavigne et al. (1996) conducted a large-scale epidemiologic study to estimate the 
prevalence of psychiatric disorders in pre-school-aged children outside the psychiatric setting. 
Data for the study were collected through the use of the Child Behavior Checklist (CBCL) which 
was administered to 3,860 parents of children aged 2 to 5 years visiting 68 pediatricians residing 
in the Chicago area. The children who scored 90% or above on the CBCL were invited for a 
second evaluation. The authors reported that in this sample, the proportion of patients diagnosed 
with ODD was 16.8% and nearly 50% of these cases were classified as severe. Additionally, the 
authors reported that the prevalence of ADHD was around 2% in the preschool-aged population. 
Prevalence of separation anxiety disorder (0.5%) and depression (0.3%) were also reported by 
the authors.4 A study by Angold et al. (2006) conducted on a sample of 307 children between the 
ages of 2 to 5 years after administration of the Preschool Age Psychiatric Assessment (PAPA) 
also reported similar results. The authors reported that the prevalence of ODD was 
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approximately 6.6% followed by ADHD (2.1%), separation anxiety disorder (2.4%), and general 
anxiety disorder (6.5%).  
More recently, Lavigne et al. (2009) conducted a study to estimate the prevalence of 
ODD, anxiety, depression, and ADHD in young children. Parents of children from 13 Chicago 
public schools preschool programs and 23 primary care pediatric practices throughout Cook 
County, including inner city clinics and schools, were approached and detailed about the 
intervention program. Parents were selected for further questioning if: their children were 4 years 
old at the time of assessment and had no psychiatric disorders which included ODD symptoms; 
the child and parent both spoke either English or Spanish; the child had the same caretaker for 
six months; the child obtained a standard score on a language screen of 70 or greater at baseline; 
the child was not enrolled in the school as mentally retarded; and he/she did not have a school IQ 
test below 70. Of all the cases in the study, the rate of ADHD with any kind of impairment was 
12.8%, and the rate of ODD with any kind of impairment was 13.4%.42 Previous studies on 
preschoolers were confined to particular geographic locations and included very few cases. A 
review of the literature showed that no national studies have been conducted to estimate the 






2.6 Economic burden of ADHD 
ADHD also imposes a significant economic burden on society. A systematic review by 
Doshi et al. (2012) showed that the direct and indirect medical costs for children diagnosed with 
ADHD were mostly attributable to healthcare and educational expenditures, respectively. The 
same study reported that the indirect cost due to special educational arrangements for children 
with ADHD was approximately $15 to $25 billion in 2010.43 Additionally, the authors reported 
that the total ADHD-related cost for children and adolescents from the ages of 7 to 18 years was 
around $72 billion in 2010.43  Healthcare costs of preschoolers with ADHD have not been 
estimated in the literature. This study aimed to fill this gap in the literature by providing medical, 











2.7 ADHD treatments 
ADHD is a chronic condition; however, it is possible to manage symptoms and help 
individuals cope with the disorder. The goal of current treatment is to achieve symptomatic 
control of ADHD and to improve daily functioning. Successful management options for ADHD 
involve use of psychotherapy/psychosocial interventions, medications or a combination of 
both.44  
2.7.1 Psychosocial interventions  
Psychosocial interventions are usually considered ideal for preschool children before 
initiating medications. In the case of children diagnosed with ADHD, the AACAP emphasizes 
the role of family in treatment. Support and education of parents, including parent training, can 
increase parent competence and overall adherence, as well as improve parent-child interactions. 
Some standardized parental behavior training interventions such as the Positive Parenting 
Program (Triple P), the Incredible Years (IY) parenting program, Parent-Child Interaction 
Therapy (PCIT), and New Forest Parenting Program (NFPP) have been developed to address the 
issue of disruptive behavior in preschoolers. Similarly, studies that determined the impact of 
parental behavior therapy reported improvement in children’s interaction scores across all 
levelsof functioning.45,46 
2.7.1.1 Parent training intervention 
 Parental training can be effective in managing behavior in children diagnosed with 
ADHD. The parental training component includes behavior modifying techniques such as 
deploying antecedents (giving instructions and establishing rules) and consequences (providing 
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rewards and timeouts). Parental training programs focus either on the didactic and interaction 
component or the parent-child relationship component. In the didactic component, Barkley and 
colleagues developed a parent training program where parents were trained and participated in 
one-on-one training or group trainings.47 Parents also actively participate in role-play practice 
sessions and have assignments that can be practiced at home. In the parent-child relationship 
component, interventions focus on the intricacies of parent-child relationships and offer an in-
class parent-child interaction where parents are given active feedback from the counsellor and 
trained on skills that they can later incorporate in their interactions with their children. Programs 
such as the New Forest Parenting Package offer a combined modality of both programs.48 
2.7.1.2 Classroom training intervention 
Behavioral interventions initiated in the classroom setting have been found to be 
beneficial in improving school-related outcomes in ADHD patients. Barkley et al. (2000) 
conducted a study to evaluate the impact of kindergarten classroom intervention including direct 
child instruction in anger management, social skills, and self-control in children.47 The authors 
also evaluated the role of contingency management procedures such as token economies, a 
response-cost system, and a daily report card. The authors evaluated these children at the end of 
the school year and reported that the interventions were effective and led to improvement in the 
overall behavior. In a follow-up study, the authors reported that the observed benefit diminished 
in effect even after the schools were willing to provide support.49 
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2.7.1.3 Multimodal psychosocial intervention 
Multimodal treatments developed by Barkley et al. (2000), and the Incredible Years 
training program (IY) have shown some evidence of benefit. The IY program developed by 
Webster-Stratton has proven to be effective in managing symptoms of ADHD.50 It was also 
found to be effective in improving parents’ skills, improving parent-child interaction and 
controlling other negative behaviors in the classroom and at home.50–52 The IY program has a 
child component, a parent component, and a teacher component. Parents are trained in a group 
setting in a collaborative environment using role plays and videotapes. Child training 
encompasses emotional regulation, social skills training, and problem-solving strategies in a 
clinic setting as well as a classroom-based setting. The teacher training component is similar to 
the parent training component; however, it is tailored for management of a child’s behavior in a 
classroom setting.50  
2.7.1.4 Utilization of psychosocial interventions in children <6 years old 
Psychosocial intervention with a primary focus on parental and family training has been 
recommended as the first-line treatment for preschoolers with ADHD.53 Several studies have 
demonstrated the effectiveness of parental intervention in ADHD preschoolers. A study by Lakes 
et al. (2011) evaluated the impact of parental intervention on 154 predominantly low-income and 
Latino preschoolers. The parents participated in a community-based parent-training model 
intervention (COPE). One year later, the parents were asked to answer questions covering 10 
domains (praise, ignoring problem behavior, start chart, time-outs, physical punishment, take 
away privileges, rewards, transitional statement, when-then statements and planning ahead). The 
post-intervention evaluation of parents showed that they demonstrated improvements on at least 
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1 of the 10 domains. Also, children in the study showed significant behavioral improvement in 
the post-intervention assessment that was measured using the Strengths and Difficulties 
Questionnaire (SDQ).54  
Another study by Huang et al. (2003) studied the impact of parent behavioral training in 
23 preschoolers (3-6 years of age). The intervention consisted of 10 sessions and the data was 
collected at multiple (first, fourth, sixth, seventh, and tenth) sessions using the Disruptive 
Behavior Rating Scale-Parent Form, Child Attention Profile, and Home Situation Questionnaire. 
The results showed that ADHD/ODD symptoms as well as the level of severity improved for 14 
children post treatment.55  
More recently, Kern et al. (2007) studied the effect of parent education alone and 
individualized assessment along with parent education in children 3-5 years of age at-risk for 
ADHD. The authors reported that the intervention group was better off post intervention as 
compared to the no-intervention group.56 Matos et al. (2009) evaluated the impact of Parent-
Child Interaction Therapy (PCIT) for Puerto Rican preschool children aged 4-6 years with a 
diagnosis of ADHD. Participants were randomly assigned to the intervention group or the control 
group and were assessed for ADHD symptoms and behavior problems, parent or family 
functioning, and parents’ satisfaction with treatment before and after treatment. The authors 
concluded that the parental intervention was effective for Puerto Rican families that have young 





2.7.2 Pharmacotherapy of ADHD  
The most common treatment option for individuals diagnosed with ADHD is the use of 
stimulant medications (Table 2.5). In addition to stimulant medications, non-stimulants are 
available for patients who do not tolerate or respond to stimulants. Availability of the stimulants 
and non-stimulants in various delivery dosage forms (i.e., liquid, sprinkle, tablet, capsule or 
patch) and duration of action (i.e., long-acting, short-acting) offer physicians an opportunity to 
tailor the medication therapy according to each patient’s needs.58  
Although intuitively, stimulant medications should lead to exacerbated activity, the 
evidence for ADHD patients is to the contrary. Administration of stimulant medications such as 
amphetamines (e.g., Adderall and Vyvanse) and methylphenidates (e.g., Ritalin and Concerta) 
increases the ability of ADHD patients to concentrate, be more attentive and less aggressive.28 
Preclinical studies have demonstrated that stimulants increase the release of monoamines into the 
extra-neuronal space thereby inhibiting dopamine and norepinephrine transporter proteins. 59,60  
Lack of these transporters leads to lower levels of dopamine (DA) and norepinephrine (NE) into 
the presynaptic neuron.61–64 Catecholamine uptake transporter is an important mediator for action 
of amphetamine and methylphenidate.61,62 Amphetamine binds to the dopamine transporter 
protein thus blocking the reuptake of dopamine from the synapse into the cell. Amphetamine 
subsequently moves into the cell and exchanges with dopamine via the dopamine transported 
protein. Cytoplasmic dopamine moves from the interior of the cell through the sodium dependent 
transport mechanism thus increasing the concentration of dopamine in the synapse.61,62 
Methylphenidate, on the other hand, is hydrolyzed in the intestine before reaching the systemic 
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circulation and acts by increasing the dopamine concentration in the synapse by interacting with 
dopamine transport protein in a way similar to other sympathomimetic enzymes.59,61,65  
Non-stimulant medications are also used to manage the symptoms of ADHD (Table 2.5). 
One FDA-approved non-stimulant medication to be used in hyperactive children is atomoxetine, 
which inhibits pre-synaptic norepinephrine reuptake and leads to increased synaptic 
norepinephrine.66–68 Atomoxetine numbs the posterior attentional symptoms resulting in lowered 
response to stimuli and also improves problem solving skills.66–68    
Other non-stimulant medications approved for use in ADHD patients include guanfacine 
and clonidine. Clonidine, a derivative of imidazoline, is an alpha-adrenergic agonist and was 
originally formulated for use in hypertensive patients.69 Clonidine acts centrally as well as 
peripherally and has demonstrated benefit in the ADHD population. It affects the alpha-1 and 
alpha-2 receptors located in presynaptic and postsynaptic neurons. Clonidine blocks the release 
of norepinephrine from the central catecholaminergic nerve terminal.70 Guanfacine also acts by 
mimicking norepinephrine at alpha-2a receptor sites. Thus, both clonidine and guanfacine lead to 
elevated norepinephrine levels in the prefrontal cortex by modulating the norepinephrine in the 
pre-synaptic and post-synaptic membrane leading to better executive functioning in patients with 
ADHD.71  
Other medication classes that have shown some evidence of benefit in these patients are 
bupropion, tricyclic antidepressants, monoamine oxidase inhibitors [MAOIs], and selective 
serotonin reuptake inhibitors [SSRIs].31,72 Bupropion, an aminoketone derivative, was originally 
approved for use as an antidepressant. It has a dual mechanism of action and inhibits dopamine 
and norepinephrine reuptake.73 Tricyclic antidepressants’ effect on norepinephrine, mediated 
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thorough catecholamine pathways, is assumed to be the primary mechanism of action of tricyclic 
antidepressants in ADHD patients.60 Modafinil’s primary mechanism of action is the attenuation 
of cholinergic and monoaminergic components through its action on the hypothalamus. 
However, its effect in ADHD patients is attributed, although debatably, to its effect on the 
dopaminergic and noradrenergic systems.74 Other alternative explanations for modafinil’s 
mechanism of action have also been explored in the literature. Previous studies have shown that 
modafinil acts on 4 distinct sites in the brain: gamma-aminobutyric acic (GABA) located in 
ventrolateral preoptic nucleus; noradrenergic neurons of the locus ceruleus; the histamine 
neurons of the tuberomammillary nucleus; and the mesencephalic dopaminergic neurons.75 
Modafinil is also thought to regulate the reuptake of dopamine in the cerebral cortex and caudate 







Table 2.5: Types of medications used for the management of ADHD in school-aged children, adolescents, and adults77 





Initial 5-18 mg; increase as 
needed until beneficial effects 
peak or unacceptable side 
effects develop 
3-6 hours 
Two to three times daily; can 
titrate as needed as long as 
beneficial effects are greater 
than side effects 
 
Intermediate-acting (Metadate ER, 
Metadate CD, Methyllin ER, Ritalin LA, 
Ritalin SR) 
One to two times daily 3-8 hours 
 
Extended release/long-acting (Concerta, 
Daytrana Patch) 
Once daily  8-12 hours 
Dexmethylphenidate Short-acting (Focalin) 
Two to three times daily; 
initial dose half that of IR 
MPH 
4-5 hours 
 Extended-release/long-acting (Focalin XR) Once daily 8-12 hours 
Amphetamines 
Immediate-release/short-acting 
(Dexedrine, DextroStat, Adderall) 
Initial dose half that of IR 
MPH; two to three times 
daily 
4-6 hours 




Once daily 8-12 hours 






Table 2.5: Types of medications used for the management of ADHD in school-aged children, adolescents, and adults (continued) 





Initial 0.5 mg/Kg; Increase to 




Guanfacine IR Guanfacine (Tenex) 
Initial 1 mg daily; titrate as 
needed up to 4 mg twice daily 
12-24 hours 
 ER Guanfacine (Intuniv) 
Initial 1 mg; up to 4 mg; once 
daily 
~24 hours 
Clonidine  ER Guanfacine (Kapvay) 
1 mg QD; 1 mg/day every 
week 
8 – 14 hrs; up to 24 
hrs in higher doses 
D = Dopamine; N = Norepinephrine; S = Serotonin; IR = Immediate Release; MPH = Methylphenidate; mg/kg = milligrams/kilogram; QHS = before bed; TTS 
= Transdermal Therapeutic System; EKG = Electrocardiogram; Serotonin Norepinephrine Reuptake Inhibitors; Adapted from:  Antshel et al. BMC Medicine 
2011 9:72   doi:10.1186/1741-7015-9-72 
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2.7.2.1 Medication utilization and treatment patterns in children and adolescents 
Determining medication utilization patterns is important for effective management of 
disease. Previous studies have assessed utilization of medications in the private as well as 
Medicaid ADHD populations. Of the children between 4 and 17 years of age with current ADHD 
diagnosis, rate of medication use was higher in Texas (71.9%) as compared to the national rate 
(66.3%). Furthermore, of all the children (between 4 and 17 years of age) with a lifetime 
diagnosis of ADHD, medication use was lower in Texas (3.4%) as compared to the national rate 
(4.8%).78 According to the yearly reports published by the Texas Health and Human Services 
Commission, stimulants had the second highest expenditure ($168,023,838) among drug groups 
in 2012. Garfield et al. studied the trend in use of stimulants and other therapies in individuals < 
18 years of age diagnosed with ADHD.79 The overall proportion of ADHD patients with 
stimulant medication use declined in the last decade from 98% (n= 5,511) in 2000 to 87% (n = 
8,631) in 2010. The authors observed an increase in the use of guanfacine after an ER form 
(Intuniv) was launched. The authors also observed that the decline in the use of short-acting (SA) 
forms of stimulants was almost parallel to the increase in the use of long-acting (LA) forms. 
Utilization of LA forms of stimulants increased from 14% of patients (n= 771) to 87% (n= 
7,508) between 2000 and 2010. Another study that explored treatment patterns in patients 
between the ages of 6 and 12 years using multi-state Medicaid data reported that 45% of the 
children and adolescents diagnosed with ADHD were initiated on psychotherapy, nearly 41% 
were initiated on pharmacotherapy on at least one type of stimulant medication and 14% of the 
children and adolescents were initiated on combination therapy (i.e., psychotherapy along with 
pharmacotherapy).80 The authors also noted that the presence of comorbid mental conditions 
increased the chances of being initiated on combination therapy. Another study conducted 
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among ADHD patients enrolled in a commercial health plan revealed that 78.4% of the patients 
were initiated on stimulants as their index therapy.81 Molife et al. (2012) reported that patients (≥ 
6 years of age) insured through Medicaid had a higher proportion of monotherapy and 
combination therapy (> 1 medication) users as compared to the commercial population.82 
Medication use patterns in patients diagnosed with ADHD in the Texas Medicaid 
population have also been assessed by previous studies. A study by Barner et al. (2011) that 
assessed medication use among Texas Medicaid children between 3 and 18 years of age with ≥ 2 
ADHD prescriptions reported that a majority (86.4%) of the subjects were prescribed stimulant 
medications.83 Another study by Lawson et al. (2012) using Texas Medicaid data on patients 
between 6 and 63 years of age showed that the overall proportion of patients initiated on 
methylphenidates was higher (71.1%) as compared to amphetamines (28.9%). Among children, a 
higher proportion of patients were initiated on LA methylphenidates (66.2%) followed by LA 
amphetamines (23.3%). Similarly in adolescents, 64.4% were initiated on LA methylphenidates 
as compared to 29.4% being initiated on LA amphetamines.84 
In a study conducted using Medicaid managed care program data to examine whether 
care processes or severity varied according to practice settings (i.e., primary or specialty mental 
health) in children between 5 and 11 years of age, Zima et al. (2010) reported that over 80% of 
children in the primary care setting received stimulants as compared to 33% in specialty health 
care clinics.85 However, medication adherence was low in both the primary care and mental 
specialty health clinics. Differences in medication utilization patterns have been reported 
according to the level of severity, place of residence, race and ethnicity of the individuals 
diagnosed with ADHD.86  
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Treatment patterns of ADHD medications have also been discussed in the literature. In a 
retrospective claims database study conducted using medical, pharmacy, and enrollment 
information from an insurance claims data, Christensen et al. (2010) reported that patients in the 
stimulant cohort, methylphenidate group or LA medication group were more adherent as 
compared to those in the non-stimulant, amphetamine, or SA groups.81 Similarly, a retrospective 
study was conducted using Texas Medicaid data to determine the utilization patterns of stimulant 
medications in the ADHD population.84 Adherence was measured as the days in possession ratio 
defined as the proportion of days with medication in the 180-day post-index period. Persistence 
was assessed as the sum of the number of days with medication without a 30-day gap in a 150-
day post-index period. Additionally, the study also reported that children and adolescent patients 
on LA formulations had better adherence as compared to those initiated on SA forms. 
Conversely, adherence to SA forms of amphetamine was better in adults as compared to LA 
forms of methylphenidate. Another study by Sanchez et al. (2005) also noted that patients on 
extended release methylphenidate had better persistence (defined as number of days of 
continuous medication therapy without a 15-day gap period over a period of 180 days) and 
medication possession ratios (defined as days supplied/days in treatment period) as compared to 
patients on amphetamines or immediate-release methylphenidates.87   
Previous studies have also shown that switching to alternative forms of treatment takes 
place in the ADHD population. Stein et al. (2012) reported that 28% (n=238) of the children who 
were initiated on medication treatment added a psychosocial intervention and 42% (n=392) of 
the children who were initiated on a psychosocial intervention added medication to their 
treatment regimen.80 In addition, of the patients receiving combination therapy, nearly half were 
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switched to medication therapy alone. In the Texas Medicaid population with ADHD, switching 
was observed between the SA and LA forms of medications.84  
Psychotropic medications in general including antipsychotics are also being used in 
ADHD patients to achieve symptomatic control even though their use is not supported by 
evidence. A recent systematic review by Birnbaum et al. (2013) concluded that 30.5% of patients 
treated with antipsychotics were reported to have a diagnosis of ADHD. Additionally, the 
authors reported that 11.5% of ADHD youth received antipsychotics.88 Furthermore, there is 
evidence that antipsychotic use among ADHD patients in increasing. A study by Fullerton et al. 
(2012) examining the trend of psychotropic drug utilization in Medicaid patients with ADHD 
from 1996 to 2005 reported that the probability of filling at least one antipsychotic medication in 
2005 was two times that in 1996. Another study using the Medicaid population from 2001 to 
2005 was conducted to identify children newly initiated on second-generation antipsychotics. 
The authors reported that ADHD was the most frequently diagnosed disorder in children. 
Furthermore, nearly half the children identified in the study were receiving antipsychotics for 
indications that were not supported by strong evidence.89 Other psychotropic drug use has also 
been reported in the literature. In a study using US managed care claims data, Van Brunt et al. 
(2005) reported the use of bupropion, antidepressants, antipsychotics, antimanics, and anxiolytics 
in patients diagnosed with ADHD.90 In light of the current therapeutic evidence and practice 






2.7.2.2 Medication utilization in children < 6 years old  
Medications are often the treatment of choice for physicians even though there is very 
little evidence supporting medication use in preschoolers. Olfson et al. (2002) conducted a study 
using the Medical Expenditure Panel Survey (MEPS) data for the period 1987 to 1996, and 
gathered information regarding the psychotropic medications (stimulants, antidepressants, 
anticonvulsants, sedative/hypnotics, benzodiazepines, miscellaneous anxiolytics, and lithium) 
used in children less than 18 years of age. Although not the focus of the study, the researchers 
found that the rate of ADHD declined in the population <6 years of age from 35.5% in 1987 to 
32.0% in 1996. Conversely, the use of psychotropic medications in children <6 years of age 
increased from 0.46% in 1987 to 0.82% in 1996. Stimulant medication use also increased from 
0.22% in 1987 to 0.31% in 1996.91  
Zito et al. (2000) conducted a population-based analysis to estimate the prevalence of 
psychotropic medication (stimulants, antidepressants and neuroleptics) use in preschool-aged 
youths and to determine their utilization trends across a 5-year span based on prescription data 
from two Medicaid programs and a salaried group model health maintenance organization 
(HMO). The authors reported that in the 2 to 4 year age group, the use of stimulants increased 
almost 3-fold for the Midwest Medicaid program and the HMO and almost 2-fold for the Mid-
Atlantic Medicaid program. Furthermore, the authors also stated that the use of methylphenidate, 
antidepressants, tricyclic antidepressants (TCAs), clonidine and neuroleptics increased in the 5-
year span. The authors also graphed the trend of methylphenidate prevalence per 1,000 enrollees 
by age for the Midwestern State Medicaid program and reported that the prevalence of 
methylphenidate use increased from 6.9 per 1,000 enrollees to 20.8 per 1,000 enrollees between 
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1991 and 1995.92 Conversely, a study by Zuvekas et al. (2012) observed that the stimulant 
medication use in children 0 to 5 years old for the period 1987 to 2008 remained low in the 
population.93 However, previous literature on the use of medications other than methylphenidate 













2.8 Age-of-onset and prognosis of ADHD  
ADHD is a chronic condition that is usually detected in early childhood.94 Prior to the 
publication of DSM-V, all previous versions of the DSM criteria for ADHD diagnosis required 
symptom presentation before 7 years of age. The criterion of age-of-onset of < 7 as defined in 
DSM-IV and earlier versions was criticized in the literature; however, it also was established as 
the de facto standard for identification of ADHD. A report by Barkley and Biederman (1997) 
suggests that the criteria for diagnosis specified in DSM-III was based on clinical observations of 
a few experts in the field.95 In an effort to address the widespread debate regarding the age-of-
onset of ADHD, the most recent version of the DSM (version V published in 2011) changed the 
age-of-onset from < 7 years to < 12 years for certain types of ADHD.  
Biederman et al. (1996) used a longitudinal sample to examine the remission patterns of 
ADHD patients. The authors categorized 14 DSM-III-R symptoms of ADHD according to 
inattentive, hyperactive, and impulsive types. The authors reported that age was a significant 
factor associated with all forms of remission for ADHD and with the three-symptom clusters 
(i.e., inattentive, hyperactive, and impulsive).96 Langberg et al. (2008) used data from the 
multisite Multimodal Treatment Study of Children with ADHD to examine manifestations of 
ADHD symptoms before, during, and after transition to middle school.97 The authors reported a 
transient reversal in ADHD symptoms associated with transitioning to middle school.97 A 
number of similar studies in the past have assessed the clinical course of ADHD symptoms; 
however, most of the studies have focused on school-aged children.98  
Previous studies found that behavioral problems often manifest in ADHD patients before 
elementary school. Preschool children are usually referred, evaluated, and treated for ADHD. 
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Lahey et al. (2004) reported that a majority of children diagnosed with ADHD in preschool, 
kindergarten, or first grade continue to exhibit symptoms and impairments as they mature.99 
Additionally, the subtypes (hyperactive, impulsive, inattentive, and combined) within ADHD 
differ in prognosis as well. Children with disruptive behaviors are frequently identified in 
preschool, while identification of individuals with the inattentive subtype often occurs later.100 
Very few studies have examined the course of ADHD in children after it is identified at an early 
age. The lack of valid instruments to accurately diagnose ADHD in children between 1 and 6 
years of age makes diagnosis challenging. Furthermore, uncertainty regarding treatment options 
and lack of treatment alternatives in children < 6 years of age could also be challenging. 
However, numerous studies have demonstrated that a majority of children diagnosed with 
behavioral abnormalities at an early age exhibit long-term negative behavioral change. A 12-year 
follow-up study conducted by McGee et al. (1991) on preschool hyperactive children reported 
that only 25% of the children recovered as they aged and about 33% of children met the DSM-III 
criteria for ADHD at follow-up.101 Lahey et al. (2004) reported that nearly 79% of the patients 
diagnosed with ADHD in the initial phase of the study continued to exhibit symptoms of ADHD 
over a three-year period.99 A recent study by Riddle et al. (2013) examined the stability of 
symptom severity 6 years after the completion of a cohort study conducted earlier. The study 
utilized participants from their previous preschool ADHD treatment follow-up study that 
consisted of patients in the 3 to 5 years age group and in the 9 to 12 years age group. The study 
reported that six years after completion of the initial cohort study, nearly 90% of the clinically 
referred preschoolers initially diagnosed with mild to severe ADHD continued to be diagnosed 
with ADHD in mid- to late-childhood.102   
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Information regarding the clinical course, treatment patterns, and the costs of preschool 
kids diagnosed with ADHD at a very young age is sparse. The rise in prevalence of ADHD in 
preschoolers has gained attention and thus, it is important to understand the treatment utilization 
















2.9 Texas Medicaid program 
The Medicaid program is a means-tested entitlement program established through the 
Social Security Act of 1965 and is jointly funded by the federal and state governments.97 The 
Medicaid program is administered by the states, with federal oversight through the Centers for 
Medicare and Medicaid Services (CMS). It was initially designed to provide healthcare coverage 
to low-income children deprived of parental support, related caretakers of dependent children, 
the elderly, the blind, and individuals with disability. The program was later broadened in the 
late 1980s and early 1990s and included mandates for pregnant women (deemed eligible for 
participation in the program). Around the same time, provisions for prescription drugs rebates 
were also introduced. Through this program, the states manage a master list of drugs, generic 
substitutes, and alternative treatment options. Participating states are mandated by the CMS to 
provide a set of basic healthcare services to enrollees and since it is an entitlement program, 
there is no restriction on the number of people who can be enrolled provided they meet the 
eligibility criteria for the program. Based on the most recent available data, the Texas Medicaid 
program provided health insurance coverage for approximately 4 million non-elderly residents 
(i.e., 64 years of age and below).103 Examples of services provided by the Texas Medicaid 
program include: physician services, inpatient and outpatient hospital services, long-term care, 




2.10 Study rationale, purpose, and objectives 
2.10.1 Study rationale  
ADHD is a chronic condition often diagnosed in children before the age of 7 years, which 
may have a long-term impact on social functioning, school performance, cognitive abilities, 
and/or behavior problems. Optimal treatment of ADHD must be multidisciplinary, multimodal 
and maintained over a long period of time. The most effective treatment options for managing 
symptoms related to ADHD involve use of medications, behavioral therapies, combination of 
medications and behavioral therapies, and environmental techniques. A study by the MTA co-
operative demonstrated that medication and psychotherapy work collaboratively better than 
medication alone. Yet, use of medication alone is highly prevalent according to the literature and 
often viewed as the most effective alternative in treating children diagnosed with ADHD. A 
similar trend in the utilization of medications in preschoolers has also been reported. 
Nevertheless, scientists argue that extensive use of medications to treat ADHD during the early 
brain developmental phase might impede brain development and may be associated with long-
term behavior modifications. Preschool children are at increased risk of bearing the 
consequences of excessive medication use, which may lead to future developmental problems.  
In light of evidence supporting combination therapy, benefits of pharmacotherapy over 
psychotherapy for treatment of patients with ADHD are inconclusive and need further 
investigation. Furthermore, investigation of treatment patterns in preschoolers diagnosed with 
ADHD might provide insights into clinical practice. Additionally, current evidence regarding the 
use of treatments in preschoolers with ADHD in the Texas Medicaid population is sparse and/or 
inconclusive. In addition to understanding the current clinical practice for preschoolers with 
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ADHD, it is also important to evaluate their healthcare utilization and cost burden. Previous 
studies that estimated healthcare utilization and costs included a wide range of age categories. A 
review of the literature indicated that very few studies have estimated the healthcare utilization 















2.10.2 Study purpose 
The present study was conducted with three main purposes; 1) to characterize the 
prevalence and incidence of ADHD among preschoolers in the Texas Medicaid population; 2) to 
investigate the pharmacotherapy, psychotherapy, and combination therapy use patterns in 
preschoolers diagnosed with ADHD and to investigate adherence, persistence, switching, and 
augmentation patterns of pharmacologic agents; 3) to assess healthcare utilization (office-based, 
inpatient, outpatient hospital, ED visits, and prescription medications) and direct medical, 













2.10.3 Study objectives and hypotheses 
Objective 1 – To determine the annual prevalence and incidence of ADHD in the Texas 
Medicaid preschool population.  
1a: To determine the treated prevalence of ADHD in preschoolers <6 years of age enrolled in 
Texas Medicaid.  
No hypothesis – descriptive statistics were reported.  
1b: To determine the treated incidence of ADHD in preschoolers <6 years of age enrolled in 
Texas Medicaid. 











Objective 2 – To determine and compare the study characteristics between pharmacotherapy 
only (RX), psychotherapy only (PSY), and pharmacotherapy + psychotherapy (RX+PSY) 
groups. 
2a: To determine and compare the baseline demographic, clinical, physician, and prior utilization 
characteristics between the RX, PSY, and RX+PSY groups. 














Objective 3 – To assess the treatment patterns of preschoolers (2 to <6 years of age) diagnosed 
with ADHD.  
3a: To determine the time to “first pharmacotherapy,” “first psychotherapy,” and “first 
combination therapy.” 
No hypothesis – descriptive statistics were reported.  
3b: To compare the time to first pharmacotherapy, psychotherapy, and combination therapy in 
preschoolers with ADHD and to compare time-to-pharmacotherapy with respect to gender, 
race/ethnicity, medication duration of action, and physician specialty. 
H0(3b)1: There is no significant difference in time-to-initiation of first pharmacotherapy 
(“first RX”), first psychotherapy (“first PSY”), and first combination therapy (“first 
RX+PSY.”) 
H0(3b)2: There is no significant difference in the time-to-initiation of RX in male vs. 
female ADHD patients. 
H0(3b)3: There is no significant difference in the time-to-initiation of RX in different 
race/ethnicity groups diagnosed with ADHD. 
H0(3b)4: There is no significant difference in the time-to-initiation of RX with respect to 
long-acting (LA) vs. short-acting (SA) medications in ADHD patients. 




3c: To assess the factors associated with receiving RX, PSY, or RX+PSY treatments, after 
controlling for covariates.  
No hypotheses - inferential statistics were used to make the comparisons. 
3d: To compare adherence, persistence, augmentation, and switching of pharmacotherapy agents 
between the RX and the RX+PSY groups. 
H0(3d)1: There is no significant difference in the likelihood of medication adherence 
between the RX and the RX+PSY groups, after controlling for covariates. 
H0(3d)2: There is no significant difference in time to discontinuation of index therapy 
between the RX and the RX+PSY groups, after controlling for covariates. 
H0(3d)3: There is no significant difference in the likelihood of augmentation between 
the RX and the RX+PSY groups, after controlling for covariates. 
H0(3d)4: There is no significant difference the likelihood of switching between the RX 







Objective 4 – To determine and compare healthcare utilization between the RX and the 
RX+PSY groups.  
4a: To determine and compare the healthcare utilization frequencies for all-cause office-based, 
inpatient, outpatient hospital, emergency department (ED) visits, and prescriptions between the 
RX and the RX+PSY groups. 
H(4a)1: The number of all-cause office-based visits is significantly higher in the 
RX+PSY group as compared to the RX group, after controlling for covariates. 
H(4a)2: The number of all-cause inpatient visits is significantly higher in the RX+PSY 
group as compared to the RX group, after controlling for covariates.   
H(4a)3: The number of all-cause outpatient hospital visits is significantly higher in the 
RX+PSY group as compared to the RX group, after controlling for covariates.  
H(4a)4: The number of all-cause ED visits is significantly higher in the RX+PSY group 
as compared to the RX group, after controlling for covariates.  
H(4a)5: The number of all-cause prescriptions is significantly higher in the RX+PSY 
group as compared to the RX group, after controlling for covariates. 
4b: To determine and compare the healthcare utilization frequencies for ADHD-related office-




H(4b)1: The number of ADHD-related office-based visits is significantly higher in the 
RX+ PSY group as compared to the RX group, after controlling for covariates. 
H(4b)2: The number of ADHD-related inpatient visits is significantly higher in the 
RX+ PSY group as compared to the RX group, after controlling for covariates.   
H(4b)3: The number of ADHD-related outpatient hospital visits is significantly higher 
in the RX+PSY group as compared to the RX group, after controlling for covariates.  
H(4b)4: The number of ADHD-related ED visits is significantly higher in the RX+PSY 
group as compared to the RX group, after controlling for covariates.  
H(4b)5: The number of ADHD-related prescriptions is significantly higher in the 
RX+PSY group as compared to the RX group, after controlling for covariates. 
4c: To determine and compare the healthcare utilization frequencies for other mental health-
related office-based, inpatient, outpatient hospital, ED visits, and prescriptions between the RX 
and RX+ PSY groups. 
H(4c)1: The number of other mental health-related office-based visits is significantly 
higher in the RX+PSY group as compared to the RX group, after controlling for 
covariates. 
H(4c)2: The number of other mental health-related inpatient visits is significantly 
higher in the RX+PSY group as compared to the RX group, after controlling for  
covariates.   
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H(4c)3: The number of other mental health-related outpatient hospital visits is 
significantly higher in the RX+PSY group as compared to the RX group, after controlling 
for covariates.  
H(4c)4: The number of other mental health-related ED visits is significantly higher in 
the RX+PSY group as compared to the RX group, after controlling for covariates.  
H(4c)5: The number of other mental health-related prescriptions is significantly 
higher in the RX+PSY group as compared to the RX group, after controlling for 
covariates. 
Objective 5 – To determine and compare the healthcare costs between the RX and the RX+PSY 
groups. 
5a: To determine and compare the all-cause medical (office-based, inpatient, outpatient hospital, 
and ED), prescription, and total costs between the RX and RX+ PSY groups. 
H(5a)1: The all-cause medical costs are significantly higher in the RX+ PSY group as 
compared to the RX group, after controlling for covariates.   
H(5a)2: The all-cause prescription costs are significantly higher in the RX+ PSY group 
as compared to the RX group, after controlling for covariates.  
H(5a)3: The all-cause total costs are significantly higher in the RX+PSY group as 
compared to the RX group, after controlling for covariates.  
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5b: To determine and compare the ADHD-related medical (office-based, inpatient, outpatient, 
and ED), prescription, and total costs between the RX and RX+PSY groups. 
H(5b)1: The ADHD-related medical costs are significantly higher in the RX+PSY 
group as compared to the RX group, after controlling for covariates.   
H(5b)2: The ADHD-related prescription costs are significantly higher in the RX+PSY 
group as compared to the RX group, after controlling for covariates.  
H(5b)3: The ADHD-related total costs are significantly higher in the RX+PSY group as 
compared to the RX group, after controlling for covariates.  
5c: To determine and compare the other mental health-related medical (office-based, inpatient, 
outpatient, and ED), prescription, and total costs between the RX and RX+PSY groups. 
H(5c)1: The other mental health-related medical costs are significantly higher in the 
RX+PSY group as compared to the RX group, after controlling for covariates.   
H(5c)2: The other mental health-related prescription costs are significantly higher in 
the RX+PSY group as compared to the RX group, after controlling for covariates.  
H(5c)3: The other mental health-related total costs are significantly higher in the 






CHAPTER 3: METHODOLOGY 
Chapter Overview 
This chapter provides a detailed description of the study methodology, which includes 
information pertaining to the study design, data source, study population, data extraction, study 
timeframe, inclusion and exclusion criteria, and the study variables. This chapter also discusses 
operational definitions, the coding structure, sample size assumptions and calculations, and the 
statistical analyses that were employed for testing the hypotheses listed in the previous chapter.  
Institutional Review Board (IRB) approval 
Before commencement of the study, approval was sought from the Institutional Review 
Board of The University of Texas at Austin and Texas Medicaid. Approval with a waiver of 
informed consent was granted because this was a retrospective database study containing de-









3.1 Data source 
This retrospective study used data from Texas Medicaid. Information pertaining to 
patient demographics, medical services, and prescription claims from the years 2008 – 2013 was 
utilized for the purpose of this study. Data files included the patient eligibility file, medical 
claims file, inpatient claims file, and prescription claims file. The following components for each 
of the files listed below were extracted: 
Patient eligibility file: Person-level file with unique identification number, gender, year 
of birth, race/ethnicity, county of residence, and enrollment periods for the beneficiaries enrolled 
in Texas Medicaid. 
Medical claims file: Event-level file with information pertaining to office-based visits, 
hospital outpatient visits, ED visits, diagnoses (e.g., ICD-9 codes), procedure codes (e.g., CPT 
codes), date of service, amount paid, and provider type.  
Inpatient claims file: Event-level file with information pertaining to inpatient stays, 
diagnoses, admission and discharge dates, and amount paid. 
Prescription claims file: Event-level file with information pertaining to the prescription 
medications dispensed, dispense dates, quantity dispensed, number of authorized refills, number 




3.2 Study design 
This study utilized the Texas Medicaid database to conduct a retrospective analysis of 
medical and pharmacy claims data. Based on the information provided by Texas Medicaid, 
nearly 6 million children < 6 years of age were eligible to be included in this study. Different 
patient selection criteria were used for prevalence and incidence calculations (i.e., for objectives 
1a and 1b).Two patient cohorts were used for objectives 2 to 5. The overall cohort was used to 
assess time-to-initiation, utilization, and cost (i.e., for objectives 2, 3a-c, 4, and 5). The treatment 
pattern cohort was used to assess adherence, persistence, augmentation, and switching (i.e., for 
objective 3d). The patient selection processes for all the cohorts are described below. 
3.2.1 Patient selection – Prevalence  
 The treated prevalence rate of ADHD among preschool children with continuous 
enrollment in Texas Medicaid for a 12-month period was estimated for objective 1a. The patients 
included in the numerator (the prevalent ADHD cases) for this estimate were selected if they met 
the following criteria:  
i. had a diagnosis of ADHD (ICD-9 code = 314.00 or 314.01) recorded in the 
medical claims file during a specific year – 2008, 2009, 2010, 2011, or 2012;  
ii. had at least two paid claims for an ADHD medication in the same year;  
iii. were < 6 years of age at the end of each year; and  
iv. had continuous enrollment in Medicaid for a full 12 months of each year noted in 
(i) and (ii).  
56 
 
Since it is difficult to establish a diagnosis of ADHD in preschoolers we included an 
additional criterion of two paid ADHD prescription claims to validate the ADHD diagnosis. 
Also, enrollment data for 2013 (provided by Texas Medicaid) were incomplete; thus, the 
prevalence estimate for 2013 was not calculated. The denominator for calculating prevalence 
was the total number of preschoolers < 6 years of age covered by Medicaid in each year (2008 – 
2012). An estimated annual enrollment of 1.2 million children < 6 years of age was provided by 
Texas Medicaid and used as the denominator for each year’s prevalence calculations based on 
the assumption that enrollment was relatively stable during this period as indicated by Texas 
Medicaid personnel.  
3.2.2 Patient selection – Incidence  
 The treated incidence rate of ADHD among preschool children with continuous 
enrollment in Texas Medicaid for a 24-month period was estimated for objective 1b. The patients 
included in the numerator (the incident ADHD cases) for this estimate were selected if they met 
the following criteria: 
i. had a diagnosis of ADHD (ICD-9 code = 314.00 or 314.01) recorded in the 
medical claims file during a specific year – 2008, 2009, 2010, 2011, or 2012 but 
with no claims associated with ADHD in the previous 12-month period;  
ii. had at least two paid claims for an ADHD medication in the same year;  
iii. were < 6 years of age at the end of each year; and  
iv. had continuous enrollment in Medicaid for a full 12 months during the year in 
which the diagnosis was recorded and for the previous 12-month period.  
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The same denominator figure that was used in the prevalence rate calculation described above 
(1.2 million enrollees) was used in the incidence rate calculation.  
3.2.3 Patient selection – Overall cohort 
The base population consists of patients enrolled in Texas Medicaid between January 01, 
2008 and August 01, 2013 (the observation period). Texas Medicaid enrollees who met the 
following eligibility criteria were included in the overall cohort for the study:  
i. had at least one ADHD diagnosis based on ICD-9 codes – (314.00, 314.01); 
ii. was 2 to < 6 years of age at the index date;  
iii. had continuous Medicaid enrollment for at least 6 months before and 12 months 
after the index date; (see section 3.2.3.1)  
iv. had at least two ADHD medication claims (e.g., for brand or generic formulations 
of amphetamines, methylphenidates, guanfacine, clonidine, or atomoxetine) or at 
least one psychotherapy visit (e.g., see Appendix I) indicated for the treatment of 
ADHD during the index period; and 
v. had no ADHD medication claim or psychotherapy visit in the 6-month pre-index 
period.  
3.2.3.1 Index date – Overall cohort 
The index date is the date of the first ADHD diagnosis within the index period. The pre-
index period was defined as the 6-month period before the first ADHD diagnosis (index date). 
The post-index period was defined as the 12-month period after the first ADHD diagnosis (index 
58 
 
date). Index dates between July 01, 2008 and August 01, 2012 were included in the study 
(Figure 3.1).  




3.2.4 Patient selection – Treatment pattern cohort 
A sub-sample of patients from the overall cohort were included in the treatment pattern cohort 
to study adherence, persistence, augmentation, and switching. The patient selection criteria used 
for the overall cohort were in effect for the treatment pattern cohort; however, a different index 
date was used for this cohort as described below.  
3.2.4.1 Index date – Treatment pattern cohort 
The index date is the date of the first ADHD prescription within the index period. The 
pre-index period was defined as the 6-month period before the first ADHD prescription (index 
date). The post-index period was defined as the 12-month period after the first ADHD 
prescription (index date). The index dates between July 01, 2008 and August 01, 2012 were 
included in the study (Figure 3.2). 
August 01, 
2013 
July 01,  
2008 
6 months  





Index Period Pre-index  Post-index  
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3.2.5 Data collection/study timeframe 
Information extracted from the Texas Medicaid files consisted of: patient demographics 
(i.e., age, gender, race/ethnicity, enrollment dates, and county of residence [used to determine 
urban/rural status]), diagnoses, NDC codes, dispense dates, quantity dispensed, number of 
authorized refills, number of days supplied, physician specialty, and the amount paid for 
prescription medications and medical services. Additional information related to generic 
sequence (GCN codes), American Hospital Formulary Service (AHFS codes), medication class, 
label name, medication duration of action were appended to the prescription claims file using a 
crosswalk file. Data between January 01, 2008 and August 01, 2013 were extracted for the 
purpose of this study. Subjects were identified during the index period from July 01, 2008 to 
August 01, 2012 (i.e., allowing for 6-month pre-index and 12-month post-index periods).  
3.2.6 Treatment groups 
The study population was sub-divided in three treatment groups based on the type of 
therapy received:  
i) Pharmacotherapy only (RX only): Pharmacotherapy only group (i.e., RX only) included 
patients with claims for ADHD stimulant or non-stimulant medications in the follow-up period 
August 01, 
2013  
July 01,  
2008 
6 months  





Index Period Pre-index  Post-index  
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who did not have a psychotherapy visit. Stimulant medications included brand and generic 
formulations for amphetamine and its derivatives, and methylphenidate and its derivatives. 
Non-stimulant medications included brand and generic formulations for atomoxetine, 
clonidine, and guanfacine. Brand and generic names along with their medication class and 
duration of action for the ADHD medications included in the study are shown in Appendix I. 
ii) Psychotherapy only (PSY only): Patients with psychotherapy visits associated with ADHD 
but no ADHD medication claims during the follow-up period were assigned to the 
psychotherapy only group. Appendix II contains a list of the psychotherapy codes used in the 
study.   
iii) Combination therapy (RX+PSY): The combination therapy group included patients who 
received ADHD pharmacotherapy as well as psychotherapy anytime (i.e., concurrently or 





3.3 Study variables  
3.3.1 Dependent variables 
The dependent variables included: prevalence and incidence; time-to-initiation of 
pharmacotherapy, time-to-initiation of psychotherapy, time-to-initiation of combination therapy, 
medication adherence, persistence, augmentation, and switching; number of office-based visits, 
inpatient visits, outpatient hospital visits, ED visits, and prescription medications (all-cause, 
ADHD-related, and other mental healthcare-related); and medical, prescription, and total costs 
(all-cause, ADHD-related, and other mental health-related). Definitions of study measures are 
provided in Table 3.1. 
3.3.1.1 Prevalence estimate of ADHD in preschoolers 
 The numerator for the prevalent cases was identified based on the patient selection 
criteria enlisted in section 3.2.1. We assumed enrollment of 1.2 million preschool patients (each 
year) as the denominator. The prevalence rates were calculated and expressed as cases per 1,000 
preschoolers. Enrollment data for 2013 (provided by Texas Medicaid) were incomplete; thus, the 
prevalence estimate for 2013 was not calculated. 
3.3.1.2 Incidence estimate of ADHD in preschoolers 
 The numerator for the incident cases was identified based on the patient selection criteria 
enlisted in section 3.2.2. We assumed enrollment of 1.2 million preschool patients (each year) as 
the denominator. The incidence rates were estimated as the number of new cases per 1,000 
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preschoolers. Enrollment data for 2013 (provided by Texas Medicaid) were incomplete; thus, the 
incidence estimate for 2013 was not calculated. 
3.3.1.3 Treatment patterns  
Treatment pattern analyses that were conducted included determining the time-to-
initiation of treatment (RX, PSY, or RX+PSY) and investigating the relationships between time-
to-initiation of RX and gender, race/ethnicity, and medication duration of action. Use of 
physician specialty was planned; however, physician specialty information was incomplete and 
potentially inaccurate. Therefore, physician specialty was dropped from all analyses. The 
relationships between treatment group membership (RX, PSY, or RX+PSY) and patient 
demographic, clinical, and prior utilization characteristics were also assessed. Finally, analyses 
evaluated adherence and persistence to ADHD pharmacotherapy, as well as medication 
augmentation and switching. 
3.3.1.3.1 Time-to-initiation of RX, PSY, or RX+PSY  
Time-to-initiation of ADHD treatment was measured as the number of days between the 
first ADHD diagnosis (index date) and the date of receiving the first ADHD-related treatment 
(i.e., ADHD medication, ADHD-related psychotherapy, or medication + psychotherapy). 
Differences in time-to-initiation of pharmacotherapy were tested with respect to race/ethnicity 
(White, African American, Hispanic, and other/unknown), gender (male and female), and 
medication duration of action (LA and SA). Patients initiating both LA and SA medications on 
the same date were categorized in the LA group as it was speculated that the SA formulation 
may have been prescribed on an “as needed” basis.  
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3.3.1.3.2 Factors associated with receiving RX, PSY, or RX+PSY  
Previous research has shown that differences in treatment occur in children and 
adolescents according to patient age, gender, race/ethnicity, and urban/rural status. Since similar 
differences might exist in the preschool population, the likelihood of receiving ADHD treatment 
(RX, PSY, or RX+PSY) was assessed while controlling for covariates. Patients were categorized 
into RX, PSY, or RX+PSY groups based on the type of therapy received.  
3.3.1.3.3 Measurement of medication adherence 
Medication adherence can be defined as “the extent to which a patient acts in accordance 
with the prescribed interval and dose of a dosing regimen.”104 The most widely used insurance 
claims-based methods for measuring medication adherence are the medication possession ratio 
(MPR) and the proportion of days covered (PDC). While the PDC and MPR calculations will 
yield almost identical results when assessing adherence to a single medication as is the case in 
the current study, the PDC was selected for use in this study because it has been endorsed by the 
Pharmacy Quality Alliance (PQA).105 The PDC was calculated as follows: the numerator was 
calculated by summing the number of days with medications; the denominator was calculated by 
summing the number of days in the follow-up period (Figure 3.3). PDC was used to measure 
adherence in the current study over a 365-day period. Patients with < 80 % PDC value were 
categorized as non-adherent and patients with ≥ 80% PDC value were categorized as 
adherent.106   
Figure 3.3: Proportion of Days Covered (PDC) 
 
PDC = (Σ Days of drug available) 
(Days in follow-up period) 
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3.3.1.3.4 Measurement of medication persistence  
Medication persistence can be defined as “the duration of time from initiation to 
discontinuation of therapy.”104 Medication persistence was assessed for patients receiving RX 
and was defined as the time between treatment initiation and discontinuation of the index 
ADHD-related medication.104,107–109 A continuous variable measuring the number of days a 
patient diagnosed with ADHD was on the index ADHD medication without a gap of > 30 days. 
Medication persistence was measured over a 365-day observation period. A 30-day allowable 
gap period has been used in previous studies to estimate medication persistence in patients with 
ADHD.81,83,110–112 Since “drug holidays” cannot be identified using claims data, a sensitivity 
analysis with 60-, and 90-day gap was conducted to test for variability that might be accounted 
for by “drug holidays” and other factors that might be directly or indirectly associated with 
patients’ medication therapy behavior. Previous studies have used these gap periods to study 
medication persistence in the ADHD population.  Persistence with medications in preschoolers 
has not been assessed in the past and thus, the current study provides insight into their 
persistence rates with ADHD medications.  
3.3.1.3.5 Measurement of medication augmentation and switching 
Augmentation was defined as initiation of a new ADHD medication (i.e., a different 
chemical entity) with a continuous overlap of at least 30 days with the index medication. 
Switching was defined as having a prescription claim for an alternative ADHD medication (i.e., 
a different chemical entity) to the index ADHD medication (received on or after the index date), 
before or within 30 days of discontinuation of the index medication. Index medication 
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discontinuation was defined as no subsequent dispensing for ≥ 60 days. The “switched-to” 
medication must have had a days supply of at least 30 days to be considered switching.  
3.3.1.4 Healthcare utilization and costs 
Healthcare resource utilization and expenditure variables associated with office-based 
visits, inpatient stays, outpatient hospital visits, ED visits, and prescription fills are the main 
outcomes for this component of the study.  
3.3.1.4.1 Healthcare utilization – Medical visits 
All-cause utilization and ADHD-related utilization were analyzed, with services associated 
with primary or secondary ADHD diagnosis being defined as ADHD-related. Other mental 
health-related visits were included if associated with the following primary diagnoses (ADHD 
could not be a secondary diagnosis for this group of services): pervasive developmental disorders 
(ICD-9 codes: 299.xx), conduct disorder (ICD-9 codes:312.0x, 312.1x, 312.2x, 312.4, 312.8, 
312.8x, and 312.9) , oppositional defiant disorder (ICD-9 code: 313.81), developmental delays 
(ICD-9 codes: 307.0, 307.9, 315.x, 315.0x, 315.3x, 317, 318.0, 318.1, 318.2, 319, V400, and 
V401) listed as the primary diagnosis without ADHD as one of the secondary diagnosis were 
included in this category.   
3.3.1.4.2 Healthcare utilization – Prescription medications 




ADHD-related prescriptions: Prescription claims for ADHD medications were included in 
this category. 
Other mental health-related prescriptions: Prescription claims for other mental health-
related medications were included in this category (defined later in the methods).  
3.3.1.4.3 Healthcare costs 
Costs (all-cause, ADHD-related, and other mental health-related) reflect costs to the Texas 
Medicaid program and are based on “paid amount” variable for each claim. Medical costs (i.e., 
sum of office-based, inpatient, outpatient hospital, and ED visits), prescription costs, and total 
costs (medical + RX + other) were calculated. All costs were converted to 2013 dollars based on 
the medical consumer price index (CPI).
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Table 3.1: Operational definitions for the dependent variables included in the study 
Dependent Variables Operational Definitions 
Prevalence and Incidence  
Prevalence rate Ratio of the number of preschoolers who meet the inclusion criteria for prevalent cases each 
year/estimated total number of preschoolers < 6 years of age enrolled in Texas Medicaid each year 
(proportion). 
Incidence rate Ratio of the number of preschoolers who meet the inclusion criteria for incident cases each 
year/estimated total number of preschoolers < 6 years of age enrolled in Texas Medicaid each year 
(proportion). 
Treatment patterns 
Time-to-initiationa  Number of days between the first ADHD diagnosis (index date) and the first therapy (i.e., 
pharmacotherapy, psychotherapy, or combination therapy). 
Treatment adherenceb ADHD medication adherence measured in the post-index period using PDC. 
0 = Non-Adherent (PDC < 0.8 or 80%) 
1 = Adherent (PDC ≥ 0.8 or 80%) 
Treatment persistenceb  Number of days of continuous therapy without a gap of >30 days in the post-index period. Sensitivity 
analyses with 60-, and 90-day gap periods were conducted. 
Treatment augmentationb Prescription claims for new ADHD medication in addition to the index medication with an overlap of at 
least 30 days. 
0 = Did not add medications to the index treatment  
1 = Added medications to the index treatment  
Treatment switchingb Prescription claim for an ADHD medication (different chemical entity) other than the index medication 
before or within 30 days of discontinuation of the index medication with no subsequent dispensing of 
the index medication for ≥ 60 days. “Switched-to” drug should be taken for at least 30 consecutive days. 
0 = Did not switch from index treatment  





Table 3.1: Operational definitions for the dependent variables included in the study (continued) 
Dependent Variables Operational Definitions 
Healthcare utilizationa 
All-cause 
Office-based visits Number of all-cause office-based visits in the post-index study period (frequency count). 
Outpatient hospital visits Number of all-cause outpatient hospital visits in the post-index study period (frequency count). 
Inpatient hospital visits Number of all-cause inpatient visits in the post-index study period (frequency count). 
Emergency department 
visits 
Number of all-cause ED visits in the post-index study period (frequency count). 
Prescriptions  Number of all-cause prescriptions in the post-index study period (frequency count). 
ADHD-related 
Office-based visits Number of ADHD-related office-based visits in the post-index study period (frequency count). 
Outpatient hospital visits Number of ADHD-related outpatient hospital visits in the post-index study period (frequency count). 
Inpatient hospital visits Number of ADHD-related inpatient visits in the post-index study period (frequency count). 
Emergency department 
visits 
Number of ADHD-related ED visits in the post-index study period (frequency count). 
Prescriptions  Number of ADHD-related prescriptions in the post-index study period (frequency count). 
Other mental health-related 
Office-based visits Number of other mental health-related office-based visits in the post-index study period (frequency 
count). 
Outpatient hospital visits Number of other mental health-related outpatient hospital visits in the post-index study period 
(frequency count). 
Inpatient hospital visits Number of other mental health-related inpatient visits in the post-index study period (frequency count). 
Emergency department 
visits 
Number of other mental health-related ED visits in the post-index study period (frequency count). 





Table 3.1: Operational definitions for the dependent variables included in the study (continued) 
Dependent Variables Operational Definitions 
Healthcare costsa 
All-cause 
Post-index medical costs Sum of costs related to office-based, inpatient, outpatient hospital, and ED visits in the post-index study 
period adjusted to 2013 dollars using the medical CPI (continuous). 
Post-index prescription 
medication costs  
Sum of prescription-related costs in the post-index study period adjusted to 2013 dollars using the 
medical CPI (continuous). 
Post-index total costs  Total (medical + prescription + otherc) costs in the post-index study period adjusted to 2013 dollars 
using the medical CPI (continuous). 
ADHD-related 
Post-index medical costs Sum of ADHD-related costs for office-based, inpatient, outpatient hospital, and ED visits in the post-
index study period adjusted to 2013 dollars using the medical CPI (continuous). 
Post-index prescription 
medication costs  
Sum of ADHD-related prescription costs in the post-index study period adjusted to 2013 dollars using 
the medical CPI (continuous). 
Post-index total costs  Sum of ADHD-related total (medical + prescription + otherc) costs in the post-index study period 
adjusted to 2013 dollars using the medical CPI (continuous). 
Other mental health-related 
Post-index medical costs Sum of other mental health-related costs for office-based, inpatient, outpatient hospital, and ED visits in 
the post-index study period adjusted to 2013 dollars using the medical CPI (continuous). 
Post-index prescription 
medication costs  
Sum of other mental health-related prescription costs in the post-index study period adjusted to 2013 
dollars using the medical CPI (continuous). 
Post-index total costs  Sum of other mental health-related total (medical + prescription + otherc) costs in the post-index study 
period adjusted to 2013 dollars using the medical CPI (continuous).  
CPI = Consumer Price Index; ADHD = Attention Deficit Hyperactivity Disorder; ED = Emergency Department; PDC = Proportion of Days Covered; 
a Conducted on the overall cohort [i.e., patients with 1 year follow-up after the first ADHD diagnosis (index date = diagnosis date)]; 
b Conducted on treatment pattern cohort patients [i.e., patients with 1 year follow-up after the first ADHD-related prescription (index date = date of first 
prescription)]  
c Other costs included cost that could not be captured in the medical or prescription-related categories (e.g., Ultrasound procedures, culture coding, routine 
venipuncture, thyroid function tests, X-ray, or psychotherapy without place of service code) 
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3.3.2 Independent variables  
The primary independent variable was type of therapy (i.e., pharmacotherapy, 
psychotherapy, and combination therapy). Covariates included in the study were age, gender, 
race/ethnicity, urban/rural status, number of pre-index visits (psychiatric and non-psychiatric 
office-based visits), number of pre-index psychotropic prescription claims, other mental health 
diagnosis, pre-index total healthcare costs, medication duration of action, and medication class. 
Definitions of study measures are provided in Table 3.2. 
3.3.2.1 Patient demographics 
Patient demographic characteristics included age at the index date (diagnosis date), 
gender, race/ethnicity (White, African American, Hispanic, other/unknown). Urban/rural status 
was defined based on the patient’s county of residence. 
3.3.2.2 Physician specialty 
Use of physician specialty was planned; however, physician specialty information was 
incomplete and potentially inaccurate. Therefore, physician specialty was dropped from all 
analyses.  
3.3.2.3 Clinical and prior utilization characteristics 
Patients’ pre-index utilization of psychiatric office-based visits, non-psychiatric office-
based visits, and psychotropic medications, as well as pre-index all-cause total healthcare costs 
served as independent variables. Psychotropic medications were identified based on AHFS codes 
71 
 
28:16.04 (antidepressants), 28:16.08 (antipsychotics), 28:24 (anxiolytics/sedatives/hypnotics), 
28:28 (antimanics), and 28:12 (anticonvulsants).  
Clinical characteristics included were other mental health diagnoses, medication class, 
and medication duration of action. Other mental health diagnoses were identified based on the 
ICD-9 codes of the most commonly-occurring mental health conditions in patients with ADHD. 
Other mental health diagnoses are listed in section 3.3.1.4.1. 
With respect to medication class, index medications were classified as stimulants and 
non-stimulants. The stimulant medications include amphetamine and its derivatives, and 
methylphenidate and its derivatives. The non-stimulant medications include atomoxetine, 
clonidine, and guanfacine.  
With respect to medication duration of action, ADHD medications were classified as 
short-acting or long-acting depending on their product names and product literature. See 









Table 3.2: Operational definitions for the independent variables included in the study  
Variables  Operational Definitions 
Treatment group Categorized as 
0 = Pharmacotherapy only (RX only) 
1 = Psychotherapy only (PSY only) 
2 = Combination therapy (RX+PSY) 
Age Age of the respondent at the index date (continuous) 
Gender Dichotomized as  
0 = Female 
1 = Male  
Race/Ethnicity Categorized as  
0 = White  
1 = African American  
2 = Hispanic 
3 = Other/Unknown 
Urban/rural status  Categorized as  
0 = Urban 
1 = Rural 
Pre-index psychiatric office-
based visits 
Visits with a other mental health diagnosis as a primary 
diagnosis in the pre-index period (frequency count) 
Pre-index non-psychiatric 
office-based visits 
Visits without other mental health diagnosis as a primary 
diagnosis in the pre-index period (frequency count) 
Pre-index psychotropic 
prescription claims 
Presence of psychotropic medication claims for one of the 
following  
Antipsychotics (AHFS code – 28:16.08) 
Antidepressants (AHFS code – 28:16.04) 
Anxiolytics/Sedatives/Hypnotics (AHFS code – 28:24) 
Antimanics (AHFS code – 28:28) 
Anticonvulsants (AHFS code – 28:12)  
Categorized as 
0 = No psychotropic medication claim 
1 = Psychotropic medication claim 
Pre-index all-cause total 
healthcare costs  
Total costs in the pre-index period for patients diagnosed 







Table 3.2: Operational definitions for the independent variables included in the study 
(continued) 
Variables  Operational Definitions 
Other mental health diagnosis Presence of mental health diagnoses for one of the following  
Pervasive developmental disordersa  
Conduct disorderb 
Oppositional defiant disorderc 
Developmental delaysd 
Categorized as 
0 = Absence of other mental health diagnosis 
1 = Presence of other mental health diagnosis 
Medication class Presence of claims for stimulants and non-stimulants. 
Stimulant medications included methylphenidate and its 
derivatives and amphetamines and its derivatives. Non-
stimulant medications include atomoxetine, clonidine, and 
guanfacine. 
Categorized as 
0 = Stimulant 
1 = Non-stimulant 
Medication duration of action Presence of claims for long-acting or short-acting 
medications. Long-acting medications included Concerta, 
Ritalin LA, Ritalin SR, Metadate CD, Metadate ER, 
Methylin ER, Daytrana, Adderall XR, Focalin XR, Intuniv, 
Kapvay, and Vyvanse. Short-acting medications include 
Ritalin, Methylin, Focalin, Dexedrine, Dextrostat, Procentra, 
Strattera, and Adderall. 
Categorized as  
0 = Long-acting [LA] 
1 = Short-acting [SA] 
ADHD = Attention Deficit Hyperactivity Disorder; ICD-9 = International classification of disease, 9th revision; 
AHFS = American Hospital Formulary System; RX = Pharmacotherapy only; PSY = Psychotherapy only; RX+PSY = 
Combination therapy; 
a pervasive developmental disorders (ICD-9 codes: 299.xx);  
b conduct disorder (ICD-9 codes: 312.0x, 312.1x, 312.2x, 312.4, 312.8, 312.8x, and 312.9);  
c oppositional defiant disorder (ICD-9 code: 313.81);  







3.4 Statistical analyses 
Preliminary analyses involved basic descriptive statistics to identify patient baseline 
characteristics. Preliminary tests were used to identify potential outliers in the data and to assess 
the statistical test assumptions proposed for each analysis. All analyses were two-tailed with an a 
priori significance level of 0.05. 
 Frequencies and percentages were used to summarize categorical variables (i.e., gender, 
race/ethnicity, urban/rural status, pre-index psychotropic prescriptions, medication class, 
medication duration of action, other mental health diagnoses, adherence status, switching status, 
and augmentation status). Mean, median, and distribution statistics were used to summarize 
continuous variables (i.e., age, pre-index psychiatric office-based visits, pre-index non-
psychiatric office-based visits, time-to-initiation, adherence, persistence, office-based visits, 
inpatient visits, outpatient hospital visits, ED visits, prescriptions, and costs).  
Data management and analyses were performed using SAS® for Windows version 9.3 






3.4.1 Objective 1: Prevalence and incidence 
Proportions were used to describe the prevalence and incidence statistics. The annual 
prevalence and incidence rates were calculated as described in sections 3.3.1.1 and 3.3.1.2, and 
reported as ratios.  
3.4.2 Objective 2: Comparing demographic and patient, clinical, and prior utilization 
characteristics between RX, PSY, and RX+PSY groups 
Baseline patient demographics, pre-index psychiatric office-based visits, pre-index non-
psychiatric office-based visits, pre-index psychotropic prescription claims, pre-index all-cause 
total healthcare costs, other mental health diagnosis, medication class, and medication duration 
of action were assessed and compared across the pharmacotherapy only (RX), psychotherapy 
only (PSY), and pharmacotherapy + psychotherapy (RX+PSY) groups. Categorical variables 
were compared using chi-square tests and continuous variables were compared using ANOVA or 
Kruskal-Wallis tests (for data violating normality assumption). 
3.4.3 Objective 3: Treatment patterns of preschoolers between 2 and < 6 years of age 
Objective 3a: Time-to-initiation of RX, PSY, or RX+PSY 
In this study, median times to initiate each type of therapy were estimated from the time 
of the first ADHD diagnosis (index date) to the date of receiving the first treatment (i.e., first 
RX, first PSY, or first RX+PSY). Kaplan-Meier curves were plotted to estimate the time-to-
initiation of “first PSY,” “first RX,” and “first RX+PSY.” Patients not receiving RX (in the 
estimation of time-to-initiation of “first RX”), patients not receiving PSY (in the estimation of 
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time-to-initiation of “first PSY”), and patients not receiving RX+PSY (in the estimation of time-
to-initiation of “first RX+PSY”) were ‘censored.’ Unadjusted Cox proportional hazards models 
were used to compare time-to-initiation among the three treatment groups.  
Objective 3b: Time-to-initiation of RX according to gender, race/ethnicity, and medication 
duration of action 
Time from diagnosis of ADHD (index date) to initiation of first RX was assessed in this 
objective. Log-rank tests were conducted to test differences in time-to-initiation of “first RX” in 
relation to gender and medication duration of action. Cox proportional hazards regression models 
were used to assess time-to-initiation of “first RX” by race/ethnicity. Patients not receiving 
pharmacotherapy were ‘censored.’ 
Objective 3c: Factors associated with receiving RX, PSY, or RX+PSY 
Multinomial logistic regression models were used to assess the relationships of patient 
demographics, clinical, and prior utilization characteristics with the likelihood of receiving RX, 
PSY, or RX+PSY in the post-index period, while controlling for the covariates. 
Objective 3d: Adherence, persistence, augmentation, and switching 
The adherence rates of the index medication therapy were calculated for patients in the 
RX and RX+PSY treatment groups. Chi-square tests were used to compare proportions of 
adherent patients (PDC ≥ 80%), and proportions of patients augmenting and switching between 
the RX and RX+PSY groups. An independent groups t-test was used to compare adherence 
(PDC) and persistence between the RX and RX+PSY groups. Multiple linear regression was also 
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used to compare the adherence and persistence between RX and RX+PSY groups, while 
controlling for covariates. Logistic regression analysis was used to compare the likelihood of 
adherence, augmentation, and switching between the RX and RX+PSY groups, while controlling 
for covariates.   
Persistence was compared between the RX and RX+PSY groups using a Kaplan-Meier 
estimator curve. Cox proportional hazards regression analysis was used to compare time to 
discontinuation of pharmacotherapy between the RX and RX+PSY groups while controlling for 
covariates. Patients who still persist with their initial therapy at the end of the follow-up period 
were ‘censored.’ 
3.4.4 Objectives 4 & 5: Healthcare utilization and costs 
Healthcare utilization data are often recorded as counts whereas healthcare cost data are the 
absolute dollar value for a particular service. Since utilization data usually violate the normality 
distribution assumption, it is important to account for non-normality by fitting appropriate 
models.113 Because the data do not always satisfy the normality assumption, analysis of 
healthcare data based on OLS regression assumptions may not be warranted. Analyzing 
healthcare data using OLS regression may increase the type I error rate due to erroneous standard 
errors and confidence intervals. Also, healthcare utilization data tends to have a higher number of 
zero values (e.g., few patients incur hospitalization costs because it is very rare to be hospitalized 
for a particular condition) and are highly skewed (e.g., a few patients incur disproportionately 
higher costs relative to a majority of the patients). Additionally, utilization data may be highly 
correlated especially for chronic conditions. Also, previous studies have shown that utilization 
data is rarely homoscedastic.  
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Inadequacy of the OLS regression in handling count outcomes can be overcome by use of 
Poisson regression models. Poisson regressions may provide a more appropriate alternative for 
analyzing count data (e.g., inpatient, outpatient, and ED visits) often encountered in healthcare 
research. Poisson regression models assume that the variance of the population is equal to the 
mean. However, Poisson distributions could be over-dispersed (i.e., where the variance is greater 
than the mean), thus violating the assumption of equidispersion. In such cases, the negative 
binomial models would be appropriate to model over-dispersed count data with unobserved 
heterogeneity. Alternatively, data could be skewed or lumped due to the presence of excessive 
zeros. When the data have an excessive number of zero observations, zero-inflated regression 
models or hurdle models are recommended. The choice between zero-inflated regression models 
and hurdle models is based on identifying the source of zeros. The excessive zeros observed in 
the zero-inflated model could be due to a chance occurrence (known as ‘sampling zeros’) or due 
to the method of data collection (known as ‘structural zeros’) (e.g., lack of hospitalizations 
because everyone in the cohort is healthy). On the other hand, hurdle models have an important 
distinction and assume that all the zeros observed in the data are structural. Zero-inflated Poisson 
regression models were used to model utilization data for this study because the data included a 
high number of zero values in all the utilization categories, except for all-cause ADHD-related 






Objective 4: To determine and compare healthcare utilization between the RX and the 
RX+PSY groups 
Objectives 4a-c: To determine and compare the healthcare utilization frequencies for all-cause, 
ADHD-related, and other mental health-related office-based, inpatient, outpatient hospital, ED 
visits, and prescriptions between the RX and RX+PSY groups 
Based on the distribution of the data, Possion regression and zero-inflated regression 
models were used to compare the number of all-cause, ADHD-related, other mental health-
related office-based, inpatient, outpatient hospital, ED visits, and prescriptions between the RX 
and the RX+PSY groups while controlling for patient demographics and treatment covariates.   
Objective 5: To determine and compare healthcare costs between the RX and the RX+PSY 
groups 
Objective 5a-c: To determine and compare all-cause, ADHD-related, and other mental health-
related medical costs (office-based, inpatient, outpatient hospital, and ED), prescription drug 
costs, and total costs between the RX and RX+PSY groups 
Means and median all-cause, ADHD-related, and other mental health-related medical, 
prescription, and total costs were reported for the RX and RX+PSY groups. A Modified Park test 
was conducted to identify the distribution and select the appropriate functional form and link 
function. Separate generalized linear regression models with a gamma distribution and a log-link 
were used to compare all-cause, ADHD-related, other mental health-related costs between the 
RX and RX+PSY groups while controlling for covariates. Cost data were adjusted to 2013 
dollars using the medical CPI index for 2013 (published by the Bureau of Labor Statistics.) 
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Table 3.3 provides a list of objectives and the corresponding statistical tests that were 
carried out.   
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Table 3.3: Summary of study objectives, hypotheses, variables, and statistical analyses 












Objective 1 – To determine the annual prevalence and incidence of ADHD diagnosis in the Texas Medicaid preschool population 
1a: To determine the treated prevalence of 
ADHD in preschoolers <6 years of age 
enrolled in Texas Medicaid  
Prevalence (number of 
preschoolers diagnosed 
with ADHD)  
Count  N/A  N/A Descriptive 
1b: To determine the treated incidence of 
ADHD in preschoolers <6 years of age 
enrolled in Texas Medicaid 




Count N/A N/A Descriptive 
Objective 2 – To determine and compare the baseline characteristics between RX, PSY, and RX+PSY groups 
2a: To determine and compare the 
baseline demographic, clinical, and prior 
utilization characteristics between the 
pharmacotherapy only (RX), 
psychotherapy only (PSY), and 
pharmacotherapy + psychotherapy 






based visits, pre-index 
non-psychiatric office-
based visits, pre-index 
all-cause total healthcare 
costs, pre-index 
psychotropic medication 
use, other mental health 
diagnosis, medication 
class, and medication 























Table 3.3: Summary of study objectives, hypotheses, variables, and statistical analyses (continued) 












Objective 3 – To assess the treatment patterns of preschoolers (2 to <6 years of age) diagnosed with ADHD  
3a: To determine the time to “first 
pharmacotherapy,” “first psychotherapy” 






Psychotherapy (time to 
“first psychotherapy”) 
“first combination 
therapy” (time to 
combination therapy) 
Continuous  Pharmacotherapy  
(Yes, No) 
Psychotherapy  






3b: To compare the time to first 
pharmacotherapy, psychotherapy, and 
combination therapy in preschoolers with 
ADHD and to compare time to 
pharmacotherapy with respect to gender, 
race/ethnicity, medication duration of 
action, and physician specialty 
     
H0(3b)1: There is no difference in time-to-
initiation of pharmacotherapy (“first RX”), 
psychotherapy (“first PSY”), or “first 
combination therapy” 
Time to therapy (first 
pharmacotherapy, first 
psychotherapy, or first 
combination therapy)  
Continuous  Type of therapy  
(“first RX,” “first 





PH) regression  
H0(3b)2: There is no significant difference in 
the time-to-initiation of RX in male vs. 
female ADHD patients 
Time to “first 
pharmacotherapy” 
Continuous  Gender  




Log-rank test  
H0(3b)3: There is no significant difference in 
the time-to-initiation of RX in different 
race/ethnicity groups diagnosed with 
ADHD 
Time to “first 
pharmacotherapy” 
Continuous Race/ethnicity   
(White, Black, 







H0(3b)4: There is no significant difference in 
the time-to-initiation of RX with respect to 
long-acting (LA) vs. short-acting (SA) 
medications in ADHD patients  
Time to “first 
pharmacotherapy” 
Continuous  Medication 
duration of action  
(short-acting [SA], 





















H0(3b)5: There is no significant difference in 
the time-to-initiation of RX by physician 
specialty 
 
Time to “first 
pharmacotherapy” 
Continuous Physician specialty 
(Psychiatrist, 
Primary care, Other 






3c: To assess the factors associated with 
receiving RX, PSY, or RX+PSY, after 






(RX = 1, PSY = 2, or  
RX+PSY = 3) 






3d: To compare adherence, persistence, 
augmentation, and switching of 
pharmacotherapy between the RX and the 
RX+PSY groups      
H0(3d)1: There is no significant difference in 
the likelihood of medication adherence 
between the RX and the RX+PSY groups, 
after controlling for covariates 
Medication adherence 
(PDC)   
[Yes = 1 (PDC ≥ 80),  











H0(3d)2: There is no significant difference in 
time to discontinuation between the RX and 
the RX+PSY groups, after controlling for 
covariates 
Medication persistence 
(time to discontinuation)   
Continuous   Treatment groups 









H0(3d)3: There is no significant difference in 
the likelihood of medication augmentation 
between the RX and the RX+PSY groups, 
after controlling for covariates 
Medication 
augmentation 











H0(3d)4: There is no significant difference in 
the likelihood of switching between the RX 
and the RX+PSY groups, after controlling 
for covariates 
Medication switching 




























Objective 4 – To determine and compare healthcare utilization between the RX and the RX+PSY groups 
4a: To determine and compare healthcare 
utilization frequencies for all-cause office-
based, inpatient, outpatient hospital, 
emergency department (ED) visits, and 
prescription medications between the RX 
and the RX+PSY groups 
     
H(4a)1: The number of all-cause office-
based visits is significantly higher in the 
RX+PSY group as compared to the RX 
group, after controlling for covariates 
Number of all-cause 
office-based visits 
Count Treatment groups 








H(4a)2: The number of all-cause inpatient 
visits is significantly higher in the RX+PSY 
group as compared to the RX group, after 
controlling for covariates 
Number of all-cause 
inpatient visits 
Count Treatment groups  






H(4a)3: The number of all-cause outpatient 
hospital visits is significantly higher in the 
RX+PSY group as compared to the RX 
group, after controlling for covariates 
Number of all-cause 
outpatient hospital visits 
Count Treatment groups 






H(4a)4: The number of all-cause ED visits is 
significantly higher in the RX+PSY group as 
compared to the RX group, after controlling 
for covariates 
Number of all-cause ER 
visits 
Count Treatment groups 






H(4a)5: The number of all-cause 
prescriptions is significantly higher in the 
RX+PSY group as compared to the RX 
group, after controlling for covariates 
Number of prescription 
fills 
Count Treatment groups 

























4b: To determine and compare healthcare 
utilization frequencies for ADHD-related 
office-based, inpatient, outpatient hospital, 
ED visits, and prescription medications 
between the RX and RX+PSY groups 
     
H(4b)1: The number of ADHD-related 
office-based visits is significantly higher in 
the RX+PSY group as compared to the RX 




Count Treatment groups  






H(4b)2: The number of ADHD-related 
inpatient visits is significantly higher in the 
RX+PSY group as compared to the RX 
group, after controlling for covariates 
Number of ADHD-
related inpatient visits 
Count Treatment groups  






H(4b)3: The number of ADHD-related 
outpatient hospital visits is significantly 
higher in the RX+PSY group as compared to 




Count Treatment groups  






H(4b)4: The number of ADHD-related ED 
visits is significantly higher in the RX+PSY 
group as compared to the RX group, after 
controlling for covariates 
Number of ADHD-
related ED visits 
Count Treatment groups  






H(4b)5: The number of ADHD-related 
prescriptions is significantly higher in the 
RX+PSY group as compared to the RX 
group, after controlling for covariates 
Number of prescription 
fills 
Count Treatment groups 


























4c: To determine and compare healthcare 
utilization frequencies for other mental 
health-related office-based, inpatient, 
outpatient hospital, ED visits, and 
prescription medications between the RX 
and RX+PSY groups      
H(4c)1: The number of other mental health-
related office-based visits is significantly 
higher in the RX+PSY group as compared to 
the RX group, after controlling for covariates 
Number of other mental 
health-related office 
based visits 
Count Treatment groups  






H(4c)2: The number of other mental health-
related inpatient visits is significantly 
higher in the RX+PSY group as compared to 
the RX group, after controlling for covariates 
Number of other mental 
health-related inpatient 
visits 
Count Treatment groups  






H(4c)3: The number of other mental health-
related outpatient hospital visits is 
significantly higher in the RX+PSY group as 
compared to the RX group, after controlling 
for covariates 
Number of other mental 
health-related outpatient  
hospital visits 
Count Treatment groups  






H(4c)4: The number of other mental health-
related ED visits is significantly higher in 
the RX+PSY group as compared to the RX 
group, after controlling for covariates 
Number of other mental 
health-related ER visits 
Count Treatment groups  






H(4c)5: The number of other mental health-
related prescriptions is significantly higher 
in the RX+PSY group as compared to the 
RX group, after controlling for covariates 
Number of prescription 
fills 
Count Treatment groups 
























Objective 5: To determine and compare the healthcare costs between the RX and the RX+PSY groups 
5a: To determine and compare the all-
cause medical costs (office-based, 
inpatient, outpatient hospital, and ED), 
prescription drug costs, and total costs 
between the RX and RX+PSY groups      
H(5a)1: The all-cause medical costs are 
significantly higher in the RX+PSY group as 
compared to the RX group, after controlling 
for covariates 
All-cause medical costs Continuous  Treatment groups  








H(5a)2: The all-cause prescription costs are 
significantly higher in the RX+PSY group as 




Continuous  Treatment groups  






H(5a)3: The all-cause total costs are 
significantly higher in the RX+PSY group as 
compared to the RX group, after controlling 
for covariates 
All-cause total costs Continuous  Treatment groups  






5b: To determine and compare the 
ADHD-related medical costs (office-based, 
inpatient, outpatient hospital, and ED), 
prescription drug costs, and total costs 
between the RX and RX+PSY groups 
     
H(5b)1: The ADHD-related medical costs 
are significantly higher in the RX+PSY 
group as compared to the RX group, after 
controlling for covariates 
ADHD-related medical 
costs 
Continuous  Treatment groups  
























H(5b)2: The ADHD-related prescription 
costs are significantly higher in the RX+PSY 
group as compared to the RX group, after 
controlling for covariates 
ADHD-related 
prescription costs 
Continuous  Treatment groups  






H(5b)3: The ADHD-related total costs are 
significantly higher in the RX+PSY group as 




Continuous  Treatment groups  






5c: To determine and compare the other 
mental health-related medical costs 
(office-based, inpatient, outpatient 
hospital, and ED), prescription drug costs, 
and total costs between the RX and 
RX+PSY groups 
 
    
H(5c)1: The other mental health-related 
medical costs are significantly higher in the 
RX+PSY group as compared to the RX 
group, after controlling for covariates 
Other mental health-
related medical costs 
Continuous  Treatment groups  






H(5c)2: The other mental health-related 
prescription costs are significantly higher in 
the RX+PSY group as compared to the RX 
group, after controlling for covariates 
Other mental health-
related prescription costs 
Continuous  Treatment groups  






H(5c)3: The other mental health-related 
total costs are significantly higher in the 
RX+PSY group as compared to the RX 
group, after controlling for covariates 
Other mental health-
related total costs 
Continuous  Treatment groups  






ZIP = Zero-Inflated Poisson regression; GzLM = Generalized Linear Models; ADHD = Attention Deficit Hyperactivity Disorder; PDC = Proportion of Days 
Covered; 
a Covariates include age, gender, race/ethnicity, urban/rural status, pre-index psychiatric office based visits, pre-index non-psychiatric office-based visits, pre-index 
total healthcare costs, other mental health diagnosis, medication class, and medication duration of action 
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3.5 Statistical assumptions and sample size calculations 
The sample size calculations were done a priori for each objective of the study. The 
sample sizes were based on four parameters: (i) type I error rate or alpha of 0.05; (ii) type II error 
rate or power of 0.80; (iii) effect size depending on the type of statistical test performed; and (iv) 
prevalence rates in the population (previous studies have estimated a prevalence rate ranging 
from 2 – 5 %. A conservative estimate of 3% was utilized in this study).3,4  
3.5.1 Kaplan-Meier estimators  
A Kapan-Meier (KM) curve generates survival probabilities within a given time 
frame.114,115 KM curves are usually an estimate of probability of experiencing the event plotted 
against time. The proportion of patients surviving until the end of the specified period is given 
by114,115  






St = survival probability  
ri = number entering the cohort at the beginning of the study period 
di = number of people experiencing the event during the specified follow-up time 
3.5.2 Log-Rank test  
To help understand the treatment patterns, time-to-initiation of pharmacotherapy with 
respect to gender and medication duration of action were tested using log-rank tests. The log-
rank test was also used to compare time-to-discontinuation (persistence) between the RX and 
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RX+PSY treatment groups. The curves for each treatment group were compared statistically by 
testing the null hypothesis that there is no difference between time to discontinuation of these 
therapies. The log-rank test statistic requires that the proportional hazards assumption is 
met.114,115 The test statistic is calculated as follows: 
Figure 3.5: Log-rank equation 








O1 = Total number of observed events in group 1 
O2 = Total number of observed events in group 2 
E1 = Total number of expected events in group 1 
E2 = Total number of expected events in group 2 
Sample sizes for the log-rank test were estimated using Stata software. A range of values 
were entered and the largest sample size was chosen as the sample size for analyzing objective 2. 
Table 3.4 represents the sample size estimates for different input parameters. An 
estimated sample size of 887 patients were required for two-sample comparisons of survivor 
functions. 






Events Prob1 Prob2 
Hazard 
Ratio 
1,326 663 663 1,272 0.03 0.05 0.854 
1,516 758 758 1,456 0.03 0.05 0.854 




3.5.3 Cox Proportional-Hazards regression (Cox PH) 
Cox Proportional-Hazards regression (Cox PH) models are similar to multiple regression 
models. In Cox PH regression models, no assumption regarding the probability distribution is 
made, but it does assume that the hazard ratios (i.e., conditional probability of having the event at 
time ‘t’ given that the event has not occurred until that time) are constant over time.114,115  
Assumptions of the proportional-hazards models can be tested based on Schoenfelds’ 
residual plots to detect possible departures from the assumptions.116 Also, since the hazard 
function in the Cox model assumes a log-linear relationship with its covariates, it is important to 
test this assumption. This linearity assumption can be tested by plotting the deviance residuals 
and the Martingale residuals against the covariates.114–116   
Sample sizes for Cox PH regressions were estimated using PASS 13 software. A range of 
parameters (power = 0.80; 𝛼 = 0.05, log hazard = [1.5-2.0], R2 = 0.1 – 0.3) were entered into the 
sample size calculations and the largest sample size was chosen for the analyses.  
Table 3.5 represents the sample size estimates required for the Cox PH regression 
analyses. Based on the sample size estimates, a total sample size of 1,662 patients were required 







Table 3.5: Sample size estimates for Cox proportional hazards regression models 
Parameters      
B (log hazard ratio)a 1.50 1.50 1.50 1.50 1.50 
P (overall event rate)b 0.30 0.35 0.40 0.45 0.50 
R-squaredc 0.10 0.10 0.10 0.10 0.10 
Total sample size 1,292 1,108 969 862 776 
 
B (log hazard ratio) 1.50 1.50 1.50 1.50 1.50 
P (overall event rate) 0.30 0.35 0.40 0.45 0.50 
R-squared 0.20 0.20 0.20 0.20 0.20 
Total sample size 1,454 1,246 1,091 969 873 
 
B (log hazard ratio) 1.50 1.50 1.50 1.50 1.50 
P (overall event rate) 0.30 0.35 0.40 0.45 0.50 
R-squared 0.30 0.30 0.30 0.30 0.30 
Total sample size 1,662 1,424 1,246 1,108 997 
      
B (log hazard ratio) 2.00 2.00 2.00 2.00 2.00 
P (overall event rate) 0.30 0.35 0.40 0.45 0.50 
R-squared 0.10 0.10 0.10 0.10 0.10 
Total sample size 727 623 546 485 437 
 
B (log hazard ratio) 2.00 2.00 2.00 2.00 2.00 
P (overall event rate) 0.30 0.35 0.40 0.45 0.50 
R-squared 0.20 0.20 0.20 0.20 0.20 
Total sample size 818 701 614 546 491 
 
B (log hazard ratio) 2.00 2.00 2.00 2.00 2.00 
P (overall event rate) 0.30 0.35 0.40 0.45 0.50 
R-squared 0.30 0.30 0.30 0.30 0.30 
Total sample size 935 801 701 623 561 
α = 0.05 (two tailed); β = 0.20 (power = 80%);  
a Known as the regression coefficient defined as the predicted change in log(base e) hazards at one unit change in 
X1 when the other covariates are held constant;  
b Denotes the proportion of subjects in which the event of interest occurs during the duration of the study (Based 
on values reported in the across studies in the literature). The modeled event was medication discontinuation over a 
12-month follow-up period;  





3.5.4 Logistic regression models 
Logistic regression models allow for controlling the effects of confounders and are a 
common technique used for modelling binary dependent variables.117 The model is specified as 
follows: 
Figure 3.6: Logistic regression equation 
Log odds [Outcome] = β0 + β1X1 + βnXn + ε 
Where  
Outcome is a binary variable indicating type of therapy received.  
β0 = estimate for the intercept (i.e., when all the other variables are controlled for 
in the model) 
X1…Xn = Variables to be included in the model (demographic, physician, clinical 
characteristics, and prior utilization characteristics) 
β1 …βn = Corresponding predicted values associated with each variable  
Logistic regression analysis overcomes the restrictions posed by linear regression models 
that use OLS estimation principles. Logistic regression assumptions require that the variables 
should be nonlinear, independent variables are measured without error, and dependent variables 
are mutually exclusive and dichotomous in nature. Logistic regression uses a maximum 




 Model fit was tested based on the R2, Chi-square goodness of fit statistics, deviance test, 
and Hosmer-Lemeshow test. Chi-square tests help to determine if the model is correctly 
specified. R2 is a measure of how well the independent variables specified in the model explain 
the dependent variable.117 The Hosmer-Lemeshow test is similar to the Chi-square test where the 
observations are partitioned into deciles based on the predicted probabilities, thus making equal 
groups of observed and expected frequencies. 117 A statistically significant difference between 
the observed and the expected frequencies indicates poor model fit. 
Sample size estimations for logistic regressions were performed using the G*Power 
software. A wide range of parameters were tested and the largest sample size was chosen as the 
required sample size for logistic regression.  
Table 3.6 represents the sample sizes for different parameters. Based on the values 
tested, a total sample size of 4,248 patients (power = 0.80; 𝛼 = 0.05) were required for 









Table 3.6: Sample size estimates for logistic regression analysis 
Parameters     
Odds Ratio 1.50 2.00 2.50 3.00 
Pr (Y=1|X=1)Hoa 0.05 0.05 0.05 0.05 
R-squared 0.10 0.10 0.10 0.10 
Total sample size 3,766 1,158 615 405 
Odds Ratio 1.50 2.00 2.50 3.00 
Pr (Y=1|X=1)Hoa 0.05 0.05 0.05 0.05 
R-squared 0.20 0.20 0.20 0.20 
Total sample size 4,237 1,303 692 456 
Odds Ratio 1.50 2.00 2.50 3.00 
Pr (Y=1|X=1)Hoa 0.05 0.05 0.05 0.05 
R-squared 0.30 0.30 0.30 0.30 
Total sample size 4,248 1,489 791 521 
Y = dependent variable; X = independent variables (IV); α = 0.05 (two tailed); β = 0.20 (power = 80%); a binomial 
distribution was assumed for the IV of interest (X1);  













3.5.5 Multinomial logistic regression  
Multinomial logistic regressions (MLR) are used to predict likelihood of group 
membership relative to other groups based on multiple predictor variables.118 It is an extension of 
the logistic regression (with dichotomous outcomes) and accommodates two or more categories 
in the dependent variable. Similar to logistic regression, MLR uses maximum likelihood 
estimation technique to evaluate the probability of group membership. MLR does not assume 
normality, linearity, and homoscedasticity of the data. However, similar to regular logistic 
regression, it does require that the data meets the requirement for independence among 
dependent variable membership.   
The model is specified as follows: 
Figure 3.7: Multinomial logistic regression model 
Log odds [Outcome] = β0 + β1X1 + βnXn + ε 
Where  
Outcome is an ordinal variable indicating type of therapy received.  
β0 = estimate for the intercept (i.e., when all the other variables are controlled for 
in the model) 
X1…Xn = Variables to be included in the model (demographic, clinical, and prior 
utilization characteristics) 
β1 …βn = Corresponding predicted values associated with each variable  
Because no procedure for calculating sample sizes needed for multinomial logistic 
regression was found, the sample size estimates for binomial logistic regression (estimated in 
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section 3.5.4) were used.119,118 Therefore, a sample size of 4,248 patients was required for 
multinomial logistic regression analysis.  
3.5.6 Generalized Linear Models (GzLM) 
Cost data were analyzed using generalized linear models. GzLM is an extension of the 
traditional linear model and consists of three components:120 





xi = column vector of covariates for observation i  
𝜷 = column vector of unknown coefficients. 
Second, a monotonic differentiable link function ‘g’ which describes how the expected value of a 
response ‘yi’ is related to the linear predictor: 
g(𝜇i) = x’i𝛽 
Where 
𝝁i = E(yi) and  
Third, the response variables y1; y2; . . . are independent, each having a probability distribution 
from an exponential family: 




 ∅ = constant known as the dispersion parameter 
 V = function of the mean response 
The exponential family of probability distributions includes the normal (Gaussian), the 
binomial, the Poisson, the gamma, and the inverse Gaussian distributions. 
A Modified Park test was conducted to identify the distribution. A Vuong test was 
conducted to identify select the best model to model the healthcare utilization outcomes.121 The 
Vuong test measure uses the Kullback-Leibler information criterion to measure the closeness of 
the estimated model to the true model. Since we speculated that the source of zeros in the 
healthcare utilization could be a chance occurrence, ZIP and Poisson regression models were 
compared to identify the best fit model.  
Sample size estimation for the Poisson regression models used to model healthcare 
utilization was conducted using G*Power software. A range of baselines rates (5 to 20%) were 
tested to estimate the final sample size. The sample size required to detect at least 10% 
difference in healthcare utilization is listed in Table 3.7. Based on the values tested, a total 
sample size of 1,056 patients (power = 0.80; 𝛼 = 0.05,) was required for conducting a Poisson 





Table 3.7: Sample size estimates for Poisson regression analysis 
Parameters     
Base rate 0.05 0.1 0.2 
R-squared 0.1 0.1 0.1 
Total sample size 821 411 206 
Base rate 0.05 0.1 0.2 
R-squared 0.2 0.2 0.2 
Total sample size 924 462 231 
Base rate 0.05 0.1 0.2 
R-squared 0.3 0.3 0.3 
Total sample size 1,056 528 264 
A Modified Park test was conducted to identify the distribution and select the appropriate 
functional form and link function for cost outcomes as well.122 Cost data were adjusted to 2013 
dollars using the medical CPI index for 2013 (published by the Bureau of Labor Statistics.)  
Sample sizes for the GzLM were estimated using the linear regression test in the 
G*power software. Estimates were calculated using the fixed effects linear multiple regression 
model with R2 deviation from zero. Based on the number of predictor variables (n = 11), with a 









3.6 Sensitivity analyses 
 School-aged children may be given drug holidays to evaluate the therapeutic need and 
side-effect profile of ADHD medications. Previous research has shown that ADHD medications 
were associated with side-effects in school-aged children including stunted growth, reduced 
appetite, and difficulty falling asleep. These side-effects may be more pronounced in 
preschoolers than in school-aged children thus warranting a break in therapy to evaluate the 
therapeutic and side-effect profiles of ADHD medications. Moreover, parents may choose to 
avoid medications during holidays and weekends due to apprehension related to medication 
therapy management in preschoolers. To circumvent issues related to drug holidays, we 
conducted sensitivity analyses of medication persistence with 60- and 90-day allowable gap 
periods.   
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CHAPTER 4: RESULTS 
Chapter overview 
This chapter presents the study results describing the incidence, prevalence, treatment 
patterns, healthcare utilization, and costs in preschoolers with ADHD. Baseline demographic, 
clinical, and prior utilization characteristics are discussed for the “overall cohort” and the 
“treatment pattern cohort.” The results are discussed in the order stated in the methods section. 
Within each section, the hypotheses and associated statistical analyses are presented. 
4.1 Sample selection 
There were 7.2 million pediatric beneficiaries enrolled in Texas Medicaid across the six 
study years, 2008-2013. Overall, 71,071 patients with a diagnosis of ADHD between 2008 and 
2013 were eligible to be included in the study. After applying the inclusion and exclusion 
criteria, a total sample of 10,877 preschoolers between 2 and 6 years of age were identified. 
Objectives 2, 3a-c, 4 and 5 were analyzed using the “overall cohort.” Figure 4.1 shows the study 
selection flowchart for the overall cohort. A subsample of this population, the “treatment pattern 
cohort” (n = 8,833), was selected to address the treatment pattern objective 3d (i.e., adherence, 












Diagnosis of ADHD based on ICD-9 codes: 314.00 and 
314.01 between July 1, 2008 and August 31, 2012  
(n = 43,292) 
 
Have at least two ADHD medication claims or at least one 
psychotherapy visit indicated for the treatment of ADHD in 
index period  
(n = 28,640) 
Do not have any medication claim or psychotherapy visit in 
the 6-month pre-index period  
(n = 19,975) 
 
Continuous Medicaid enrollment for at least 6 months 
before and 12 months after the index date & < 6 years of age 
at index date 
(n = 10,939) 
 
Patients 2 - <6 years of age at index date 
(n = 10,877) 
Initial sample (identified by Texas Medicaid as ADHD 
patients) (n = 71,071) No claim for ADHD in 
the claims dataset 
(n = 27,779) 
< 2 ADHD medication 
claims or no 
psychotherapy visit in 
index period 
(n = 14,652) 
ADHD medication use 
or a psychotherapy visit 
in pre-index period 
(n = 8,665) 
Not continuously 
enrolled or ≥ 6 years at 
index date 
(n = 9,036) 
< 2 years of age at index 
date 
(n = 62) 
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4.2 Descriptive statistics 
The following paragraph provides a detailed description of the baseline characteristics in 
the “overall cohort” (n = 10,877) and the “treatment pattern cohort” (n = 8,833). The results for 
comparison of patient demographic, clinical, and prior utilization characteristics are also 
presented.  
4.2.1 Patient demographic, clinical, and prior utilization characteristics – overall cohort 
Demographic, clinical, and prior utilization characteristics of 10,877 preschoolers 
diagnosed with ADHD who were enrolled in Texas Medicaid are presented in Table 4.1. 
Overall, the mean age of preschoolers at diagnosis was 4.7(± 0.9) years. A higher proportion of 
patients were males (72.9%), Hispanics (51.1%), residing in urban areas (68.2%), without other 
mental health diagnosis (69.0%), without pre-index psychotropic medication use (95.2%), on 
long-acting medications (80.0%), and taking stimulants (89.0%). The patients in the overall 
group had 3.3 (± 4.4) pre-index non-psychiatric visits on average (±SD). The average (±SD) 
number of pre-index psychiatric visits in the overall cohort was 1.4 (± 6.7). The average (±SD) 
total pre-index cost in the overall cohort was $2,372.16 (± 4,999.66). The physician specialty 
variable was not included in the analysis due to questions regarding the validity of the data. 
4.2.2 Patient demographic, clinical, and prior utilization characteristics – treatment pattern 
cohort 
Demographic, clinical, and prior utilization characteristics of 8,833 preschoolers 
diagnosed with ADHD who were enrolled in Texas Medicaid and in the treatment pattern cohort 
are also presented in Table 4.1. Similar to the overall cohort, a higher proportion of patients 
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were males (72.9%), Hispanics (50.4%), residing in urban areas (68.3%), without other mental 
health diagnosis (64.8%), without pre-index psychotropic medication use (88.1%), taking long-
acting medications (68.6%), and taking stimulants (89.8%). The patients in the treatment cohort 
had 4.6 (± 5.3) pre-index non-psychiatric visits on average (± SD). The average (± SD) number 
of psychiatric visits in the treatment pattern cohort was 1.8 (± 7.6). The average (± SD) total 
pre-index cost in the treatment cohort was $2,525.42 (± 4,131.37).  
Table 4.1: Descriptive. Patient demographic, clinical, and prior utilization characteristics for the 




(n = 10,877) 
Treatment pattern  
cohortb 
(n = 8,833) 
Age (Mean +/- SD) 4.7 0.9 4.7 0.9 
Gender     
Female 2,944 27.1% 2,393 27.1% 
Male 7,933 72.9% 6,440 72.9% 
Race/Ethnicity      
White 2,584 23.8% 2,088 23.6% 
African American  1,657 15.2% 1,374 15.5% 
Hispanic 5,556 51.1% 4,447 50.4% 
Other/unknown 1,080 9.9% 924 10.5% 
Urban/rural status     
Urban 7,419 68.2% 6,035 68.3% 
Rural 3,458 31.8% 2,798 31.7% 
Pre-index psychotropic medications     
Yes 526 4.8% 1,049 11.9% 
No 10,351 95.2% 7,784 88.1% 
Other mental health diagnosis      
Yes 3,370 31.0% 3,108 35.2% 
No 7,507 69.0% 5,725 64.8% 
Long-acting medicationsc     
Yes 8,698 80.0% 6,059 68.6% 
No 2,179 20.0% - - 
Short-acting medicationsd     
Yes 4,391 40.4% 2,774 31.4% 
No 6,486 59.6% - - 
Stimulants     
Yes 9,681 89.0% 7,931 89.8% 




Table 4.1: Descriptive. Patient demographic, clinical, and prior utilization characteristics for the 




(n = 10,877) 
Treatment pattern 
cohortb 
(n = 8,833) 
Pre-index psychiatric visits  




6.7 1.8 7.6 
Pre-index non-psychiatric 
visits 






Total pre-index costs 




$4,999.66 $2,525.42 $4,131.37 
a Overall cohort includes patients with a diagnosis of ADHD identified between July 01, 2008 and August 01, 
2012 and followed for a 12-month period after the first ADHD diagnosis; 
b Treatment pattern cohort includes a subset of the overall cohort patients followed for a 12-month period after 
the first ADHD-related prescription; 
c,d Long-acting medication non-users in the treatment pattern cohort by default use short-acting medications, 
which differs from the definition used in the overall cohort; 















4.3 Objective 1: Prevalence and incidence of ADHD in preschoolers  
This part of the results provides insight into the epidemiology (i.e., prevalence and 
incidence) of ADHD in the Texas Medicaid preschool population between the years 2008 and 
2012. 
4.3.1 Prevalence 
Objective 1a: To determine the prevalence of ADHD in preschoolers <6 years of age enrolled in 
Texas Medicaid 
Table 4.2 presents the prevalence estimates of ADHD in preschoolers stratified by each 
year. The numbers of ADHD patients as defined for the prevalence estimates were 2,511 (2008), 
4,717 (2009), 7,049 (2010), 9,168 (2011), and 10,238 (2012). Prevalence rates for ADHD were 
estimated at 2.1, 3.9, 5.9, 7.6, and 8.5 per 1,000 enrollees for the years 2008, 2009, 2010, 2011, 
and 2012, respectively.  
Table 4.2: Descriptive. Estimated prevalence rates of ADHD in preschoolers enrolled in Texas 
Medicaid – stratified by year 
Year Number of ADHD patients  Prevalence/1,000a,b 
2008 2,511 2.1 
2009 4,717 3.9 
2010 7,049 5.9 
2011 9,168 7.6 
2012 10,238 8.5 
ADHD = Attention deficit hyperactivity disorder;  
a Numerator for the prevalence calculation included all the patients < 6 years of age diagnosed with ADHD with 12 
months of continuous enrollment in Texas Medicaid and taking at least 2 ADHD medications in the same year; 
b Denominator for the prevalence calculation was assumed to be 1.2 million enrollees each year based on a 2-year 







Objective 1b: To determine the incidence of ADHD in preschoolers <6 years of age enrolled in 
Texas Medicaid 
Table 4.3 presents the incidence estimates of newly diagnosed ADHD (as defined for the 
incidence estimates) in preschoolers stratified by year. The numbers of incident ADHD patients 
were 2,814 (2009), 3,154 (2010), 3,216 (2011), and 2,562 (2012). Incidence rates for ADHD 
were estimated at 2.4, 2.6, 2.7, and 2.1 per 1,000 enrollees for the years 2009, 2010, 2011, and 
2012, respectively.  
Table 4.3: Descriptive. Estimated incidence rates of ADHD in preschoolers enrolled in Texas 
Medicaid – stratified by year 
Year Number of newly diagnosed patients with ADHD Incidence/1,000a,b 
2009 2,814 2.4 
2010 3,154 2.6 
2011 3,216 2.7 
2012 2,562 2.1 
ADHD = Attention deficit hyperactivity disorder;  
a Numerator for incidence calculation included all the newly diagnosed ADHD patients < 6 years of age with 24 
months of continuous enrollment in Texas Medicaid and taking at least 2 medications in the same year (i.e., year of 
diagnosis); 
b Denominator for incidence calculation was assumed to be 1.2 million enrollees each year based on a 2-year 











4.4 Objective 2: Comparison of treatment groups with respect to patient demographics, 
clinical, and prior utilization characteristics 
Objective 2a: To determine and compare the patient demographic, clinical, and prior utilization 
characteristics between the pharmacotherapy only (RX), psychotherapy only 
(PSY), and pharmacotherapy + psychotherapy combined (RX+PSY) groups 
4.4.1 Overall cohort 
Table 4.4 provides a detailed description and comparison of patient demographic, 
clinical, and prior utilization characteristics between the pharmacotherapy, psychotherapy and 
combination therapy groups. Comparison of the pharmacotherapy, psychotherapy, and 
combination therapy groups revealed a similar trend in all the covariate categories. In all groups, 
a higher proportion of patients were male (72.9% vs. 74.1% vs. 72.9%; p = 0.79), Hispanic 
(50.8% vs. 60.6% vs 50.0%; p< 0.0001), residing in urban areas (68.3% vs. 73.1% vs. 67.3%; p 
= 0.01), did not have other mental health diagnosis (69.8% vs. 62.2% vs. 68.9%; p< 0.01), and 
were without pre-index psychotropic medication use (95.4% vs. 96.1% vs. 94.8%; p = 0.19). 
Chi-square tests revealed that the differences in proportions of race/ethnicity, urban/rural status, 
and other mental health diagnosis were statistically significant. Within race/ethnicity, a chi-
square test revealed that the proportion of Hispanics was relatively higher in the psychotherapy 
group as compared to the pharmacotherapy and combination therapy groups. The same 
relationship was seen for urban/rural status. Conversely, proportion of patients with other mental 
health diagnosis was lower in the psychotherapy group than the pharmacotherapy and 
combination therapy groups. By definition, patients in the psychotherapy only group did not 
have any medication use; however, the proportion of long-acting medication users was relatively 
high in the pharmacotherapy (83.9%) and combination therapy (86.0%) groups. Similarly, the 
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proportion of patients receiving stimulants was also relatively high in the pharmacotherapy 
(94.4%) and combination therapy (94.4%) groups. Analysis of age based on ANOVA revealed 
that the age at index was significantly different between the treatment groups. Age at index was 
lowest in the psychotherapy group (4.7 vs. 4.2 vs. 4.7; p < 0.0001) as compared to the 
pharmacotherapy and combination therapy groups. Kruskal-Wallis tests for continuous variables 
that did not satisfy the normality assumption revealed that pre-index office-based psychiatric, 
non-psychiatric visits, and total pre-index costs were significantly different between the three 
treatment groups. Pre-index psychiatric visits were slightly higher in the pharmacotherapy group 
as compared to the other groups (means = 1.5 visits vs. 1.4 visits vs. 1.3 visits; p < 0.01). 
Conversely, pre-index non-psychiatric visits were slightly higher in the in the psychotherapy 
group as compared to other groups (means = 3.2 visits vs. 4.5 visits vs. 3.2 visits; p < 0.0001). 
Average (±SD) total pre-index costs were higher in the psychotherapy group as compared to the 
other groups [$2,452.49 (± 5,186.51) vs. $2,632.26 (± $4,829.05) vs. $2,225.97 (± $4,756.58); 
p < 0.0001].  
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Table 4.4: Descriptive. Comparison of patient demographics, clinical, and prior utilization characteristics – stratified by treatment 
groups 
Characteristics  RX (n = 5,904) PSY (n = 622) RX+PSY (n = 4,351) Value p-value* 
Agea (Mean +/- SD) 4.7 0.9 4.2 0.9 4.7 0.9 185.1 <.0001 
Genderb       0.5 0.79 
Female 1,603 27.1% 161 25.9% 1,180 27.1%   
Male 4,301 72.9% 461 74.1% 3,171 72.9%   
Race/Ethnicityb       71.0 <.0001 
White 1,517 25.7% 119 19.1% 948 21.8%   
African American  813 13.8% 73 11.7% 771 17.7%   
Hispanic 3,002 50.8% 377 60.6% 2,177 50.0%   
Other/unknown 572 9.7% 53 8.6% 455 10.4%   
Urban/rural statusb       8.6 0.01 
Urban 4,034 68.3% 455 73.1% 2,930 67.3%   
Rural 1,870 31.7%       167  26.9% 1,421 32.7%   
Pre-index psychotropic medicationsb       3.3 0.19 
Yes 274 4.6% 24 3.9% 228 5.2%   
No 5,630 95.4% 598 96.1% 4,123 94.8%   
Other mental health diagnosisb       15.2 <.01 
Yes 1,783 30.2% 235 37.8% 1,352 31.1%   
No 4,121 69.8% 387 62.2% 2,999 68.9%   
Long-acting medicationsb       2640.4 <.0001 
Yes 4,955 83.9%          -   0.0% 3,743 86.0%   
No 949 16.1%    622  100.0% 608 14.0%   
Short-acting medicationsb       449.3 <.0001 
Yes 2,488 42.1%           -    0.0% 1,903 43.7%   
No 3,416 57.9%  622  100.0% 2,448 56.3%   
Stimulantsb       5340.1 <.0001 
Yes 5,574 94.4%             -    0.0% 4,107 94.4%   
No 330 5.6%     622  100.0% 244 5.6%   
Pre-index psychiatric visitsc  
(Mean +/- SD) 
         
1.5  
 
 7.3  
      
1.4  
 









Pre-index non-psychiatric visitsc  
(Mean +/- SD) 
      
  3.2  
 















Table 4.4: Descriptive. Comparison of patient demographics, clinical, and prior utilization characteristics – stratified by treatment 
groups (continued) 
Characteristics  RX (n = 5,904) PSY (n = 622) RX+PSY (n = 4,351) Value p-value* 
Total pre-index costsc  






 $2,632.26  
 
 $4,829.05  
 







*p < 0.05 (in bold); SD = Standard Deviation; RX = Pharmacotherapy only, PSY = Psychotherapy only; RX+PSY = Combination therapy;  
a Age was tested using ANOVA;  
b Chi-square tests were used for categorical variables;  
c Kruskal-Wallis tests were used for continuous variables; 




4.4.2 Treatment pattern cohort 
Table 4.5 provides a detailed description and comparison of patient demographic, 
clinical, and prior utilization characteristics between the pharmacotherapy and combination 
therapy groups. Comparison of the pharmacotherapy and combination therapy groups revealed 
similar trends across all categories. Chi-square tests revealed statistically significant differences 
in race/ethnicity, pre-index psychotropic medication use, and other mental health diagnosis 
between the pharmacotherapy and combination therapy groups. In both treatment groups, the 
proportion of patients were relatively high and similar for male gender (72.8% vs. 73.1%; p = 
0.77), Hispanic ethnicity (50.2% vs. 50.5%; p < 0.0001), urban residents (67.7% vs. 69.3%; p = 
0.11), without pre-index psychotropic medication use (89.0% vs. 86.8%; p < 0.01), and without 
other mental health diagnosis (66.3% vs. 62.5%; p < 0.01). Within race/ethnicity, although 
Hispanics formed the largest group, the proportion of African Americans (13.9% vs. 18.2%; p < 
0.0001) was higher in the combination therapy group as compared to the pharmacotherapy 
group. The proportion of long-acting medication initiators was relatively high in the 
pharmacotherapy (69.0%) and combination therapy (68.0%) groups. Short-acting medications 
were not included as a separate category in the treatment pattern cohort since by default, patients 
not receiving long-acting medications were taking short-acting medications. The proportion of 
patients receiving stimulants was also relatively high in the pharmacotherapy (90.0%) and the 
combination therapy (89.5%) groups. Age was tested using ANOVA and other continuous 
variables were tested using Kruskal-Wallis tests due to violation of the normality assumption. 
The mean age did not differ significantly between the pharmacotherapy and combination therapy 
groups. However, the average (±SD) pre-index psychiatric visits was higher in the 
pharmacotherapy group as compared to the combination therapy group (2.0 visits vs. 1.6 visits; p 
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< 0.01). Conversely, the average (±SD) pre-index non-psychiatric visits was higher in the 
combination therapy group as compared to the pharmacotherapy group (5.3 visits vs. 4.1 visits; 
p< 0.0001). Average (±SD) total pre-index costs was higher in the pharmacotherapy group as 
compared to the combination therapy group ($2,577.52 [±$4,532.10] vs. $2,444.17 [±$3,412.86]; 
p < 0.0001).  
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Table 4.5: Descriptive. Comparison of patient demographics, clinical, and prior utilization characteristics – stratified by treatment 
groups (treatment pattern cohort) 
Characteristics RX (n = 5,382) RX+PSY (n = 3,451) Value p-value* 
Agea (Mean +/- SD) 4.7 0.9 4.7 0.9 0.0 0.83 
Genderb     0.1 0.77 
Female 1,464 27.2% 929 26.9%   
Male 3,918 72.8% 2,522 73.1%   
Race/Ethnicityb     50.9 <.0001 
White 1,383 25.7% 705 20.4%   
African American  746 13.9% 628 18.2%   
Hispanic 2,703 50.2% 1,744 50.5%   
Unknown/Other  550 10.2% 374 10.8%   
Urban/rural statusb     2.6 0.11 
Urban 3,643 67.7% 2,392 69.3%   
Rural 1,739 32.3% 1,059 30.7%   
Pre-index psychotropic medicationsb     9.7 <.01 
Yes 593 11.0% 456 13.2%   
No 4,789 89.0% 2,995 86.8%   
Other mental health diagnosisb              13.6  <.01 
Yes 1,813 33.7% 1,295 37.5%   
No 3,569 66.3% 2,156 62.5%   
Long-acting medicationsb     0.8 0.37 
Yes 3,711 69.0% 2,348 68.0%   
No 1,671 31.0% 1,103 32.0%   
Stimulantsb     1.0 0.31 
Yes 4,844 90.0% 3,087 89.5%   
No 538 10.0% 364 10.5%   
Pre-index psychiatric visitsc (Mean +/- SD)         2.0           8.2           1.6         6.5  13.6 <.01 
Pre-index non-psychiatric visitsc (Mean +/- SD)         4.1            5.0           5.3          5.6  170.8 <.0001 
Total pre-index costsc (Mean +/- SD) $2,577.52 $4,532.10 $2,444.17 $3,412.86 32.2 <.0001 
*p < 0.05 (in bold); SD = Standard Deviation; RX = Pharmacotherapy only, PSY = Psychotherapy only; RX+PSY = Combination therapy; 
a Age was tested using ANOVA;  
b Chi-square tests were used for categorical variables;  
c Wilcoxon-Mann-Whitney tests were used for continuous variables;  
Cost adjusted to 2013 dollars 
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4.5 Objective 3: Treatment patterns in preschoolers with ADHD 
Objective 3 was to assess the treatment patterns including time-to-initiation, medication 
adherence, persistence, augmentation, and switching.  
4.5.1 Time-to-initiation of first pharmacotherapy, psychotherapy, and combination therapy  
Objective 3a: To determine the time to “first pharmacotherapy,” “first psychotherapy,” or “first 
combination therapy” 
Time-to-initiation of RX, PSY, or RX+PSY was measured as the number of days 
between the first ADHD diagnosis and the date of receiving the first ADHD-related treatment 
(i.e., “first RX,” “first PSY,” or “first RX+PSY”). The definitions used for first RX 
(pharmacotherapy initiators), first PSY (psychotherapy initiators), and first RX+PSY 
(combination therapy initiators) for this analysis vary from the definitions used for RX, PSY, and 
RX+PSY in the rest of the study. For this objective, patients were categorized into one of the 
three groups based on the initial therapy received. Patients initiating both psychotherapy and 
pharmacotherapy on the same day were categorized in the combination therapy group. 
Table 4.6 shows the descriptive statistics for time-to-initiation of first therapy (i.e., 
pharmacotherapy initiators, psychotherapy initiators, or combination therapy initiators). Of the 
patients diagnosed with ADHD, a higher proportion of patients initiated pharmacotherapy (n = 
7,184; 66.0%), followed by psychotherapy (n = 3,513; 32.3%), and combination therapy (n = 
180; 1.7%). The mean time-to-therapy was smallest for the psychotherapy initiators (43.0 ± 89.7 
days) followed by combination therapy initiators (68.9 ± 92.7 days), and pharmacotherapy 




Table 4.6: Descriptive. Time-to-initiation of pharmacotherapy, psychotherapy, or combination 
therapy after ADHD diagnosis 
Treatment initiators 
(N = 10,877) 




Pharmacotherapy initiatorsa 7,184 66.0% 107.4 112.1 67.0 
Psychotherapy initiatorsb 3,513 32.3% 43.0 89.7 15.0 
Combination therapy initiatorsc 180 1.7% 68.9 92.7 28.0 
SD = Standard deviation; 
a Pharmacotherapy initiators include patients who were started on pharmacotherapy irrespective of the type of 
therapy they received later; 
b Psychotherapy initiators include patients who were started on psychotherapy irrespective of the type of therapy 
they received later; 
c Combination therapy initiators include patients who were started on pharmacotherapy and psychotherapy on the 
same day irrespective of the type of therapy they received later 
 
Objective 3b: To compare the time to first pharmacotherapy, time to first psychotherapy, and 
time to first combination therapy in preschoolers with ADHD and to compare 
time-to-pharmacotherapy with respect to gender, race, and medication duration of 
action 
H03b1: There is no difference in time-to-initiation of first pharmacotherapy (“first RX”), first 
psychotherapy (“first PSY”), and “first combination therapy” - Rejected 
Table 4.7 presents the unadjusted Cox proportional hazards regression estimates for 
comparison of time-to-initiation of first pharmacotherapy, first psychotherapy, and first 
combination therapy in preschoolers with ADHD. Time-to-initiation was significantly different 
between the pharmacotherapy initiators, psychotherapy initiators, and combination therapy 
initiators. The hazard rate of psychotherapy initiators was 82.7% higher as compared to 
pharmacotherapy initiators (𝛽 = 0.602; HR = 1.827; x2= 800.7; p = <0.0001). Similarly, the 
hazard rate of combination therapy initiators was 40.8% higher as compared to pharmacotherapy 
initiators (𝛽 = 0.342; HR = 1.408; x2= 20.5; p = <0.0001). Figure 4.2 represents the time-to-
initiation curves for pharmacotherapy initiators, psychotherapy initiators, and combination 
therapy initiators. The median time-to-initiation for psychotherapy was 15 days, followed by 
combination therapy (28 days) and psychotherapy initiators (67 days).   
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Table 4.7: Cox proportional hazards regression. Comparison of time-to-initiation of 
pharmacotherapy initiators, psychotherapy initiators, and combination therapy 
initiators  
Treatment initiators 
(N = 10,877) 
𝜷 HR x2 p-value 
Pharmacotherapy initiatorsa Reference 
Psychotherapy initiatorsb 0.602 1.827 800.7 <.0001 
Combination therapy initiatorsc 0.342 1.408 20.5 <.0001 
*p < 0.05 (in bold); 𝛽= Log Hazard Rate (parameter estimate); HR = Hazard Ratio; x2 = Chi-square; 
a Pharmacotherapy initiators include patients who were started on pharmacotherapy irrespective of the type of therapy 
they received later; 
b Psychotherapy initiators include patients who were started on psychotherapy irrespective of the type of therapy they 
received later; 
a Combination therapy initiators include patients who were started on pharmacotherapy and psychotherapy on the 
same day irrespective of the type of therapy they received later 
 
Figure 4.2: Kaplan-Meier estimate of time-to-therapy for pharmacotherapy, psychotherapy, and 
combination therapy initiators (N = 10,877) 
 
Time-to-initiation (days)  
 
Median time-to-therapy 
Pharmacotherapy initiators (RX) (n = 7,184)  67 days 
Psychotherapy initiators (PSY) (n= 3,513)  15 days 




4.5.2 Time-to-pharmacotherapy with respect to gender, race/ethnicity, and medication 
duration of action 
Figures 4.3, 4.4, and 4.5 show time-to-pharmacotherapy according to gender, 
race/ethnicity, and medication duration of action. As shown in Table 4.8, time-to-
pharmacotherapy did not differ significantly with respect to gender. Time-to-pharmacotherapy 
was significantly different among certain race/ethnicity groups, and medication duration of 
action.    
Figure 4.3: Time-to-pharmacotherapy stratified by gender (N = 7,184) 
 
Y = Survival probability (proportion of patients); X = Time-to-therapy (in days); 
Estimated using Log-Rank test; + censored observations include patients receiving psychotherapy 





Males ------ 70 days 
Females ------ 61 days 
 
              Males                                          Females 
Time-to-therapy (in days) 
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Figure 4.4: Time-to-pharmacotherapy stratified by race/ethnicity (N = 7,184) 
 
Y = Survival probability (proportion of patients); X = Time-to-therapy (in days); 
Estimated using Cox proportional hazard regression; + censored observations include patients 













Time-to-therapy (in days) 
          Whites             Hispanics            African American             Other/unknown 
Median time-to-pharmacotherapy 
African American ------ 43 days 
Whites ------ 52 days 
Hispanic ------ 82 days 




Figure 4.5: Time-to-pharmacotherapy stratified by medication duration of action (N = 7,184) 
 
Y = Survival probability (proportion of patients); X = Time-to-therapy (in days);  
Estimated using Log-Rank test; + censored observations include patients receiving psychotherapy 













Time-to-therapy (in days) 
              Short-acting                           Long-acting 
Median time-to-pharmacotherapy 
Long-acting ------ 68 days 




H03b2: There is no significant difference in the time-to-initiation of RX in male vs. female ADHD 
patients – Failed to reject 
H03b3: There is no significant difference in the time-to-initiation of RX in different race/ethnicity 
groups diagnosed with ADHD – Rejected for Hispanic vs. White and for                      
Others/unknown vs. White 
H03b4: There is no significant difference in the time-to-initiation of RX with respect to long-
acting (LA) vs. short-acting (SA) medications in ADHD patients – Rejected 
H03b5: There is no significant difference in the time-to-initiation of RX by physician specialty –
Could not test 
Table 4.8 represents results for time-to-pharmacotherapy according to gender, 
race/ethnicity, and medication duration of action. Compared to Whites (100.0 ± 111.6 days), the 
mean time-to-pharmacotherapy was significantly higher in Hispanics (115.1 ± 112.6 days; p < 
0.0001) and other/unknown races (106.2 ± 112.1 days; p = 0.03). Similarly, compared to short-
acting medication users (103.0 ± 108.0 days), the mean time-to-pharmacotherapy was 
significantly higher in the long-acting (109.3 ± 113.8 days; p<0.01) medication users. We could 
not test time-to-initiation of RX with respect to physician specialty due to issues surrounding the 









Table 4.8: Cox proportional hazards regression/Log-rank test. Time-to-pharmacotherapy 
stratified according to gender, race/ethnicity, and medication duration of action (N = 
7,184) 
Characteristics N % Mean 
(days) 
SD Median  
(days) 
x2 p-value* 
Gendera        
Male 5,233 72.8% 108.6 107.6 70.0 1.8 0.17 
Female 1,951 27.2% 104.1 107.1 61.0   
Race/Ethnicityb        
White 1,765 24.6% 100.0 111.6 52.0   
African American  1,028 14.3% 93.4 109.2 43.0 0.8 0.37 
Hispanic 3,680 51.2% 115.1 112.6 82.0 25.3 <.0001 
Others/unknown 711 9.9% 106.2 112.1 66.0 4.9 0.03 
Medication duration of 
actiona,c  
 
   
  
Long-acting medication 5,041 70.2% 109.3 113.8 68.0 7.9 <.01 
Short-acting medication  2,143 29.8% 103.0 108.0 67.0   
*p < 0.05 (in bold); SD = Standard deviation; x2 = Chi Square; 
a Log-rank test was used to test gender and medication duration of action;  
b Cox proportional hazards regression (unadjusted) was used to test race/ethnicity;  
c Long-acting medications and short-acting medications are defined based on the type of medications the patients were 
















4.5.3 Multinomial logistic regression – predictors of treatment group membership 
Objective 3c: To assess the factors associated with receiving RX, PSY, or RX+PSY treatments 
Table 4.9 presents the results for multinomial logistic regression comparing the factors 
associated with receiving pharmacotherapy, psychotherapy, or combination therapy treatments, 
after controlling for covariates. The results for the multinomial logistic regression reveal that a 
one-year increase in age was significantly associated with 44.0% lower odds of receiving 
psychotherapy as compared to pharmacotherapy (Odds ratio [OR] = 0.560; Confidence Interval 
[CI] = 0.510 – 0.615; p <0.0001) while controlling for covariates. Patients with one additional 
pre-index non-psychiatric visit (OR= 1.050; CI = 1.033 – 1.068; p < 0.0001) had a 5% higher 
odds of receiving psychotherapy as compared to pharmacotherapy, while controlling for 
covariates. Compared to Whites, Hispanic patients had a 30.5% higher odds of receiving 
psychotherapy (OR= 1.305; CI = 1.022 – 1.666; p = 0.03) as compared to pharmacotherapy, 
while controlling for covariates. Similarly, compared to patients with no other psychotropic use, 
patients receiving other psychotropics (OR= 1.687; CI = 1.082 – 2.628; p = 0.02) had a 68.7% 
higher odds of receiving psychotherapy as compared to pharmacotherapy, while controlling for 
covariates. Compared to patients with no other mental disorders, the patients diagnosed with 
other mental disorders (OR= 1.294; CI = 1.073 – 1.560; p = 0.01) had a 29.4% higher odds of 
receiving psychotherapy as compared to pharmacotherapy, while controlling for covariates.  
Comparison of combination therapy group with pharmacotherapy revealed that compared 
to Whites, African Americans (OR= 1.554; CI = 1.366 – 1.768; p < 0.0001), Hispanics (OR = 
1.181; CI = 1.059 – 1.317; p < 0.01), other/unknown race/ethnicity (OR= 1.291; CI = 1.111 – 
1.500; p <0.01),  had a 55.4%, 18.1%, 29.1% higher odds, respectively,  of receiving 
combination therapy as compared to pharmacotherapy, while controlling for covariates. 
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Compared to patients with no other mental disorders, the patients diagnosed with other mental 
diagnosis (OR= 1.201; CI = 1.101 – 1.311; p < 0.0001) were associated with a 20.1% higher 
odds, of receiving combination therapy as compared to pharmacotherapy, while controlling for 
covariates. Although, total pre-index costs were significant according to the p-value, the 
confidence interval crosses 1 and was considered non-significant for the psychotherapy and 
combination therapy groups.  
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Table 4.9: Multinomial logistic regression. Factors associated with receiving pharmacotherapy (RX), psychotherapy (PSY), or 
combination therapy (RX+PSY) 
 PSY (N = 622) RX+PSY (N = 3,451) 
Characteristics OR 95% CI x2 p-value OR 95% CI x2 p-value* 
Agea  0.560 0.510 – 0.615 146.2 <.0001 1.012 0.965 – 1.061 0.2 0.63 
Total pre-index costsa 1.000 1.000 – 1.000 6.7 0.01 1.000 1.000 – 1.000 7.6 0.01 
Pre-index psychiatric visitsa 0.989 0.974 – 1.004 2.2 0.14 0.994 0.987 – 1.000 3.9 0.05 
Pre-index non-psychiatric visitsa 1.050 1.033 – 1.068 32.4 <.0001 1.009 0.999 – 1.019 2.9 0.09 
Gender         
Male Reference Reference 
Female 0.945 0.781 – 1.144 0.3 0.56 1.005 0.920 – 1.098 0.0 0.91 
Race/Ethnicity         
Whites Reference Reference 
African American  1.224 0.899 – 1.667 1.7 0.20 1.554 1.366 – 1.768 44.7 <.0001 
Hispanics 1.305 1.022 – 1.666 4.6 0.03 1.181 1.059 – 1.317 8.9 <.01 
Other/unknown 1.044 0.738 – 1.476 0.1 0.81 1.291 1.111 – 1.500 11.1 <.01 
Urban/Rural status         
Urban Reference Reference 
Rural 1.090 0.880 – 1.350 0.6 0.43 1.091 0.994 – 1.199 3.3 0.07 
Other pre-index psychotropics         
No Reference Reference 
Yes 1.687 1.082 – 2.628 5.3 0.02 1.150 0.955 – 1.384 2.2 0.14 
Other mental health diagnosis          
No Reference Reference 
Yes 1.294 1.073 – 1.560 7.3 0.01 1.201 1.101 – 1.311 16.8 <.0001 
*p < 0.05 (in bold); Reference class= Pharmacotherapy (N = 5,382); OR = Odds Ratio; x2 = Chi-square; CI = Confidence Interval; PSY = Psychotherapy only 
group (N = 622); RX+PSY = Combination therapy group (N = 3,451);  
a Recorded as a continuous variable in the model; 





4.5.4 Medication adherence, persistence, augmentation and switching 
Objective 3d: To compare adherence, discontinuation (medication persistence), switching, and 
augmentation of pharmacotherapy between the RX and the RX+PSY groups 
4.5.4.1 Medication adherence 
Table 4.10 presents the mean adherence rates to index medications for the 
pharmacotherapy and combination therapy groups for the treatment pattern cohort. The mean 
(±SD) adherence rate (proportion of days covered) was 0.48 (± 0.3) in the pharmacotherapy 
group and 0.50 (±0.3) in the combination therapy group. 
Table 4.10: Descriptive statistics. Medication adherence rate stratified by treatment groups 
Treatment group N % Mean SD Median 
RX 5,382 60.9% 0.48 0.3 0.44 
RX+PSY 3,451 39.1% 0.50 0.3 0.49 
Overall 8,833 100.0% 0.48 0.3 0.46 
SD = Standard Deviation; RX = Pharmacotherapy; PSY = Psychotherapy; RX+PSY = Combination therapy; 
Adherence to index medications was measured using proportion of days covered methodology 
 
Table 4.11 provides a chi-square comparison of the proportion of patients between the 
pharmacotherapy and the combination therapy groups according to adherence status. Patients 
with a PDC ≥ 80% were defined as adherent and those with a PDC < 80% were defined as non-
adherent. A majority of the patients were non-adherent in the pharmacotherapy (n = 4,244; 








Table 4.11: Chi-square test. Adherence (dichotomous) stratified by treatment groups 
Treatment group 
(N = 8,833) 
RX (n = 5,382) RX+PSY (n = 3,451) x2 p-value 
   2.3 0.13 
Adherence status n % n %   
Adherenta,b 1,138 21.1% 777 22.5%   
Non-adherenta,b 4,244 78.9% 2,674 77.5%   
Total 5,382 100.0% 3,451 100.0%   
RX = Pharmacotherapy; PSY = Psychotherapy; RX+PSY = Combination therapy; x2 = Chi-square; 
a Adherence to index medications was measured using proportion of days covered (PDC) methodology;  
b PDC ≥ 80% was defined as adherent and < 80% was defined as non-adherent 
Table 4.12 presents results for a t-test comparison of adherence as a continuous measure 
between the pharmacotherapy and combination therapy groups. The mean (±SD) adherence rate 
was significantly higher (t = 2.9, p < 0.01) in the combination therapy group (0.50 [±0.3]) as 
compared to the pharmacotherapy group (0.48 [±0.3]); however, this difference was very small.   
Table 4.12: T-test. Adherence (continuous) stratified by treatment groups 
Treatment group 
(N = 8,883) 
N % Meana SD 95% CI t-value p-value* 
      2.9 <.01 
RX 5,382 60.9% 0.48 0.30 0.47 - 0.48   
RX+PSY 3,451 39.1% 0.50 0.31 0.49 - 0.51   
*p < 0.05 (in bold); SD = Standard Deviation; CI = Confidence Interval; RX = Pharmacotherapy; PSY = 
Psychotherapy; RX+PSY = Combination therapy; 
aAdherence to index medications was measured using proportion of days covered (PDC) methodology 
  
Table 4.13 shows the result for linear regression analysis of adherence as a continuous 
measure between the pharmacotherapy and combination therapy groups, after controlling for 
covariates. The adherence rate for the index medication was significantly lower in the 
pharmacotherapy group (𝛽 = -0.021; t = -3.10; p < 0.01) as compared to the combination therapy 
group. Adherence in the pharmacotherapy group was lower by a factor of -0.021 as compared to 
the combination therapy group, while controlling for covariates. Although significant, difference 
in adherence between the pharmacotherapy and combination therapy group was small. Tolerance 
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and variance inflation factors for the main independent variable as well as the covariates did not 
reveal multi-collinearity among the selected variables.    
Table 4.13: Linear regression. Medication adherence (continuous) by treatment group (N = 
8,883) – after controlling for covariates 
Characteristics Estimate t value p-value* Tolerance VIF 
Pharmacotherapya  -0.021 -3.10 <.01 0.980 1.021 
Covariates 
Age 0.026 6.55 <.0001 0.874 1.144 
Pre-index psychiatric visits 0.000 0.23 0.81 0.886 1.128 
Pre-index non-psychiatric visits -0.001 -0.78 0.43 0.849 1.178 
Total pre-index costs 0.000 0.25 0.80 0.723 1.382 
Female -0.020 -2.79 0.01 0.994 1.006 
Non-whites -0.022 -6.20 <.0001 0.862 1.160 
Rural 0.020 2.72 0.01 0.869 1.151 
Other psychotropics -0.001 -0.11 0.91 0.951 1.052 
Other mental health diagnosis 0.011 1.51 0.13 0.796 1.256 
Long-acting medications 0.023 2.44 0.01 0.941 1.063 
Stimulants -0.031 -2.10 0.04 0.981 1.019 
*p < 0.05 (in bold); VIF = Variance Inflation Factor; a Combination therapy group was the primary reference group 
H03d1: There is no significant difference in the medication adherence status between the RX and 
the RX+PSY groups, after controlling for covariates – Rejected 
Table 4.14 presents the results for a logistic regression analysis of adherence status 
between the pharmacotherapy and combination therapy group, after controlling for covariates. 
After controlling for covariates, the odds of adherence were 11.1% lower in the pharmacotherapy 
group as compared to the combination therapy group (OR = 0.889; CI = 0.799 – 0.988; p = 0.03). 
Model fit was assessed using deviance and Pearson goodness-of-fit statistic and the Hosmer-
Lemeshow test. Deviance and Pearson goodness-of-fit statistics were non-significant indicating 
that the model-fit was appropriate. However, since the number of unique values was too high (n 
= 8,831) this test result was considered invalid. Another model fit test, the Hosmer-Lemeshow 
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test, did not detect significant differences between the observed and predicted values thus 
validating adequate model fit.  
Covariates that were significantly associated with higher odds of being adherent included 
increasing age and long-acting medication use. Conversely, the covariates significantly 
associated with lower odds of being adherent included females, Hispanics, African Americans, 















Table 4.14: Logistic regression. Adherence status by pharmacotherapy and combination therapy 
treatment groups (N = 8,883) – after controlling for covariates 
Characteristics OR 95% CI x2 p-value* 
Pharmacotherapy 0.889 0.799 – 0.988 4.8 0.03 
Covariates 
Agea 1.123 1.053 – 1.197 12.5 <.01 
Pre-index psychiatric visitsa 1.003 0.996 – 1.010 0.6 0.46 
Pre-index non-psychiatric visitsa  0.994 0.983 – 1.005 1.2 0.28 
Total pre-index costsa 1.000 1.000 – 1.000  0.4 0.52 
Gender     
Males Reference 
Females 0.865 0.768 – 0.973 5.9 0.02 
Race/Ethnicity     
Whites Reference 
African Americans  0.508 0.430 – 0.599 63.9 <.0001 
Hispanics 0.513 0.449 – 0.587 94.2 <.0001 
Others/unknown  0.585 0.485 – 0.706 31.1 <.0001 
Urban/rural status     
Urban Reference 
Rural 1.071 0.951 – 1.207 1.3 0.26 
Other psychotropics     
No Reference 
Yes 1.057 0.897 – 1.245 0.4 0.51 
Other mental health diagnosis     
No Reference 
Yes 1.073 0.955 – 1.205 1.4 0.24 
Medication duration of action     
Short-acting medications Reference 
Long-acting medications 1.591 1.346 – 1.882 29.5 <.0001 
Medication type     
Non-stimulants Reference 
Stimulants 0.737 0.594 – 0.913 7.8 0.01 
*p < 0.05 (in bold); OR = Odds Ratio; CI = Confidence Interval; x2= Chi-square; 
a Recorded as a continuous variable in the model; 
Adherence to index medications was measured using proportion of days covered (PDC) methodology;  







4.5.4.2 Medication persistence 
Table 4.15 presents the mean medication persistence of the index medication for the 
pharmacotherapy and combination therapy groups. The mean (±SD) medication persistence was 
141.8 (±127.2) days in the combination therapy group and 137.1 (±127.3) days in the 
pharmacotherapy group.  
Table 4.15: Descriptive. Medication persistence (continuous) stratified by treatment groups 
Treatment group 
(N = 8,883) 
N % Mean (days) SD Median (days) 
RX 5,382  60.9% 137.1 127.3 79.0 
RX+PSY 3,451  39.1% 141.8 127.2 87.0 
Overall 8,833  100.0% 139.0 127.3 82.0 
SD = Standard Deviation; RX = Pharmacotherapy; RX+PSY = Combination therapy; Persistence measured over a 
365-day follow-up period with a 30-day allowable gap 
 
Table 4.16 shows the results of a t-test comparison of mean medication persistence 
between the pharmacotherapy and combination therapy groups. There was no statistically 
significant difference (t = 1.7, p = 0.09) in the mean persistence between the pharmacotherapy 
and combination therapy groups.  
Table 4.16: T-test. Medication persistence (continuous) stratified by treatment groups 
Treatment group 
(N = 8,883) 
N Mean (days)a SD 95% CI t-value p-value 
     1.7 0.09 
RX 5,382  137.1 127.3 133.7 – 140.5   
RX+PSY 3,451  141.8 127.2 137.6 – 146.1   
SD = Standard Deviation; CI = Confidence Interval; RX = Pharmacotherapy; PSY = Psychotherapy; RX+PSY = 
Combination therapy; 
a Persistence was calculated over a 365-day period with a 30-day allowable gap 
 
Table 4.17 shows the result for linear regression analysis of medication persistence as a 
continuous measure between the pharmacotherapy and combination therapy groups, after 
controlling for patient demographics, clinical, and prior utilization characteristics. Medication 
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persistence for the index medication was significantly lower in the pharmacotherapy group (𝛽 = -
5.617; t-value = -2.02; p = 0.04) as compared to the combination therapy group. Persistence in 
the combination therapy group was lower by approximately 6 days as compared to the 
combination therapy group, after controlling for covariates. Tolerance and variance inflation 
factors for the main independent variable as well as the covariates did not indicate multi-
collinearity among the selected variables.    
Table 4.17: Linear regression. Persistence (continuous) by treatment groups (N = 8,883) – after 
controlling for covariates 
Characteristics Estimate t-value p-value Tolerance VIF 
Pharmacotherapy  -5.617 -2.02 0.04 0.980 1.021 
Covariates 
Age 9.913 6.07 <.0001 0.876 1.142 
Pre-index psychiatric visits 0.052 0.28 0.78 0.886 1.129 
Pre-index non-psychiatric visits -0.366 -1.32 0.19 0.848 1.179 
Total pre-index costs 0.000 0.24 0.81 0.727 1.376 
Females -10.847 -3.59 <.01 0.995 1.005 
Non-whites -12.517 -8.69 <.0001 0.930 1.076 
Rural 2.919 1.93 0.05 0.983 1.017 
Other psychotropic 1.541 0.36 0.72 0.952 1.050 
Other mental health diagnosis 2.262 0.75 0.46 0.802 1.247 
Long acting medications 14.765 3.81 <.01 0.940 1.064 
Stimulants -18.635 -3.05 <.01 0.981 1.020 
*p < 0.05 (in bold); VIF = Variance Inflation Factor; Combination therapy group was the primary reference group 
 
H03d2: There is no significant difference in time to discontinuation of index therapy between the 
RX and the RX+PSY groups, after controlling for covariates – Failed to reject  
Table 4.18 shows the Cox proportional hazards regression of persistence as a continuous 
measure between the pharmacotherapy and combination therapy groups, after controlling for 
covariates. The hazard rate of discontinuation of medication therapy did not differ significantly 
between the pharmacotherapy and combination therapy treatment groups (HR = 1.044; CI = 
0.997 – 1.093; p = 0.07.) Proportional hazards assumptions were tested using the Schoenfeld 
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residuals test (Appendix III). The results show that the curves for all the covariates were close to 
zero, indicating that the proportional hazards assumption was not violated. 
Covariates that were significantly associated with higher hazard rates of discontinuation 
included females, African American, Hispanics, Other/unknown race/ethnicity, and stimulant 
medication use. Conversely, covariates significantly associated with lower hazard rates of 
discontinuation included age, rural residence status, and long-acting medication use. Figure 4.6 



















Table 4.18: Cox proportional hazards regression. Determinants of time to discontinuation 
between pharmacotherapy and combination therapy groups (N = 8,883) – after 
controlling for covariates 
Characteristics HR 95% CI x2 p-value* 
Pharmacotherapy  1.044 0.997 – 1.093 3.3 0.07 
Covariates 
Agea 0.920 0.895 – 0.945 36.1 <.0001 
Pre-index psychiatric visitsa 1.000 0.997 – 1.003 0.0 0.87 
Pre-index non-psychiatric visitsa  1.005 1.000 – 1.009 3.8 0.05 
Total pre-index costsa 1.000 1.000 – 1.000 0.5 0.46 
Gender     
Males Reference 
Females 1.099 1.045 – 1.155 13.6 <.01 
Race/Ethnicity     
Whites Reference 
African Americans  1.355 1.257 – 1.460 63.5 <.0001 
Hispanics 1.319 1.239 – 1.405 74.1 <.0001 
Others/unknown  1.257 1.154 – 1.370 27.3 <.0001 
Urban/rural status     
Urban Reference 
Rural 0.938 0.889 – 0.990 5.4 0.02 
Other psychotropics     
No Reference 
Yes 0.987 0.920 – 1.060 0.1 0.72 
Other mental health diagnosis     
No Reference 
Yes 0.983 0.934 – 1.035 0.4 0.52 
Medication duration of action     
Short-acting medications Reference 
Long-acting medications 0.876 0.822 – 0.933 16.8 <.0001 
Medication type     
Non-stimulants Reference 
Stimulants 1.151 1.037 – 1.278 6.9 0.01 
*p < 0.05 (in bold); HR = Hazard Ratio; CI = Confidence Interval; x2= Chi-square; 
a Recorded as a continuous variable in the model; 







Figure 4.6: Survival curve of time to discontinuation (N = 8,883) 
 
Y = Survival probability (proportion of patients); X = Persistence [time to discontinuation (in days)]; 
Estimated using Cox proportional hazard regression while adjusting for age, race/ethnicity, gender, pre-
index psychiatric visits, pre-index non-psychiatric visits, pre-index total costs, other psychotropics, other 
mental health diagnosis, long-acting medications, short-acting medications, and stimulants;  







Persistence (in days)  
     RX +PSY = 0                RX = 1 
Median time to discontinuation 
RX+PSY ------ 87 days 





Medication augmentation was defined as starting an alternative ADHD medication 
(different chemical entity) along with the index medication with an overlap of at least 30 days.  
Table 4.19 shows the proportion of patients by augmentation status. A majority of the 
patients did not augment (n = 7,904; 89.5%) their index medication therapy with another ADHD 
medication. Overall, 10.5% of the patients from the treatment pattern cohort augmented therapy 
with an alternative ADHD medication with an overlap of at least 30 days.  
Table 4.19: Descriptive statistics. Proportion of patients augmenting medications with their 
index medication  
Augmentationa Frequency % 
Yes 929 10.5% 
No 7,904 89.5% 
Yes = Augmented; No = Did not augment; 
a Augmentation was defined as initiation of a new ADHD medication (chemical entity) with a continuous overlap of 
at least 30 days with the index medication  
 
Table 4.20 reports the chi-square results for the proportion of patients augmenting 
medications in the pharmacotherapy and combination therapy groups. Nearly 9.2% (n = 495) 
patients augmented medication in the pharmacotherapy group as compared to 12.6% (n = 434) 
patients in the combination therapy group. The difference in proportions of patients augmenting 
medications was statistically significant (x2 = 25.5; p < 0.0001) between the pharmacotherapy 








Table 4.20: Chi-square test. Proportion of patients augmenting medications in the 
pharmacotherapy and combination therapy groups 
Treatment group 
(N = 8,883) 
RX RX+PSY x2 p-value* 
   25.5 <.0001 
Augmentationa n % n %   
Yes 495 9.2% 434 12.6%   
No 4,887 90.8% 3,017 87.4%   
*p < 0.05 (in bold); RX = Pharmacotherapy; PSY = Psychotherapy; RX+PSY = Combination therapy; x2 = Chi-
square; Yes = Augmented; No = Did not augment; 
aAugmentation was defined as initiation of a new ADHD medication (chemical entity) with a continuous overlap of 
at least 30 days with the index medication 
 
H03d3: There is no significant difference in the augmentation status between the RX and the 
RX+PSY groups, after controlling for covariates - Rejected 
Table 4.21 reports the logistic regression results of augmentation status in the 
pharmacotherapy group as compared to the combination therapy group while controlling for 
covariates. Deviance and Pearson goodness-of-fit statistics were non-significant indicating that 
the model-fit was appropriate. However, since the number of unique values was too high (n = 
8,831) this test result was considered invalid. Model fit assessed using the Hosmer-Lemeshow 
test did not indicate a significant difference between the observed and predicted values thus 
validating adequate model fit. Patients in the pharmacotherapy group had a 26.2% lower odds of 
augmentation (OR = 0.738; CI = 0.642 – 0.850; p < 0.0001) with an alternative medication 
therapy as compared to patients in the combination therapy group while controlling for 
covariates.  
As for covariates, patients with other psychotropic drug use, other mental health 
diagnosis, long-acting, and stimulant medication use had significantly higher odds of augmenting 
their index therapy. Conversely, females, Hispanics, other/unknown race/ethnicity, and rural area 




Table 4.21: Logistic regression. Augmentation status by pharmacotherapy and combination 
therapy treatment groups (N = 8,883) – after controlling for covariates 
Characteristics OR 95% CI x2 p-value 
Pharmacotherapy  0.738 0.642 – 0.850 17.9 <.0001 
Covariates 
Agea 0.995 0.913 – 1.083 0.0 0.90 
Pre-index psychiatric visitsa 1.002 0.992 – 1.013 0.2 0.64 
Pre-index non-psychiatric 
visitsa  
1.001 0.986 – 1.016 0.0 0.86 
Total pre-index costsa 1.000 1.000 – 1.000 9.5 <.01 
Gender     
Males Reference 
Females 0.786 0.667 – 0.924 8.4 <.01 
Race/Ethnicity     
Whites Reference 
African Americans  1.009 0.816 – 1.246 0.0 0.94 
Hispanics 0.737 0.612 – 0.888 10.3 <.01 
Others/unknown  0.670 0.512 – 0.877 8.5 <.01 
Urban/rural status     
Urban Reference 
Rural 0.789 0.669 – 0.930 8.0 <.01 
Other psychotropics     
No Reference 
Yes 1.551 1.268 – 1.897 18.2 <.0001 
Other mental health diagnosis     
No Reference 
Yes 1.235 1.059 – 1.441 7.3 0.01 
Medication duration of action     
Short-acting medications Reference 
Long-acting medications 8.155 5.304 – 12.540 91.4 <.0001 
Medication type     
Non-stimulants Reference 
Stimulants 1.972 1.363 – 2.854 13.0 <.01 
*p < 0.05 (in bold); OR = Odds Ratio; CI = Confidence Interval; x2= Chi-square; 
a Recorded as a continuous variable in the model; 
Augmentation was defined as initiation of a new ADHD medication (chemical entity) with a continuous overlap 





Switching was defined as a prescription claim for an ADHD medication (i.e., long-acting 
or short-acting medication that differed from the initial medication in terms of chemical entity) 
other than the index medication, within 30 days of discontinuation of the index medication (i.e., 
no subsequent dispensing of the index medication for ≥ 60 days). The “switched-to” medication 
must have been prescribed for at least 30 days to be considered as switching.  
Table 4.22 shows the proportion of patients by switch status. A majority of the patients 
did not switch (n = 6,024; 68.2%) their index medication. Overall, 31.8% (n = 2,809) of the 
patients in the treatment pattern cohort switched to an alternative ADHD medication.  
Table 4.22: Descriptive statistics. Proportion of patients switching to alternative ADHD 
medications 
Switchinga Frequency % 
Yes 2,809 31.8% 
No 6,024 68.2% 
Yes = Switched; No = Did not switch; 
 a Switching was defined as a prescription claim for an alternative ADHD medication (i.e., long-acting or short-acting 
medications that differed from the initial medication in terms of chemical entity) other than the index medication, 
before or within 30 days of discontinuation of the index medication (i.e., no subsequent dispensing of the index 
medication for ≥ 60 days). The “switched-to” medication must have been prescribed for at least 30 days to be 
considered as switching. 
 
Table 4.23 reports the chi-square results for the proportion of patients switching 
medications in each treatment group. A total of 29.6% (n = 1,594) patients switched in the 
pharmacotherapy group as compared to 35.2% (n = 1,215) patients in the combination therapy 
group. This difference in proportions of patients switching between the pharmacotherapy and 






Table 4.23: Chi-square test. Proportion of patients switching medications in the 
pharmacotherapy and combination therapy treatment groups 
Treatment group 
(N = 8,883) 
RX RX+PSY x2 p-value* 
     30.3 <.0001 
Switchinga n % n %   
Yes 1,594 29.6% 1,215 35.2%   
No 3,788 70.4% 2,236 64.8%   
*p < 0.05 (in bold); RX = Pharmacotherapy; PSY = Psychotherapy; RX+PSY = Combination therapy; x2 = Chi-
square; Yes = Switched; No = Did not switch; 
a Switching was defined as a prescription claim for an alternative ADHD medication (i.e., long-acting or short-acting 
medications that differed from the initial medication in terms of chemical entity) other than the index medication, 
before or within 30 days of discontinuation of the index medication (i.e., no subsequent dispensing of the index 
medication for ≥ 60 days). The “switched-to” medication should have been prescribed for at least 30 days to be 
considered as switching. 
 
H03d4: There is no significant difference in the switch status between the RX and the RX+PSY 
groups, after controlling for covariates – Rejected 
Table 4.24 reports the logistic regression results by switching status in the 
pharmacotherapy group as compared to the combination therapy group while controlling for 
covariates. Deviance and Pearson goodness-of-fit statistics were significant indicating that the 
model-fit was not appropriate. However, since the number of unique values was too high (n = 
8,831) this test result was considered invalid. Model fit assessed using a Hosmer-Lemeshow test 
did not indicate a significant difference between the observed and predicted values thus 
validating adequate model fit. Patients in the pharmacotherapy group had a 20.2% (OR = 0.798; 
CI = 0.725 – 0.878; p < 0.0001) lower odds of switching as compared to patients in the 
combination therapy group while controlling for covariates. As for covariates, patients with other 
psychotropic drug use, with other mental health diagnosis, long-acting, and stimulant medication 
use had significantly higher odds of switching medications. Conversely, females, Hispanics, 
African Americans, and other/unknown race/ethnicity had a lower likelihood of switching to 




Table 4.24: Logistic regression. Switching status by pharmacotherapy and combination therapy 
treatment groups (N = 8,883) – after controlling for covariates 
Characteristics OR 95% CI x2 p-value* 
Pharmacotherapy  0.798 0.725-0.878 21.4 <.0001 
Covariates 
Agea 0.978 0.924 – 1.036 0.6 0.45 
Pre-index psychiatric visitsa 1.002 0.995 – 1.008 0.2 0.64 
Pre-index non-psychiatric visitsa  1.007 0.997 – 1.017 2.1 0.15 
Total pre-index costsa 1.000 1.000 – 1.000 15.1 <.01 
Gender     
Males Reference 
Females 0.882 0.793 – 0.980 5.4 0.02 
Race/Ethnicity     
Whites Reference 
African Americans  0.733 0.631 – 0.852 16.4 <.0001 
Hispanics 0.670 0.590 – 0.760 38.8 <.0001 
Others/Unknown  0.814 0.685 – 0.966 5.5 0.02 
Urban/rural status     
Urban Reference 
Rural 0.971 0.870 – 1.084 0.3 0.60 
Other psychotropics     
No Reference 
Yes 1.282 1.105 – 1.486 10.8 <.01 
Other mental health diagnosis     
No Reference 
Yes 1.218 1.096 – 1.353 13.4 <.01 
Medication duration of action     
Short-acting medications Reference 
Long-acting medications 7.177 5.810 – 8.866 334.1 <.0001 
Medication type     
Non-stimulants Reference 
Stimulants 3.317 2.561 – 4.296 82.5 <.0001 
*p < 0.05 (in bold); OR = Odds Ratio; CI = Confidence Interval; x2= Chi-square; 
a Recorded as a continuous variable in the model; 
Switching was defined as a prescription claim for an alternative ADHD medication (i.e., long-acting or short-acting 
medications that differed from the initial medication in terms of chemical entity) other than the index medication, 
before or within 30 days of discontinuation of the index medication (i.e., no subsequent dispensing of the index 
medication for ≥ 60 days). The “switched-to” medication must have been prescribed for at least 30 days to be 






4.6 Objective 4: Healthcare utilization between pharmacotherapy and combination therapy 
groups 
Objectives 4a-4c were to determine and compare all-cause, ADHD-related, and other 
mental health-related healthcare utilization between the pharmacotherapy and combination 
therapy groups after controlling for covariates. A Modified Park test was conducted to identify 
the distribution and functional form for each resource utilization category (Appendix VI). Based 
on the results of the Vuong test, in adjusted analysis, resource utilization in pharmacotherapy 
group was compared to combination therapy using separate zero-inflated Poisson regression 
models for each resource utilization category (i.e., office-based, inpatient, outpatient hospital, 
ED visits, and prescriptions) except for all-cause and ADHD-related prescriptions (Appendix 
VII.) The Vuong test indicated that the Poisson model is a better fit for all-cause and ADHD-
related prescriptions and thus, these variables were modelled using a Poisson regression.  
4.6.1 All-cause healthcare utilization 
Objective 4a: To determine and compare the healthcare utilization for all-cause office-based, 
inpatient, outpatient hospital, ED visits, and prescriptions between the RX and the 
RX+PSY groups 
4.6.1.1 All-cause office-based visits 
H4a1: The number of all-cause office-based visits are significantly higher in the RX+PSY group 
as compared to the RX group – Failed to reject 
Table 4.25 presents a zero-inflated Poisson regression comparison of all-cause office-
based visits between the pharmacotherapy and combination therapy groups in the overall cohort. 
After controlling for covariates, for patients with visits, the expected number of all-cause office-
based visits in the pharmacotherapy group was 0.782 times [exp (-0.246)] the expected number 
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of all-cause office-based visits in the combination therapy group (𝛽 = -0.246; x2= 2,414.3; p < 
0.0001). Thus, among those who have all-cause office-based visits, being in the 
pharmacotherapy group decreases the expected number of all-cause office-based visits by 21.8%, 
holding other covariates constant, and this is statistically significant (p < 0.0001).  
As for the covariates, patients with higher age, females, and rural area status had 
significantly lower all-cause office-based visits. Conversely, patients with higher pre-index 
psychiatric visits, pre-index non-psychiatric visits, total pre-index costs, Hispanic, 
other/unknown race/ethnicity, other psychotropic use, other mental health disorders, long- or 
short-acting medication use, and stimulant use were associated with significantly higher all-cause 
office-based visits. The unit increments on the scale for total pre-index costs ($1) were relatively 
small; therefore, a one unit change in pre-index costs may result in a very small change in post-
index utilization.      
4.6.1.2 All-cause inpatient visits 
H4a2: The number of all-cause inpatient visits are significantly higher in the RX+PSY group as 
compared to the RX group – Failed to reject 
Table 4.26 presents a zero-inflated Poisson regression comparison of all-cause inpatient 
visits between the pharmacotherapy and combination therapy groups in the overall cohort. After 
controlling for covariates, for patients with visits, the expected number of all-cause inpatient 
visits in the pharmacotherapy group was 0.827 times [exp (-0.190)] the expected number of all-
cause inpatient visits in the combination therapy group (𝛽 = -0.190; x2= 21.5; p < 0.0001). Thus, 
among those who have all-cause inpatient visits, being in the pharmacotherapy group decreases 
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the expected number of all-cause inpatient visits by 17.3%, holding other covariates constant, 
and this is statistically significant (p < 0.0001). 
As for the covariates, rural area status had significantly lower all-cause inpatient visits. 
Conversely, African American, Hispanic, other/unknown race/ethnicity, other mental health 
disorders, and long-acting medication use were associated with significantly higher all-cause 
inpatient visits. The unit increments on the scale for total pre-index costs were relatively small; 
therefore, a one unit change in pre-index costs may result in a very small change in post-index 
utilization.      
4.6.1.3 All-cause outpatient hospital visits 
H4a3: The number of all-cause outpatient hospital visits are significantly higher in the RX+PSY 
group as compared to the RX group – Failed to reject 
Table 4.27 presents a zero-inflated Poisson regression comparison of all-cause outpatient 
hospital visits between the pharmacotherapy and combination therapy groups in the overall 
cohort. After controlling for covariates, for patients with visits, the expected number of all-cause 
outpatient hospital visits in the pharmacotherapy group was 0.945 times [exp (-0.057)] the 
expected number of all-cause outpatient hospital visits in the combination therapy group (𝛽 = -
0.057; x2= 70.3; p < 0.0001). Thus, among those who have all-cause outpatient hospital visits, 
being in the pharmacotherapy group decreases the expected number of all-cause outpatient 
hospital visits by 5.5%, holding other covariates constant, and this is statistically significant (p < 
0.0001). 
As for the covariates, patients with higher age, higher pre-index psychiatric visits, female, 
African American, rural area residents, and long-acting medication users had significantly lower 
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all-cause outpatient hospital visits. Conversely, higher pre-index non-psychiatric visits, higher 
total pre-index costs, Hispanic, other/unknown race/ethnicity, other psychotropic use, other 
mental health disorders, and stimulant medication use were associated with significantly higher 
all-cause outpatient hospital visits. The unit increments on the scale for total pre-index costs 
were relatively small; therefore, a one unit change in pre-index costs may result in a very small 
change in post-index utilization.    
4.6.1.4 All-cause ED visits 
H4a4: The number of all-cause ED visits are significantly higher in the RX+PSY group as 
compared to the RX group – Failed to reject 
Table 4.28 presents a zero-inflated Poisson regression comparison of all-cause ED visits 
between the pharmacotherapy and combination therapy groups in the overall cohort. After 
controlling for covariates, for patients with ED visits, the expected number of all-cause ED visits 
in the pharmacotherapy group was 0.774 times [exp (-0.256)] the expected number of all-cause 
ED visits in the combination therapy group (𝛽 = -0.256; x2= 18.0; p < 0.0001). Thus, among 
those who have all-cause ED visits, being in the pharmacotherapy group decreases the expected 
number of all-cause ED visits by 22.6%, holding other covariates constant, and this is 
statistically significant (p < 0.0001). 
As for the covariates, patients with higher age and Hispanic race/ethnicity were 
associated with significantly lower all-cause ED visits. Conversely, patients with higher pre-
index non-psychiatric visits, total pre-index costs, other/unknown race, and residing in the rural 
area were associated with a higher number of all-cause ED visits. The unit increments on the 
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scale for total pre-index costs were relatively small; therefore, a one unit change in pre-index 
costs may result in a very small change in post-index utilization. 
4.6.1.5 All-cause prescriptions  
H4a5: The number of all-cause prescriptions are significantly higher in the RX+PSY group as 
compared to the RX group – Failed to reject 
Table 4.29 represents a Poisson regression comparison of all-cause prescription 
medications between the pharmacotherapy and combination therapy groups in the overall cohort. 
After controlling for covariates, the difference in the expected number of all-cause prescriptions 
in the pharmacotherapy group is 0.962 times (exp[-0.039]) that in the combination therapy group 
(𝛽 = -0.039; x2= 81.2; p < 0.0001).  Thus, being in the pharmacotherapy group decreases the 
expected number of all-cause prescriptions counts by 3.8%, holding other covariates constant, 
and this is statistically significant (p < 0.0001). 
As for the covariates, patients with higher age, higher pre-index psychiatric visits, 
African American race, Hispanic, other/unknown race/ethnicity, residency in rural area, and 
using other psychotropic medications were associated with a significantly lower number of all-
cause prescriptions. Conversely, higher pre-index non-psychiatric visits, total pre-index costs, 
female, having other mental health diagnosis, and using long-acting or short-acting medications 
were associated with a significantly higher number of all-cause prescriptions. The unit 
increments on the scale for total pre-index costs were relatively small; therefore, a one unit 
change in pre-index costs may result in a very small change in post-index utilization.
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Table 4.25: Zero-Inflated Poisson Regression: Comparison of all-cause office-based visits between the pharmacotherapy (RX) and 
combination (RX+PSY) groups (N = 10,255) – after controlling for covariates 
 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  -0.246 -0.256- -0.236 2,414.3 <.0001 
Covariates 
Ageb -0.079 -0.085- -0.073 722.4 <.0001 
Pre-index psychiatric visitsb 0.023 0.023-  0.024 20,751.8 <.0001 
Pre-index non-psychiatric visitsb 0.048 0.047-  0.049 15,912.1 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 97.8 <.0001 
Femalea -0.062 -0.074- -0.051 117.9 <.0001 
African Americana  -0.002 -0.022-  0.017 0.1 0.83 
Hispanica 0.172 0.157-  0.187 489.4 <.0001 
Other/unknowna race/ethnicity 0.248 0.229-  0.267 666.6 <.0001 
Rurala -0.059 -0.071- -0.046 78.8 <.0001 
Other psychotropicsa 0.114 0.089-  0.139 79.4 <.0001 
Other mental health diagnosisa 0.581 0.570-  0.593 10,027.2 <.0001 
Long-acting medicationsa 0.049 0.034-  0.064 40.6 <.0001 
Short-acting medicationsa 0.019 0.007-  0.030 10.4 <.01 
Stimulantsa 0.102 0.079-  0.126 71.7 <.0001 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 




Table 4.26: Zero-Inflated Poisson Regression: Comparison of all-cause inpatient visits between the pharmacotherapy (RX) and 
combination (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  -0.190 -0.270- -0.110 21.5 <.0001 
Covariates 
Ageb 0.042 -0.005-  0.090 3.1 0.08 
Pre-index psychiatric visitsb -0.005 -0.010-  0.000 3.3 0.07 
Pre-index non-psychiatric visitsb 0.008 0.000-  0.016 3.9 0.05 
Total pre-index costsb 0.000 0.000-  0.000 1.5 0.22 
Femalea -0.065 -0.161-  0.032 1.7 0.19 
African Americana  0.268 0.101-  0.435 9.9 <.01 
Hispanica 0.250 0.116-  0.383 13.4 <.01 
Other/unknowna race/ethnicity 0.380 0.230-  0.529 24.8 <.0001 
Rurala -0.206 -0.320- -0.092 12.5 <.01 
Other psychotropicsa 0.148 -0.029-  0.325 2.7 0.10 
Other mental health diagnosisa 0.410 0.316-  0.505 72.3 <.0001 
Long-acting medicationsa 0.131 0.006-  0.255 4.2 0.04 
Short-acting medicationsa 0.052 -0.037-  0.140 1.3 0.25 
Stimulantsa 0.124 -0.064-  0.312 1.7 0.20 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 




Table 4.27: Zero-Inflated Poisson Regression: Comparison of all-cause outpatient hospital visits between the pharmacotherapy (RX) 
and combination (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  -0.057 -0.070- -0.044 70.3 <.0001 
Covariates 
Ageb -0.114 -0.122- -0.107 886.7 <.0001 
Pre-index psychiatric visitsb -0.016 -0.017- -0.015 953.7 <.0001 
Pre-index non-psychiatric visitsb 0.012 0.011-  0.013 370.3 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 8,136.0 <.0001 
Femalea -0.066 -0.082- -0.051 69.9 <.0001 
African Americana  -0.359 -0.401- -0.317 281.6 <.0001 
Hispanica 0.643 0.618-  0.668 2,468.4 <.0001 
Other/ unknowna race/ethnicity 0.305 0.275-  0.336 379.1 <.0001 
Rurala -0.357 -0.378- -0.336 1,082.8 <.0001 
Other psychotropicsa 0.177 0.143-  0.212 101.8 <.0001 
Other mental health diagnosisa 1.224 1.205-  1.244 14,948.4 <.0001 
Long-acting medicationsa -0.022 -0.041- -0.003 4.9 0.03 
Short-acting medicationsa 0.004 -0.012-  0.020 0.3 0.61 
Stimulantsa 0.065 0.034-  0.096 16.5 <.0001 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 




Table 4.28: Zero-Inflated Poisson Regression: Comparison of all-cause emergency department visits between the pharmacotherapy 
(RX) and combination (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  -0.256 -0.375- -0.138 18.0 <.0001 
Covariates 
Ageb -0.183 -0.232- -0.135 55.1 <.0001 
Pre-index psychiatric visitsb -0.004 -0.011-  0.003 1.4 0.23 
Pre-index non-psychiatric visitsb 0.019 0.010-  0.028 16.4 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 7.6 0.01 
Femalea -0.027 -0.120-  0.065 0.3 0.56 
African Americana -0.013 -0.136-  0.110 0.0 0.84 
Hispanica -0.376 -0.487- -0.265 44.1 <.0001 
Other/ unknowna race/ethnicity 0.207 0.078-  0.336 9.9 <.01 
Rurala 0.478 0.387-  0.570 105.2 <.0001 
Other psychotropicsa 0.055 -0.144-  0.254 0.3 0.59 
Other mental health diagnosisa 0.008 -0.080-  0.096 0.0 0.86 
Long-acting medicationsa -0.075 -0.200-  0.050 1.4 0.24 
Short-acting medicationsa 0.063 -0.031-  0.158 1.7 0.19 
Stimulantsa -0.007 -0.181-  0.167 0.0 0.94 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 






Table 4.29: Poisson Regression: Comparison of all-cause prescriptions between the pharmacotherapy (RX) and combination 
(RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  -0.039 -0.047- -0.030 81.2 <.0001 
Covariates 
Ageb -0.091 -0.096- -0.086 1,292.7 <.0001 
Pre-index psychiatric visitsb -0.003 -0.003- -0.002 87.7 <.0001 
Pre-index non-psychiatric visitsb 0.029 0.028-  0.030 5,244.5 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 2,037.8 <.0001 
Femalea 0.043 0.034-  0.053 84.7 <.0001 
African Americana  -0.143 -0.158- -0.128 350.0 <.0001 
Hispanica -0.026 -0.037- -0.014 18.4 <.0001 
Other/ unknowna race/ethnicity -0.025 -0.041- -0.009 9.4 <.01 
Rurala -0.222 -0.233- -0.211 1,691.7 <.0001 
Other psychotropicsa -0.046 -0.067- -0.025 17.9 <.0001 
Other mental health diagnosisa 0.142 0.133-  0.151 922.7 <.0001 
Long-acting medicationsa 0.192 0.179-  0.205 820.9 <.0001 
Short-acting medicationsa 0.126 0.117-  0.136 660.3 <.0001 
Stimulantsa 0.003 -0.016-  0.021 0.1 0.79 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 
b Recorded as continuous variable in the model 
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4.6.2 ADHD-related healthcare utilization 
Objective 4b: To determine and compare the healthcare utilization frequencies for ADHD-
related office-based, inpatient, outpatient hospital, ED visits, and prescription 
medications between the RX and the RX+PSY groups 
4.6.2.1 ADHD-related office-based visits 
H4b1: The number of ADHD-related office-based visits are significantly higher in the RX+PSY 
group as compared to the RX group – Failed to reject 
Table 4.30 presents a zero-inflated Poisson regression comparison of ADHD-related 
office-based visits between pharmacotherapy and combination therapy groups in the overall 
cohort. After controlling for covariates, for patients with ADHD-related office-based visits, the 
expected number of ADHD-related office-based visits in the pharmacotherapy group was 0.472 
times [exp (-0.750)] the expected number of ADHD-related office-based visits in the 
combination therapy group (𝛽 = -0.750; x2= 6464.3; p < 0.0001). Thus, among those who have 
ADHD-related office-based visits, being in the pharmacotherapy group decreases the expected 
number of ADHD-related office-based visits by 52.8%, holding other covariates constant, and 
this is statistically significant (p < 0.0001). 
As for the covariates, patients with higher age, higher pre-index psychiatric visits, and 
females had a significantly lower ADHD-related office-based visits. Conversely, higher pre-
index non-psychiatric visits, Hispanic, other/unknown race/ethnicity, other psychotropic use, 
other mental health diagnosis, long- or short-acting medication use, and stimulant medication use 
were associated with a significantly higher number of ADHD-related office-based visits.  
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4.6.2.2 ADHD-related inpatient visits 
H4b2: The number of ADHD-related inpatient visits are significantly higher in the RX+PSY 
group as compared to the RX group – Failed to reject 
Table 4.31 presents a zero-inflated Poisson regression comparison of ADHD-related 
inpatient visits between the pharmacotherapy and combination therapy groups in the overall 
cohort. After controlling for covariates, for patients with ADHD-related inpatient visits, the 
expected number of ADHD-related inpatient visits in the pharmacotherapy group was 0.725 
times [exp (-0.322)] the expected number of ADHD-related inpatient visits in the combination 
therapy group (𝛽 = -0.322; x2= 11.8; p <0.01). Thus, among those who have ADHD-related 
inpatient visits, being in the pharmacotherapy group decreases the expected number of ADHD-
related inpatient visits by 27.5%, holding other covariates constant, and this is statistically 
significant (p < 0.01). 
As for the covariates, patients with higher age, higher pre-index psychiatric visits, 
females, rural area residents, and short-acting medication users were significantly associated 
with lower ADHD-related inpatient visits. Conversely, higher pre-index non-psychiatric visits, 
Hispanic, other/unknown race/ethnicity, other mental health diagnosis, long-acting medication 
use, and stimulant medication use were associated with significantly higher ADHD-related 
inpatient visits.  
4.6.2.3 ADHD-related outpatient hospital visits 
H4b3: The number of ADHD-related outpatient hospital visits are significantly higher in the 
RX+PSY group as compared to the RX group – Failed to reject 
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Table 4.32 presents a zero-inflated Poisson regression comparison of ADHD-related 
outpatient hospital visits between the pharmacotherapy and combination therapy groups in the 
overall cohort. After controlling for covariates, for patients with ADHD-related outpatient 
hospital visits, the expected number of ADHD-related outpatient hospital visits in the 
pharmacotherapy group was 0.705 times [exp (-0.350)] the expected number of ADHD-related 
outpatient hospital visits in the combination therapy group (𝛽 = -0.350, x2= 294.0, p < 0.0001). 
Thus, among those who have ADHD-related outpatient hospital visits, being in the 
pharmacotherapy group decreases the expected number of ADHD-related outpatient hospital 
visits by 29.5%, holding other covariates constant, and this is statistically significant (p < 
0.0001). 
As for the covariates, patient with higher age, higher pre-index psychiatric visits, African 
American, rural residence status, and stimulant medication use were associated with a 
significantly lower number of ADHD-related outpatient hospital visits. Conversely, higher pre-
index non-psychiatric visits, total pre-index costs, Hispanics, other/unknown race/ethnicity, other 
mental health diagnosis, and long-acting medication use were associated with a significantly 
higher number of ADHD-related outpatient hospital visits. The unit increments on the scale for 
total pre-index costs were relatively small; therefore, a one unit change in pre-index costs may 
result in a very small change in post-index utilization. 
4.6.2.4 ADHD-related ED visits 
H4b4: The number of ADHD-related ED visits are significantly higher in the RX+PSY group as 
compared to the RX group – Could not test 
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Since the number of events in both treatment groups was mostly zero, this hypothesis 
could not be tested. 
4.6.2.5 ADHD-related prescriptions  
H4b5: The number of ADHD-related prescriptions are significantly higher in the RX+PSY group 
as compared to the RX group - Rejected 
Table 4.33 presents a Poisson regression comparison of ADHD-related prescriptions 
between pharmacotherapy and combination therapy groups in the overall population. After 
controlling for covariates, there was no significant difference in ADHD-related prescription 
counts in the pharmacotherapy group as compared to the combination therapy group.  
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Table 4.30: Zero-Inflated Poisson Regression: Comparison of ADHD-related office-based visits between the pharmacotherapy (RX) 
and combination (RX+PSY) groups (N = 10,255) – after controlling for covariates 
 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  -0.750 -0.769- -0.732 6464.3 <.0001 
Covariates 
Ageb -0.017 -0.028- -0.070 10.6 <.01 
Pre-index psychiatric visitsb -0.003 -0.004- -0.001 14.0 <.01 
Pre-index non-psychiatric visitsb 0.016 0.015-  0.018 293.2 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 0.7 0.42 
Femalea -0.031 -0.051- -0.012 10.2 <.01 
African Americana  0.006 -0.024-  0.036 0.2 0.68 
Hispanica 0.131 0.106-  0.156 106.9 <.0001 
Other/unknowna race/ethnicity 0.048 0.014-  0.082 7.8 0.01 
Rurala -0.020 -0.042-  0.001 3.6 0.06 
Other psychotropicsa 0.064 0.024-  0.103 9.9 <.01 
Other mental health diagnosisa 0.101 0.082-  0.120 110.1 <.0001 
Long-acting medicationsa 0.234 0.206-  0.262 268.8 <.0001 
Short-acting medicationsa 0.125 0.106-  0.145 158.7 <.0001 
Stimulantsa 0.202 0.159-  0.245 85.4 <.0001 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 




Table 4.31: Zero-Inflated Poisson Regression: Comparison of ADHD-related inpatient visits between the pharmacotherapy (RX) and 
combination (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  -0.322 -0.506- -0.138 11.8 <.01 
Covariates 
Ageb -0.165 -0.271- -0.060 9.5 <.01 
Pre-index psychiatric visitsb -0.016 -0.030- -0.002 5.1 0.02 
Pre-index non-psychiatric visitsb 0.023 0.002-  0.043 4.6 0.03 
Total pre-index costsb 0.000 0.000-  0.000 2.0 0.16 
Femalea -0.365 -0.596- -0.135 9.7 <.01 
African Americana  0.474 -0.080-  1.028 2.8 0.09 
Hispanica 1.009 0.544-  1.473 18.1 <.0001 
Other/unknowna race/ethnicity 0.638 0.114-  1.161 5.7 0.02 
Rurala -1.179 -1.621- -0.736 27.2 <.0001 
Other psychotropicsa -0.173 -0.574-  0.227 0.7 0.40 
Other mental health diagnosisa 0.592 0.348-  0.837 22.5 <.0001 
Long-acting medicationsa 0.514 0.194-  0.833 10.0 <.01 
Short-acting medicationsa -0.258 -0.445- -0.071 7.3 0.01 
Stimulantsa 0.815 0.320-  1.310 10.4 <.01 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 





Table 4.32: Zero-Inflated Poisson Regression: Comparison of ADHD-related outpatient hospital visits between the pharmacotherapy 
(RX) and combination (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  -0.350 -0.390- -0.310 294.0 <.0001 
Covariates 
Ageb -0.053 -0.077- -0.028 18.0 <.0001 
Pre-index psychiatric visitsb -0.005 -0.009- -0.001 7.3 0.01 
Pre-index non-psychiatric visitsb 0.015 0.011-  0.019 47.1 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 50.1 <.0001 
Femalea 0.018 -0.028-  0.063 0.6 0.45 
African Americana  -0.183 -0.267- -0.098 18.0 <.0001 
Hispanica 0.461 0.404-  0.518 250.8 <.0001 
Other/unknowna race/ethnicity 0.199 0.124-  0.275 26.8 <.0001 
Rurala -0.311 -0.360- -0.263 157.6 <.0001 
Other psychotropicsa 0.050 -0.041-  0.140 1.2 0.28 
Other mental health diagnosisa 0.362 0.318-  0.407 252.5 <.0001 
Long-acting medicationsa 0.088 0.027-  0.149 8.0 <.01 
Short-acting medicationsa 0.019 -0.028-  0.065 0.6 0.43 
Stimulantsa -0.110 -0.195- -0.026 6.5 0.01 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 









Table 4.33: Poisson Regression: Comparison of ADHD-related prescriptions between the pharmacotherapy (RX) and combination 
(RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  0.011 -0.004- 0.026 2.1 0.15 
Covariates 
Ageb 0.124 0.114-  0.133 643.1 <.0001 
Pre-index psychiatric visitsb 0.000 -0.001-  0.001 0.1 0.82 
Pre-index non-psychiatric visitsb -0.003 -0.005- -0.001 10.1 <.01 
Total pre-index costsb 0.000 0.000-  0.000 16.5 <.0001 
Femalea -0.056 -0.073- -0.039 42.0 <.0001 
African Americana -0.192 -0.215- -0.168 248.8 <.0001 
Hispanica  -0.229 -0.248- -0.209 521.6 <.0001 
Other/unknowna race/ethnicity -0.147 -0.175- -0.120 109.0 <.0001 
Rurala 0.021 0.004-  0.038 5.6 0.02 
Other psychotropicsa -0.146 -0.181- -0.110 65.5 <.0001 
Other mental health diagnosisa -0.026 -0.043- -0.009 9.4 <.01 
Long-acting medicationsa 0.605 0.578-  0.631 1928.8 <.0001 
Short-acting medicationsa 0.301 0.284-  0.317 1277.6 <.0001 
Stimulantsa 0.208 0.171-  0.246 118.91 <.0001 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 
b Recorded as a continuous variable in the model 
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4.6.3 Other mental health-related utilization 
Objective 4c: To determine and compare the healthcare utilization frequencies for other mental 
health-related office-based, inpatient, outpatient hospital, ED visits, and 
prescriptions between the RX and RX+PSY groups 
4.6.3.1 Other mental health-related office-based visits 
H4c1: The number of other mental health-related office-based visits are significantly higher in 
the RX+PSY group as compared to the RX group – Rejected 
Table 4.34 presents a zero-inflated Poisson regression comparison of other mental 
health-related office-based visits between the pharmacotherapy and combination therapy groups 
in the overall cohort. After controlling for covariates, for patients with other mental health-
related office-based visits, the expected number of other mental health-related office-based visits 
in the pharmacotherapy group was 1.256 times [exp (0.228)] the expected number of other 
mental health-related office-based visits in the combination therapy group (𝛽 = 0.228, x2= 473.6, 
p < 0.0001). Thus, among those who have other mental health-related office-based visits, being 
in the pharmacotherapy group increases the expected number of other mental health-related 
office-based visits by 25.6%, holding other covariates constant, and this is statistically significant 
(p < 0.0001).  
As for the covariates, patients with higher age, females, rural area residences, and short-
acting medication users were significantly associated with a lower number of other mental 
health-related office-based visits. Conversely, patients with higher pre-index psychiatric visits, 
pre-index non-psychiatric visits, total pre-index costs, Hispanics, African American, 
other/unknown race race/ethnicity, and using other psychotropics were significantly associated 
with a higher number of other mental health-related office-based visits. The unit increments on 
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the scale for total pre-index costs were relatively small; therefore, a one unit change in pre-index 
costs may result in a very small change in post-index utilization. 
4.6.3.2 Other mental health-related inpatient visits 
H4c2: The number of other mental health-related inpatient visits are significantly higher in the 
RX+PSY group as compared to the RX group – Rejected 
Table 4.35 presents a zero-inflated Poisson regression comparison of other mental 
health-related inpatient visits between pharmacotherapy and combination therapy groups in the 
overall cohort. After controlling for covariates, for patients with other mental health-related 
inpatient visits, the expected number of other mental health-related inpatient visits in the 
pharmacotherapy group was 1.735 times [exp (0.551)] the expected number of other mental 
health-related inpatient visits in the combination therapy group (𝛽 = 0.551, x2= 6.6, p = 0.01). 
Thus, among those who have other mental health-related inpatient visits, being in the 
pharmacotherapy group increases the expected number of other mental health-related inpatient 
visits by 73.5%, holding other covariates constant, and this is statistically significant (p < 
0.0001). 
As for the covariates, rural residence status was significantly associated with a lower 
number of other mental health-related inpatient visits. Conversely, patients with higher pre-index 
psychiatric visits, pre-index non-psychiatric visits, total pre-index costs, African American 
race/ethnicity, and short-acting medication use were significantly associated with a higher 
number of other mental health-related inpatient visits. The unit increments on the scale for total 
pre-index costs were relatively small; therefore, a one unit change in pre-index costs may result 
in a very small change in post-index utilization. 
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4.6.3.3 Other mental health-related outpatient hospital visits 
H4c3: The number of other mental health-related outpatient hospital visits are significantly 
higher in the RX+PSY group as compared to the RX group – Failed to reject 
Table 4.36 presents a zero-inflated Poisson regression comparison of other mental 
health-related outpatient hospital visits between the pharmacotherapy and combination therapy 
groups in the overall cohort. After controlling for covariates, for patients with other mental 
health-related outpatient hospital visits, the expected number of other mental health-related 
inpatient visits in the pharmacotherapy group was 0.981 times [exp (-0.019)] the expected 
number of other mental health-related outpatient hospital visits in the combination therapy group 
(𝛽 = -0.019; x2= 4.4; p = 0.04). Thus, among those who have other mental health-related 
outpatient hospital visits, being in the pharmacotherapy group decreases the expected number of 
other mental health-related outpatient hospital visits by 1.9%, holding other covariates constant, 
and this is statistically significant (p < 0.0001). 
As for the covariates, patients with higher age, higher pre-index psychiatric visits, 
females, African American, rural area residents, and long- and short-acting medication users 
were significantly associated with lower other mental health-related outpatient hospital visits. 
Conversely, patients with higher pre-index non-psychiatric visits, total pre-index costs, Hispanic 
or other/unknown race/ethnicity, using other psychotropics, and stimulants were significantly 
associated with higher number of other mental health-related outpatient hospital visits. The unit 
increments on the scale for total pre-index costs were relatively small; therefore, a one unit 
change in pre-index costs may result in a very small change in post-index utilization. 
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4.6.3.4 Other mental health-related ED visits 
H4c4: The number of other mental health-related ED visits are significantly higher in the 
RX+PSY group as compared to the RX group – Could not test 
Since the number of events in both treatment groups was mostly zero, this hypothesis 
could not be tested. 
4.6.3.5 Other mental health-related prescriptions  
H4c5: The number of other mental health-related prescriptions are significantly higher in the 
RX+PSY group as compared to the RX group – Failed to reject 
Table 4.37 presents a zero-inflated Poisson regression comparison of other mental 
health-related prescriptions between the pharmacotherapy and combination therapy groups in the 
overall cohort. After controlling for covariates, for patients with other mental health-related 
prescriptions, the expected number other mental health-related prescriptions in the 
pharmacotherapy group was 0.909 times [exp (-0.095)] the expected number of other mental 
health-related prescriptions in the combination therapy group (𝛽 = -0.095; x2= 39.9; p <0.0001). 
Thus, among those who have other mental health-related prescriptions, being in the 
pharmacotherapy group decreases the expected number of other mental health-related 
prescriptions by 9.1%, holding other covariates constant, and this is statistically significant (p < 
0.0001). 
As for the covariates, Hispanic, African American race/ethnicity, other psychotropic 
users, short-acting, and stimulant medication users were significantly associated with a lower 
number of other mental health-related prescriptions. Conversely, patient with higher age and 
long-acting medication users were significantly associated with a higher number of other mental 
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health-related prescriptions. The unit increments on the scale for total pre-index costs were 




Table 4.34: Zero-Inflated Poisson Regression: Comparison of other mental health-related office-based visits between the 
pharmacotherapy (RX) and combination (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  0.228 0.208- 0.249 473.6 <.0001 
Covariates 
Ageb -0.097 -0.108- -0.085 287.7 <.0001 
Pre-index psychiatric visitsb 0.029 0.029-  0.029 22303.3 <.0001 
Pre-index non-psychiatric visitsb 0.017 0.015-  0.018 383.3 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 48.8 <.0001 
Femalea -0.201 -0.225- -0.176 259.3 <.0001 
African Americana  0.229 0.179-  0.280 78.5 <.0001 
Hispanica 0.204 0.165-  0.243 106.2 <.0001 
Other/unknowna race/ethnicity 0.379 0.336-  0.421 309.8 <.0001 
Rurala -0.157 -0.187- -0.126 101.2 <.0001 
Other psychotropicsa 0.177 0.114-  0.241 29.5 <.0001 
Long-acting medicationsa 0.007 -0.022-  0.035 0.2 0.65 
Short-acting medicationsa -0.043 -0.066- -0.019 12.5 <.01 
Stimulantsa 0.041 -0.008-  0.090 2.6 0.10 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no long-acting medication use, no short-acting 
medication use, and non-stimulant use; 
b Recorded as a continuous variable in the model; 







Table 4.35: Zero-Inflated Poisson Regression: Comparison of other mental health-related inpatient visits between the 
pharmacotherapy (RX) and combination (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  0.551 0.130- 0.972 6.6 0.01 
Covariates 
Ageb 0.105 -0.140-  0.350 0.7 0.40 
Pre-index psychiatric visitsb 0.045 0.016-  0.073 9.5 <.01 
Pre-index non-psychiatric visitsb 0.068 0.024-  0.112 9.2 <.01 
Total pre-index costsb 0.000 -0.000-  0.000 4.5 0.03 
Femalea 0.111 -0.326-  0.547 0.3 0.62 
African Americana  1.258 0.171-  2.344 5.1 0.02 
Hispanica 0.370 -0.406-  1.146 0.9 0.35 
Other/unknowna race/ethnicity -0.302 -1.316-  0.713 0.3 0.56 
Rurala -2.018 -3.068- -0.968 14.2 <.01 
Other psychotropicsa -1.706 -4.248-  0.836 1.7 0.19 
Long-acting medicationsa 0.145 -0.332-  0.621 0.4 0.55 
Short-acting medicationsa 1.054 0.490-  1.618 13.4 <.01 
Stimulantsa 0.377 -0.644-  1.398 0.5 0.47 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no long-acting medication use, no short-acting 
medication use, and non-stimulant use; 
b Recorded as a continuous variable in the model; 






Table 4.36: Zero-Inflated Poisson Regression: Comparison of other mental health-related outpatient hospital visits between the 
pharmacotherapy (RX) and combination (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy -0.019 -0.036- -0.001 4.4 0.04 
Covariates 
Ageb -0.037 -0.046- -0.027 53.9 <.0001 
Pre-index psychiatric visitsb -0.006 -0.008- -0.005 94.5 <.0001 
Pre-index non-psychiatric visitsb 0.006 0.004-  0.008 48.5 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 1898.5 <.0001 
Femalea -0.112 -0.134- -0.091 104.6 <.0001 
African Americana  -0.461 -0.540- -0.382 130.7 <.0001 
Hispanica 0.450 0.403-  0.497 354.1 <.0001 
Other/unknowna race/ethnicity 0.290 0.238-  0.342 118.6 <.0001 
Rurala -0.584 -0.625- -0.543 773.5 <.0001 
Other psychotropicsa 0.144 0.095-  0.193 33.6 <.0001 
Long-acting medicationsa -0.077 -0.101- -0.052 37.4 <.0001 
Short-acting medicationsa -0.025 -0.046- -0.004 5.3 0.02 
Stimulantsa 0.156 0.112-  0.199 49.4 <.0001 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no long-acting medication use, no short-acting 
medication use, and non-stimulant use; 
b Recorded as a continuous variable in the model;  





Table 4.37: Zero-Inflated Poisson Regression: Comparison of other mental health-related prescriptions between the pharmacotherapy 
(RX) and combination (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy  -0.095 -0.124- -0.066 39.9 <.0001 
Covariates 
Ageb 0.021 0.004-  0.038 5.7 0.02 
Pre-index psychiatric visitsb 0.001 -0.001-  0.004 1.1 0.30 
Pre-index non-psychiatric visitsb -0.001 -0.005-  0.003 0.3 0.57 
Total pre-index costsb 0.000 0.000-  0.000 148.0 <.0001 
Femalea -0.032 -0.065-  0.001 3.6 0.06 
African Americana -0.118 -0.164- -0.073 26.0 <.0001 
Hispanica  -0.237 -0.276- -0.197 138.6 <.0001 
Other/unknowna race/ethnicity 0.004 -0.043-  0.051 0.0 0.86 
Rurala -0.005 -0.041-  0.030 0.1 0.76 
Other psychotropicsa -0.104 -0.185- -0.023 6.3 0.01 
Long-acting medicationsa 0.081 0.031-  0.131 10.1 <.01 
Short-acting medicationsa -0.067 -0.100- -0.033 14.8 <.01 
Stimulantsa -0.132 -0.190- -0.075 20.3 <.0001 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no long-acting medication use, no short-acting 
medication use, and non-stimulant use; 
b Recorded as a continuous variable in the model;  







4.7 Objective 5: Medical and prescription costs between the pharmacotherapy and 
combination therapy group 
Objectives 5a-5c were to determine and compare healthcare cost between the 
pharmacotherapy and combination therapy groups after controlling for covariates. All costs were 
adjusted to 2013 dollar value using the medical consumer price index from the Bureau of Labor 
Statistics (BLS). In the adjusted analyses, medical, prescription, and total costs of preschoolers 
diagnosed with ADHD receiving pharmacotherapy was compared to medical, prescription, and 
total costs of preschoolers diagnosed with ADHD receiving combination therapy using separate 
generalized linear regression models for each cost category (i.e., all-cause, ADHD-related, and 
other mental health-related). A Modified Park test was conducted to identify the distribution and 
functional form for each cost category (Appendix VIII). A gamma distribution with a log-link 
was specified for all cost models.  
Table 4.38 shows the results for mean medical, prescription, and total costs for the 
pharmacotherapy and combination therapy groups. The mean (±SD) all-cause medical costs 
were highest in the psychotherapy group $5,240.29 (±7,145.68) followed by the combination 
therapy group $4,163.19 (±6,235.77) and the pharmacotherapy group $3,402.86 (±6,149.12). 
Mean (±SD) all-cause prescription costs were highest in the combination therapy group 
$2,210.90 (±2,772.17) followed by the pharmacotherapy group $1,996.19 (±1,964.85), and the 
psychotherapy group $1,101.34 (±1,698.70). Mean all-cause total costs were highest in the 
combination therapy group $7,266.41 (±7,254.25) followed by the psychotherapy group 
$6,897.43 (±7,856.84), and the pharmacotherapy group $6,665.88 (±8,840.31).  
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The mean (±SD) ADHD-related medical costs were highest in combination therapy 
group $973.87 (±1,348.10) followed by the psychotherapy group $884.97 (±1,401.92) and the 
pharmacotherapy group $396.16 (±878.08). The mean (±SD) ADHD-related prescription costs 
were highest in the combination therapy group $1,151.03 (±893.16) followed by the 
pharmacotherapy group $1,112.26 (±901.72). The psychotherapy group did not have any 
ADHD-related medication use thus producing zero cost for the psychotherapy group.   
The mean (±SD) other mental health-related medical costs were highest in the 
psychotherapy group $2,150.26 (±4,818.46) followed by the combination therapy group 
$1,508.27 (± 3,989.50) and the pharmacotherapy group $1,476.99 (±3,997.84). The mean 
(±SD) other mental health-related prescription costs were highest in the combination therapy 
group $327.31 (±1,026.28) followed by the psychotherapy group $213.96 (±903.13) and the 
pharmacotherapy group $185.08 (±875.03). The mean (±SD) other mental health-related total 
costs were highest in the psychotherapy group $2,401.31 (±4,936.03) followed by the 




Table 4.38: Descriptive. All-cause, ADHD-related, and other mental health-related medical and prescription costs for 
pharmacotherapy, psychotherapy, and combination therapy groups 
 Pharmacotherapy (n=5,904) Psychotherapy (n=622) Combination therapy (n=4,351) 
 Mean SD Median Mean SD Median Mean SD Median 
All-cause 
Medical costsa $3,402.86 $6,149.12 $971.89 $5,240.29 $7,145.68 $2,282.51 $4,163.19 $6,235.77 $1,730.08 
Prescription costsb $1,996.19 $1,964.85 $1,632.04 $1,101.34 $1,698.70 $633.38 $2,210.90 $2,772.17 $1,761.07 
Total costsc $6,665.88 $8,840.31 $3,798.01 $6,897.43 $7,856.84 $3,698.10 $7,266.41 $7,254.25 $4,759.14 
ADHD-related 
Medical costsa $396.16 $878.08 $204.81 $884.97 $1,401.92 $466.91 $973.87 $1,348.10 $639.02 
Prescription costsb $1,112.26 $901.72 $930.61 $0.00 $0.00 $0.00 $1,151.03 $893.16 $979.64 
Total costsc $1,582.45 $1,337.77 $1,347.38 $1,001.94 $1,461.57 $571.57 $2,345.99 $1,766.00 $2,011.01 
Other mental health-related 
Medical costsa $1,476.99 $3,997.84 $0.00 $2,150.26 $4,818.46 $0.00 $1,508.27 $3,989.50 $0.00 
Prescription costsb $185.08 $875.03 $0.00 $213.96 $903.13 $0.00 $327.31 $1,026.28 $0.00 
Total costsc $1,820.69 $4,274.53 $15.03 $2,401.31 $4,936.03 $148.55 $1,903.86 $4,148.63 $110.43 
SD = Standard deviation; ADHD = Attention Deficit Hyperactivity Disorder; 
a Medical costs included office-based, outpatient hospital, inpatient, and emergency department costs for all-cause, ADHD-related, and other mental health-
related categories; 
b Prescription costs included prescription medication costs for all-cause, ADHD-related, and other mental health-related categories; 
c Total costs included medical, prescription, and other medical costs (costs that could not be categorized in the medical cost categories); 




4.7.1 All-cause medical, prescription, and total costs  
Objective 5a: To determine and compare the all-cause medical (office-based, inpatient, 
outpatient hospital, and ED), prescription, and total costs between the RX and 
RX+PSY groups 
4.7.1.1 All-cause medical costs  
H5a1: The all-cause medical costs are significantly higher in the RX+PSY group as compared to 
the RX group – Failed to reject 
Table 4.39 shows the results of a generalized linear regression model comparing all-
cause medical costs between the pharmacotherapy and combination therapy groups in the overall 
cohort. All-cause medical costs in the pharmacotherapy group were 0.713 [exp(-0.338)] times 
those costs in the combination therapy group while controlling for covariates (𝛽 = -0.338; x2= 
290.1; p < 0.0001). Thus, all-cause medical costs in the pharmacotherapy group were 28.7% 
lower as compared to the all-cause medical costs in the combination therapy group.   
As for the covariates, patient with higher age, females, and African American 
race/ethnicity were significantly associated with lower all-cause medical costs. Conversely, 
higher pre-index psychiatric visits, pre-index non-psychiatric visits, total pre-index costs, 
Hispanic, other/unknown race/ethnicity, rural residence status, other psychotropic drug use, and 
other mental health diagnosis were significantly associated with higher all-cause medical costs. 
The unit increments on the scale for total pre-index costs were relatively small; therefore, a one 
unit change in pre-index costs may result in a very small change in post-index utilization. 
4.7.1.2 All-cause prescription costs 
H5a2: The all-cause prescription costs are significantly higher in the RX+PSY group as 
compared to the RX group – Failed to reject 
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Table 4.40 shows the results of a generalized linear regression model comparing all-
cause prescription costs between the pharmacotherapy and combination therapy groups in the 
overall cohort. All-cause prescription costs in the pharmacotherapy group were 0.899 times 
[exp(-0.107)]  those costs in the combination therapy group, while controlling for covariates (𝛽 = 
-0.107; x2= 53.0; p < 0.0001). Thus, all-cause prescription costs in the pharmacotherapy group 
were 10.1% lower as compared to the all-cause prescription costs in the combination therapy 
group.   
As for the covariates, patients with higher pre-index psychiatric visits, Hispanics, African 
Americans, rural area residents, and other psychotropic drug users were significantly associated 
with lower all-cause prescription costs. Conversely, higher pre-index non-psychiatric visits, total 
pre-index costs, other mental health diagnosis, and long-acting medications users were 
significantly associated with higher all-cause prescription costs. The unit increments on the scale 
for total pre-index costs were relatively small; therefore, a one unit change in pre-index costs 
may result in a very small change in post-index utilization. 
4.7.1.3 All-cause total costs 
H5a3: The all-cause total costs are significantly higher in the RX+PSY group as compared to the 
RX group – Failed to reject 
Table 4.41 shows the results of a generalized linear regression model comparing all-
cause total costs between the pharmacotherapy and combination therapy groups in the overall 
cohort. All-cause total costs in the pharmacotherapy group were 0.841 times [exp(-0.173)] those 
costs in the combination therapy group, while controlling for covariates (𝛽 = -0.173; x2= 182.0; p 
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< 0.0001). Thus, all-cause total costs in the pharmacotherapy group were 15.9% lower as 
compared to the all-cause total costs in the combination therapy group.   
As for the covariates, patient with higher age, females, African American, and residing in 
rural or unknown area status were significantly associated with lower all-cause total costs. 
Conversely, higher pre-index non-psychiatric visits, total pre-index costs, Hispanic, and 
other/unknown race/ethnicity, other mental health diagnosis, and long-acting medications use 
were significantly associated with higher all-cause total costs. The unit increments on the scale 
for total pre-index costs were relatively small; therefore, a one unit change in pre-index costs 
may result in a very small change in post-index utilization.  
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Table 4.39: Generalized linear model: Comparison of all-cause medical costs between the pharmacotherapy (RX) and combination 
(RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy -0.338 -0.377- -0.299 290.1 <.0001 
Covariates 
Ageb -0.142 -0.166- -0.119 138.8 <.0001 
Pre-index psychiatric visitsb 0.004 0.001-  0.008 7.4 0.01 
Pre-index non-psychiatric visitsb 0.052 0.047-  0.058 308.1 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 684.9 <.0001 
Femalea -0.053 -0.096- -0.010 5.7 0.02 
African Americana  -0.121 -0.185- -0.058 14.2 <.01 
Hispanica 0.346 0.290-  0.401 148.6 <.0001 
Other/Unknowna race/ethnicity 0.330 0.257-  0.404 77.1 <.0001 
Rurala 0.131 0.083-  0.179 28.6 <.0001 
Other psychotropicsa 0.205 0.114-  0.295 19.6 <.0001 
Other mental health diagnosisa 1.011 0.965-  1.057 1859.8 <.0001 
Long-acting medicationsa 0.012 -0.050-  0.074 0.1 0.71 
Short-acting medicationsa 0.019 -0.027-  0.064 0.7 0.42 
Stimulantsa 0.039 -0.046-  0.125 0.8 0.37 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; Generalized linear model with gamma distribution and log-link function; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 
b Recorded as continuous variable in the model; 
Medical costs included all-cause office-based, outpatient hospital, inpatient, and emergency department costs 
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Table 4.40: Generalized linear model: Comparison of all-cause prescription costs between the pharmacotherapy (RX) and 
combination therapy (RX+PSY) groups (N = 10,255) – after controlling for covariates 
 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy -0.107 -0.136- -0.078 53.0 <.0001 
Covariates 
Ageb 0.016 -0.002-  0.033 3.0 0.08 
Pre-index psychiatric visitsb -0.004 -0.006- -0.001 9.8 <.01 
Pre-index non-psychiatric visitsb 0.021 0.017-  0.024 113.9 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 297.0 <.0001 
Femalea -0.029 -0.061-  0.003 3.2 0.07 
African Americana  -0.164 -0.210- -0.117 46.9 <.0001 
Hispanica -0.214 -0.253- -0.175 115.1 <.0001 
Other/Unknowna race/ethnicity -0.048 -0.103-  0.006 3.1 0.08 
Rurala -0.150 -0.184- -0.116 75.6 <.0001 
Other psychotropicsa -0.115 -0.182- -0.047 11.1 <.01 
Other mental health diagnosisa 0.089 0.057-  0.120 30.6 <.0001 
Long-acting medicationsa 0.446 0.400-  0.492 358.8 <.0001 
Short-acting medicationsa 0.021 -0.012-  0.055 1.5 0.22 
Stimulantsa 0.029 -0.035-  0.092 0.8 0.37 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; Generalized linear model with gamma distribution and log-link function; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 
b Recorded as continuous variable in the model; 
Prescription costs included prescription medication costs for all the medications (ADHD-related and non-ADHD related) 
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Table 4.41: Generalized linear model: Comparison of all-cause total costs between the pharmacotherapy (RX) and combination 
therapy (RX+PSY) groups (N = 10,255) – after controlling for covariates 
 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy -0.173 -0.198- -0.148 182.0 <.0001 
Covariates 
Ageb -0.082 -0.098- -0.067 108.9 <.0001 
Pre-index psychiatric visitsb 0.001 -0.001-  0.003 0.6 0.42 
Pre-index non-psychiatric visitsb 0.018 0.015-  0.021 113.0 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 1312.1 <.0001 
Femalea -0.049 -0.077- -0.021 11.9 <.01 
African Americana -0.120 -0.161- -0.080 33.4 <.0001 
Hispanica  0.051 0.016-  0.085 8.2 <.01 
Other/Unknowna race/ethnicity 0.083 0.036-  0.131 11.9 <.01 
Rurala -0.186 -0.216- -0.156 147.5 <.0001 
Other psychotropicsa -0.009 -0.067-  0.050 0.1 0.77 
Other mental health diagnosisa 0.604 0.575-  0.632 1703.1 <.0001 
Long-acting medicationsa 0.167 0.127-  0.207 67.1 <.0001 
Short-acting medicationsa 0.024 -0.005-  0.054 2.6 0.11 
Stimulantsa 0.014 -0.041-  0.070 0.3 0.61 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; Generalized linear model with gamma distribution and log-link function; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 
b Recorded as continuous variable in the model; 
Total costs included total of all-cause medical costs, prescription costs and other costs 
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4.7.2 ADHD-related medical, prescription, and total costs  
Objective 5b: To determine and compare the ADHD-related medical (office-based, inpatient, 
outpatient hospital, and ED), prescription, and total costs between the RX and 
RX+PSY groups 
4.7.2.1 ADHD-related medical costs  
H5b1: The ADHD-related medical costs are significantly higher in the RX+PSY group as 
compared to the RX group – Failed to reject 
Table 4.42 shows the results of a generalized linear regression model comparing ADHD-
related medical costs between the pharmacotherapy and combination therapy groups in the 
overall population. ADHD-related medical costs in the pharmacotherapy group were 0.446 times 
[exp(-0.808)] those costs in the combination therapy group, while controlling for covariates (𝛽 = 
-0.808; x2= 1,661.9; p <.0001). Thus, ADHD-related medical costs in the pharmacotherapy 
group were 55.4% lower as compared to the ADHD-related medical costs in the combination 
therapy group.   
As for the covariates, patients with higher age and higher pre-index psychiatric visits 
were significantly associated with lower ADHD-related medical costs. Conversely, higher pre-
index non-psychiatric visits, total pre-index costs, Hispanics, and other/unknown race/ethnicity, 
rural area residence status, other mental health diagnosis, long- and short-acting medication 
users, and stimulant medication users were associated with higher ADHD-related medical costs. 
The unit increments on the scale for total pre-index costs were relatively small; therefore, a one 
unit change in pre-index costs may result in a very small change in post-index utilization. 
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4.7.2.2 ADHD-related prescription costs 
H5b2: The ADHD-related prescription costs are significantly higher in the RX+PSY group as 
compared to the RX group – Failed to reject 
Table 4.43 shows the results of a generalized linear regression model comparing ADHD-
related prescription costs between the pharmacotherapy and combination therapy groups in the 
overall cohort. ADHD-related prescription costs in the pharmacotherapy group were 0.966 times 
[exp(-0.035)] those costs in the combination therapy group, while controlling for covariates (𝛽 = 
-0.035; x2= 4.5; p = 0.03). Thus, ADHD-related prescription costs in the pharmacotherapy group 
were 3.4% lower as compared to the ADHD-related prescription costs in the combination 
therapy group. 
As for the covariates, female, African American, Hispanic, other/unknown race/ethnicity, 
rural residence status, and other psychotropic drug use were significantly associated with lower 
ADHD-related prescription costs. Conversely, patients with higher age, higher pre-index 
psychiatric visits, long- and short-acting medication users, and stimulant medication users were 
associated with higher ADHD-related prescription costs. 
4.7.2.3 ADHD-related total costs 
H5b3: The ADHD-related total costs are significantly higher in the RX+PSY group as compared 
to the RX group – Failed to reject 
Table 4.44 shows the results of a generalized linear regression model comparing ADHD-
related total costs between the pharmacotherapy and combination therapy groups in the overall 
cohort. ADHD-related total costs in the pharmacotherapy group were 0.677 times [exp (-0.390)] 
those costs in the combination therapy group, while controlling for covariates (𝛽 = -0.390, x2= 
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779.0, p < .0001). Thus, ADHD-related total costs in the pharmacotherapy group were 32.3% 
lower as compared to the ADHD-related total costs in the combination therapy group. 
As for the covariates, females, Hispanics, African American, other/unknown 
race/ethnicity, rural residence status, and other psychotropic drug users were significantly 
associated with lower ADHD-related total costs. Conversely, patients with higher age, higher 
pre-index non-psychiatric visits, other mental health diagnosis, long- or short-acting, and 
stimulant medication users were significantly associated with higher ADHD-related total costs. 
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Table 4.42: Generalized linear model: Comparison of ADHD-related medical costs between the pharmacotherapy (RX) and 
combination therapy (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy -0.808 -0.846- -0.769 1,661.9 <.0001 
Covariates 
Ageb -0.056 -0.081- -0.032 20.7 <.0001 
Pre-index psychiatric visitsb -0.004 -0.007- -0.001 6.1 0.01 
Pre-index non-psychiatric visitsb 0.024 0.018-  0.029 74.7 <.0001 
Total pre-index costsb 0.000 0.000-  0.000 9.3 <.01 
Femalea -0.010 -0.053-  0.034 0.2 0.67 
African Americana  -0.023 -0.087-  0.040 0.5 0.47 
Hispanica 0.244 0.189-  0.299 75.6 <.0001 
Other/Unknowna race/ethnicity 0.180 0.107-  0.254 23.0 <.0001 
Rurala 0.149 0.102-  0.197 38.6 <.0001 
Other psychotropicsa 0.029 -0.062-  0.120 0.4 0.54 
Other mental health diagnosisa 0.313 0.269-  0.357 192.4 <.0001 
Long-acting medicationsa 0.180 0.117-  0.242 31.8 <.0001 
Short-acting medicationsa 0.116 0.070-  0.162 24.8 <.0001 
Stimulantsa 0.118 0.031-  0.205 7.0 0.01 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; Generalized linear model with gamma distribution and log-link function; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 
b Recorded as continuous variable in the model; 
a Medical costs included ADHD-related office-based, outpatient hospital, inpatient, and emergency department costs 
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Table 4.43: Generalized linear model: Comparison of ADHD-related prescription costs between the pharmacotherapy (RX) and 
combination therapy (RX+PSY) groups (N = 10,255) – after controlling for covariates 
 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy -0.035 -0.067- -0.003 4.5 0.03 
Covariates 
Ageb 0.123 0.103-  0.143 145.7 <.0001 
Pre-index psychiatric visitsb 0.003 0.001-  0.006 5.5 0.02 
Pre-index non-psychiatric visitsb 0.002 -0.002-  0.006 0.7 0.41 
Total pre-index costsb 0.000 0.000-  0.000 0.3 0.61 
Femalea -0.080 -0.116- -0.044 19.1 <.0001 
African Americana  -0.213 -0.265- -0.160 63.1 <.0001 
Hispanica -0.185 -0.228- -0.141 68.5 <.0001 
Other/Unknowna race/ethnicity -0.187 -0.248- -0.126 36.1 <.0001 
Rurala -0.055 -0.093- -0.017 8.1 <.01 
Other psychotropicsa -0.236 -0.312- -0.161 37.6 <.0001 
Other mental health diagnosisa 0.017 -0.018-  0.052 0.9 0.34 
Long-acting medicationsa 0.811 0.759-  0.862 942.3 <.0001 
Short-acting medicationsa 0.110 0.072-  0.148 32.3 <.0001 
Stimulantsa 0.165 0.094-  0.236 20.8 <.01 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; Generalized linear model with gamma distribution and log-link function; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 
b Recorded as continuous variable in the model 
a Prescription costs included prescription costs for ADHD-related medications 
183 
 
Table 4.44: Generalized linear model: Comparison of ADHD-related total costs between the pharmacotherapy (RX) and combination 
therapy (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Characteristics Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy -0.390 -0.417- -0.363 779.0 <.0001 
Covariates 
Ageb 0.064 0.047-  0.081 53.9 <.0001 
Pre-index psychiatric visitsb -0.001 -0.003-  0.002 0.4 0.54 
Pre-index non-psychiatric visitsb 0.006 0.003-  0.010 13.1 <.01 
Total pre-index costsb 0.000 0.000-  0.000 2.9 0.09 
Femalea -0.056 -0.086- -0.026 13.1 <.01 
African Americana -0.127 -0.171- -0.082 31.0 <.0001 
Hispanica -0.070 -0.107- -0.032 13.4 <.01 
Other/Unknowna race/ethnicity -0.061 -0.112- -0.009 5.3 0.02 
Rurala -0.050 -0.082- -0.017 9.1 <.01 
Other psychotropicsa -0.144 -0.208- -0.080 19.3 <.0001 
Other mental health diagnosisa 0.124 0.094-  0.155 64.8 <.0001 
Long-acting medicationsa 0.513 0.470-  0.557 528.1 <.0001 
Short-acting medicationsa 0.102 0.070-  0.134 38.5 <.0001 
Stimulantsa 0.123 0.062-  0.183 15.9 <.0001 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; Generalized linear model with gamma distribution and log-link function; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other mental health diagnosis, no long-acting 
medication use, no short-acting medication use, and non-stimulant use; 
b Recorded as continuous variable in the model; 




4.7.3 Other mental health-related medical, prescription, and total costs  
Objective 5c: To determine and compare the other mental health-related medical costs (office-
based, inpatient, outpatient hospital, and ER), prescription costs, and total costs 
between the RX and RX+PSY groups 
4.7.3.1 Other mental health-related medical costs  
H5c1: The other mental health-related medical costs are significantly higher in the RX+PSY 
group as compared to the RX group- Failed to reject 
Table 4.45 shows the results of a generalized linear regression model comparing other 
mental health-related medical costs between the pharmacotherapy and combination therapy 
groups in the overall cohort. Other mental health-related medical costs in the pharmacotherapy 
group were 0.691 times [exp(-0.370)] those costs in the combination therapy group, while 
controlling for covariates (𝛽 = -0.370, x2= 1.1, p < 0.0001). Thus, other mental health-related 
medical costs in the pharmacotherapy group were 30.9% lower as compared to the other mental 
health-related medical costs in the combination therapy group. 
As for the covariates, patients with higher age, females, and rural residence status were 
significantly associated with lower other mental health-related medical costs. Conversely, higher 
pre-index psychiatric visits, pre-index total costs, Hispanic, and other/unknown race/ethnicity 
were significantly associated with higher other mental health-related medical costs.  
4.7.3.2 Other mental health-related prescription costs 
H5c2: The other mental health-related prescription costs are significantly higher in the RX+PSY 
group as compared to the RX group– Failed to reject 
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Table 4.46 shows the results of a generalized linear regression model comparing other 
mental health-related prescription costs between the pharmacotherapy and combination therapy 
groups in the overall cohort. Other mental health-related prescription costs in the 
pharmacotherapy group were 0.513 times [exp(-0.668)] those costs in the combination therapy 
group, while controlling for covariates (𝛽 = -0.668, x2= 7.5, p < 0.0001). Thus, other mental 
health-related prescription costs in the pharmacotherapy group were 48.7% lower as compared to 
the other mental health-related prescription costs in the combination therapy group. 
As for the covariates, patients with higher age, higher pre-index psychiatric and non-
psychiatric visits, Hispanic race/ethnicity, and rural residence status were significantly associated 
with lower other mental health-related prescription costs. Conversely, higher total pre-index 
costs, other/unknown race/ethnicity, and long-acting medication users were significantly 
associated with higher other mental health-related prescription costs. The unit increments on the 
scale for total pre-index costs were relatively small; therefore, a one unit change in pre-index 
costs may result in a very small change in post-index utilization.  
4.7.3.3 Other mental health-related total costs 
H5c3: The other mental health-related total costs are significantly higher in the RX+PSY group 
as compared to the RX group– Failed to reject 
 
 
Table 4.47 shows the results of a generalized linear regression model comparing other 
mental health-related total costs between the pharmacotherapy and combination therapy groups 
186 
 
in the overall cohort. Other mental health-related total costs in the pharmacotherapy group were 
0.633 times [exp(-0.458)] those costs in the combination therapy group, while controlling for 
covariates (𝛽 = -0.458, x2= 6.8, p =0.03). Thus, other mental health-related total costs in the 
pharmacotherapy group were 36.7% lower as compared to the ADHD-related prescription costs 
in the combination therapy group. 
As for the covariates, patient with higher age, females, and rural area residents were 
significantly associated with lower other mental health-related total costs. Conversely, higher 
pre-index psychiatric visits, total pre-index costs, Hispanic, and other/unknown race/ethnicity 
were significantly associated with higher other mental health-related total costs. The unit 
increments on the scale for total pre-index costs were relatively small; therefore, a one unit 
change in pre-index costs may result in a very small change in post-index utilization.
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Table 4.45: Generalized linear model: Comparison of other mental health-related medical costs between the pharmacotherapy (RX) 
and combination therapy (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Parameter Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy -0.370 -0.544- -0.195 1.1 <.0001 
Covariates 
Ageb -0.416 -0.516- -0.317 44.0 <.0001 
Pre-index psychiatric visitsb 0.036 0.018-  0.053 9.6 <.0001 
Pre-index non-psychiatric visitsb 0.019 -0.006-  0.044 0.4 0.14 
Total pre-index costsb 0.000 0.000-  0.000 291.1 <.0001 
Femalea -0.307 -0.498- -0.115 16.0 <.01 
African Americana 0.278 -0.010-  0.566 3.8 0.06 
Hispanica 1.232 0.969-  1.494 21.7 <.0001 
Other/Unknowna race/ethnicity 1.121 0.793-  1.450 11.4 <.0001 
Rurala -0.562 -0.796- -0.328 73.4 <.0001 
Other psychotropicsa 0.059 -0.355-  0.474 1.4 0.78 
Long-acting medicationsa -0.118 -0.391-  0.155 2.0 0.40 
Short-acting medicationsa -0.018 -0.219-  0.182 2.0 0.86 
Stimulantsa 0.017 -0.361-  0.395 0.4 0.93 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; Generalized linear model with gamma distribution and log-link function 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no long-acting medication use, no short-acting 
medication use, and non-stimulant use; 
b Recorded as continuous variable in the model; 
Medical costs included other mental health-related office-based, outpatient hospital, inpatient, and emergency department costs; 




Table 4.46: Generalized linear model: Comparison of other mental health-related prescription costs between the pharmacotherapy 
(RX) and combination therapy (RX+PSY) groups (N = 10,255) – after controlling for covariates 
 
Parameter Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy -0.668 -0.842- -0.495 7.5 <.0001 
Covariates 
Ageb -0.206 -0.307- -0.106 0.1 <.0001 
Pre-index psychiatric visitsb -0.021 -0.036- -0.006 8.9 0.01 
Pre-index non-psychiatric visitsb -0.026 -0.045-  0.006 2.5 0.01 
Total pre-index costsb 0.000 0.000-  0.000 32.4 <.0001 
Femalea -0.119 -0.304-  0.067 2.6 0.21 
African Americana 0.072 -0.204-  0.347 0.5 0.61 
Hispanica -0.569 -0.790- -0.347 15.1 <.0001 
Other/Unknowna race/ethnicity 0.432 0.118-  0.747 3.9 0.01 
Rurala -0.270 -0.468- -0.071 5.4 0.01 
Other psychotropicsa 0.063 -0.340-  0.466 2.2 0.76 
Long-acting medicationsa 0.392 0.128-  0.657 1.6 <.01 
Short-acting medicationsa -0.089 -0.286-  0.106 19.4 0.37 
Stimulantsa -0.247 -0.613-  0.120 1.4 0.19 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; Generalized linear model with gamma distribution and log-link function; 
a Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no long-acting medication use, no short-acting 
medication use, and non-stimulant use; 
b Recorded as continuous variable in the model; 
Prescription costs included prescription costs for other mental health-related medications (antipsychotics, anticonvulsants, anxiolytics, antimanic, and 
antidepressants); 






Table 4.47: Generalized linear model: Comparison of other mental health-related total costs between the pharmacotherapy (RX) and 
combination therapy (RX+PSY) groups (N = 10,255) – after controlling for covariates 
Parameter Estimate 95% CI x2 p-value* 
Treatment groupa 
Pharmacotherapy -0.458 -0.591- -0.326 6.8 0.03 
Covariates 
Ageb -0.344 -0.419- -0.269 89.3 <.0001 
Pre-index psychiatric visitsb 0.027 0.015-  0.039 25.1 <.0001 
Pre-index non-psychiatric visitsb 0.005 -0.012-  0.023 10.1 0.54 
Total pre-index costsb 0.000 0.000-  0.000 476.5 <.0001 
Femalea -0.282 -0.423- -0.141 30.1 <.0001 
African Americana -0.172 -0.039-  0.383 0.2 0.11 
Hispanica 0.501 0.320-  0.681 91.9 <.0001 
Other/Unknowna race/ethnicity 0.632 0.394-  0.870 38.8 <.0001 
Rurala -0.632 -0.798- -0.468 25.6 <.0001 
Other psychotropicsa -0.125 -0.430-  0.181 0.8 0.42 
Long-acting medicationsa -0.055 -0.257-  0.147 3.8 0.59 
Short-acting medicationsa -0.026 -0.175-  0.123 3.7 0.73 
Stimulantsa 0.086 -0.193-  0.366 0.9 0.54 
*p < 0.05 (in bold); CI = Confidence Interval; x2= Chi-square; Generalized linear model with gamma distribution and log-link function; 
a Reference categories: Combination therapy group, males, whites, urban residents, no psychotropic use, no long-acting medication use, no short-acting 
medication use, and non-stimulant use; 
b Recorded as continuous variable in the model; 
Total costs included other mental health-related medical costs, prescription costs, and other costs 
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4.7.4 Cost estimates 
Table 4.48 shows the adjusted mean cost estimates of all-cause, ADHD-related, and 
other mental health-related costs for the pharmacotherapy and combination therapy group. The 
adjusted mean all-cause (medical, prescription, and total) costs, ADHD-related (medical and 
total) costs, and other mental health-related (medical, prescription, and total) costs were 
significantly higher in the combination therapy group as compared to pharmacotherapy group.   
Table 4.48: Generalized linear model. Mean adjusted cost estimates for all-cause, ADHD-
related, and other mental health-related medical, prescription, and total costs 
between the pharmacotherapy and combination therapy groups 
Characteristics Pharmacotherapy 
(n=5,904) 
Combination therapy  
(n = 4,351) 
z p-value 
  Mean SE Mean SE   
All-cause costs  
Medical costsa $3,233.23  $61.95  $4,554.06  $100.04  -13.46 <.0001 
Prescription costsb $2,019.20  $25.33  $2,249.70  $32.81  -5.69 <.0001 
Total costsc $6,465.85  $72.60 $7,660.07  $100.75 -10.39 <.0001 
ADHD-related costs 
Medical costsa $400.97  $9.55  $993.04  $27.41  -19.68 <.0001 
Prescription costsb $1,109.36  $12.93 $1,150.86  $19.42  -2.08 0.04 
Total costsc $1,587.26  $17.77  $2,351.86  $30.60 -21.78 <.0001 
Other mental health-related costs 
Medical costsa $1,579.29  $240.78 $2,285.66  $373.11  -3.34 <.01 
Prescription costsb $183.46  $11.07  $357.93  $25.81  -6.38 <.0001 
Total costsc $1,594.71  $108.77  $2,522.20  $202.58 -5.74 <.0001 
SE = Standard Error; ADHD = Attention Deficit Hyperactivity Disorder; 
a Medical costs included office-based, outpatient hospital, inpatient, and emergency department costs for all-cause, 
ADHD-related, and other mental health-related categories; 
b Prescription costs included prescription medication costs for all-cause, ADHD-related, and other mental health-
related categories; 
c Total costs included medical, prescription, and other medical costs 
Costs were estimated based on 2013 dollars 
The results of the hypotheses tests conducted for the study are summarized in Table 4.49.
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Table 4.49: Results of hypothesis testing 
Objectives and Hypotheses Test results 
Objective 1 – To determine the annual prevalence and incidence of ADHD in the Texas Medicaid preschool population 
1a: To determine the treated prevalence of ADHD in preschoolers <6 years of age enrolled in Texas Medicaid  No hypothesis  
1b: To determine the treated incidence of ADHD in preschoolers <6 years of age enrolled in Texas Medicaid No hypothesis 
Objective 2 – To determine and compare the baseline characteristics between RX, PSY, and RX+PSY groups 
2a: To determine and compare the baseline demographic, clinical, and prior utilization characteristics between 
the pharmacotherapy only (RX), psychotherapy only (PSY), and pharmacotherapy + psychotherapy 
combined (RX+PSY) groups 
No hypothesis  
Objective 3 – To assess the treatment patterns of preschoolers (2 to <6 years of age) with ADHD    
3a: To determine the time to “first pharmacotherapy,” “first psychotherapy,”  and “first combination therapy” No hypothesis 
3b: To compare the time to first pharmacotherapy, psychotherapy, and combination therapy in preschoolers with ADHD and to compare time to 
pharmacotherapy with respect to gender, race/ethnicity, medication duration of action 
H0(3b)1: There is no difference in time-to-initiation of pharmacotherapy (“first RX”), psychotherapy 
(“first PSY”), and “first combination therapy” 
Rejected  
H0(3b)2: There is no significant difference in the time-to-initiation of RX in male vs. female ADHD 
patients 
Failed to reject 
H0(3b)3: There is no significant difference in the time-to-initiation of RX in different race/ethnicity 
groups diagnosed with ADHD 
Rejected for Hispanic vs. 
White and for 
Others/unknown vs. White 
H0(3b)4: There is no significant difference in the time-to-initiation of RX with respect to long-acting 
(LA) vs. short-acting (SA) medications in ADHD patients  
Rejected 
H0(3b)5: There is no significant difference in the time-to-initiation of RX by physician specialty Could not test 
3c: To assess the factors associated with receiving RX, PSY, or RX+PSY, after controlling for covariates No hypothesis 
3d: To compare adherence, persistence, augmentation, and switching between the RX and the RX+PSY groups 
H0(3d)1: There is no significant difference in the likelihood of medication adherence between the RX 
and the RX+PSY groups, after controlling for covariates 
Rejected 
H0(3d)2: There is no significant difference in time to discontinuation between the RX and the RX+PSY 
groups, after controlling for covariates 
Failed to reject 
H0(3d)3: There is no significant difference in the likelihood of medication augmentation between the RX 





Table 4.49: Results of hypothesis testing (continued) 
Objectives and Hypotheses Test results 
H0(3d)4: There is no significant difference in the likelihood of switching between the RX and the 
RX+PSY groups, after controlling for covariates 
Rejected 
Objective 4 – To determine and compare healthcare utilization between the RX and the RX+PSY groups 
4a: To determine and compare the healthcare utilization frequencies for all-cause office-based, inpatient, outpatient hospital, emergency 
department (ED) visits, and prescriptions between the RX and the RX+PSY groups 
H(4a)1: The number of all-cause office-based visits is significantly higher in the RX+PSY group as 
compared to the RX group 
Failed to reject   
H(4a)2: The number of all-cause inpatient visits is significantly higher in the RX+PSY group as 
compared to the RX group 
Failed to reject   
H(4a)3: The number of all-cause outpatient hospital visits is significantly higher in the RX+PSY group 
as compared to the RX group 
Failed to reject   
H(4a)4: The number of all-cause ED visits is significantly higher in the RX+PSY group as compared to 
the RX group 
Failed to reject    
H(4a)5: The number of all-cause prescriptions is significantly higher in the RX+PSY group as 
compared to the RX group 
Failed to reject    
4b: To determine and compare the healthcare utilization frequencies for ADHD-related office-based, inpatient, outpatient hospital, ED visits, 
and prescriptions between the RX and RX+PSY groups 
H(4b)1: The number of ADHD-related office-based visits is significantly higher in the RX+PSY group 
as compared to the RX group 
Failed to reject    
H(4b)2: The number of ADHD-related inpatient visits is significantly higher in the RX+PSY group as 
compared to the RX group 
Failed to reject   
H(4b)3: The number of ADHD-related outpatient hospital visits is significantly higher in the 
RX+PSY group as compared to the RX group 
Failed to reject   
H(4b)4: The number of ADHD-related ED visits is significantly higher in the RX+PSY group as 
compared to the RX group 
Could not test due to small 
sample size   
H(4b)5: The number of ADHD-related prescriptions is significantly higher in the RX+PSY group as 







Table 4.49: Results of hypothesis testing (continued) 
Objectives and Hypotheses Test results 
4c: To determine and compare the healthcare utilization frequencies for other mental health-related office-based, inpatient, 
outpatient hospital, ED visits, and prescriptions between the RX and RX+PSY groups 
 
H(4c)1: The number of other mental health-related office-based visits is significantly higher in the RX+PSY group as 
compared to the RX group 
Rejected   
H(4c)2: The number of other mental health-related inpatient visits is significantly higher in the RX+PSY group as 
compared to the RX group 
Rejected   
H(4c)3: The number of other mental health-related outpatient hospital visits is significantly higher in the RX+PSY 
group as compared to the RX group 
Failed to reject   
H(4c)4: The number of other mental health-related ED visits is significantly higher in the RX+PSY group as compared 
to the RX group 
Could not test   
H(4a)5: The number of other mental health-related prescriptions is significantly higher in the RX+PSY group as 
compared to the RX group 
Failed to reject    
Objective 5: To determine and compare healthcare costs between the RX and the RX+PSY groups 
5a: To determine and compare the all-cause medical (office-based, inpatient, outpatient hospital, and ED), prescription, and total costs between 
the RX and RX+PSY groups 
H(5a)1: The all-cause medical costs are significantly higher in the RX+PSY group as compared to the RX group  Failed to reject   
H(5a)2: The all-cause prescription costs are significantly higher in the RX+PSY group as compared to the RX group Failed to reject   
H(5a)3: The all-cause total costs are significantly higher in the RX+PSY group as compared to the RX group Failed to reject   
5b: To determine and compare the ADHD-related medical (office-based, inpatient, outpatient hospital, and ED), prescription, and total costs 
between the RX and RX+PSY groups 
H(5b)1: The ADHD-related medical costs are significantly higher in the RX+PSY group as compared to the RX group Failed to reject   
H(5b)2: The ADHD-related prescription costs are significantly higher in the RX+PSY group as compared to the RX 
group 
Failed to reject     
H(5b)3: The ADHD-related total costs are significantly higher in the RX+PSY group as compared to the RX group Failed to reject   
5c: To determine and compare the other mental health-related medical costs (office-based, inpatient, outpatient hospital, and ED), prescription 
drug costs, and total costs between the RX and RX+PSY groups 
H(5c)1: The other mental health-related medical costs are significantly higher in the RX+PSY group as compared to 
the RX group 
Failed to reject 
H(5c)2: The other mental health-related prescription costs are significantly higher in the RX+PSY group as compared 
to the RX group 
Failed to reject   
H(5c)3: The other mental health-related total costs are significantly higher in the RX+PSY group as compared to the 
RX group 
Failed to reject   
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CHAPTER 5: DISCUSSION 
Chapter Overview  
This chapter provides a detailed discussion of the study results. The chapter begins with a 
brief review of the study objectives. This is followed by a discussion of the study results, 
comparisons with previous research, and possible explanations for study findings. The chapter 
concludes with a discussion regarding study limitations, implications, and suggestions for future 
research. 
5.1 Review of study objectives 
In an attempt to contribute to the literature on ADHD treatment in preschoolers, the aim 
of the current study was to understand the prevalence, incidence, treatment patterns (i.e., 
adherence, persistence, augmentation, and switching), resource utilization (i.e., office-based, 
outpatient hospital, inpatient, emergency department visits, and prescriptions), and costs (i.e., 
medical, prescription, and total costs) of ADHD in preschoolers using paid claims dated between 
January 2008 and December 2013 in the Texas Medicaid dataset. Historically, the prevalence of 
ADHD in Texas has been higher than the national average and thus, it is important to understand 
the burden of ADHD in preschoolers.37 Additionally, ADHD is among the conditions with the 
highest expenditures for Texas Medicaid making it important to study the factors associated with 
resource use and costs in this population.123 Apart from being the first study to assess 
preschoolers with ADHD in Texas, to our knowledge, this is the only study providing a 




5.2 Patient demographic, clinical, and prior utilization characteristics 
In the sample of 10,877 preschoolers with ADHD in this study, the patient demographic, 
clinical, and prior utilization characteristics were similar in the overall and treatment pattern 
cohorts. According to the Centers for Disease Control (CDC), the average age of current ADHD 
diagnosis was reported to be 6.2 years in patients between 4 and 17 years of age with mild, 
moderate, and severe forms of ADHD.37 The mean (± SD) age of ADHD diagnosis in the 
current study was estimated at 4.7 (± 0.9) years which is 1.5 years lower than the CDC estimate; 
however, it corresponded to the age of diagnosis reported by the CDC for severe forms of 
ADHD (4.4 years). Since the current study included preschoolers from 2 to < 6 years of age, it is 
likely that the difference in age ranges considered for the mean age calculations contributed to 
the lower age reported in the current study compared to the CDC estimate. It is also possible that 
patients in the current study were more severe, thus, being diagnosed at an early age; however, 
this relationship could not be evaluated because a direct measure of ADHD severity was not 
available in the dataset. 
In our study, males (72.9%) comprised a much higher proportion of preschoolers 
diagnosed with ADHD as compared to females (27.1%), which is in agreement with previous 
studies using the Texas Medicaid dataset.83,84 Although the predisposition to an ADHD diagnosis 
in males and females in the population is unknown, the higher proportion of males in the current 
study may be explained in part by differences in symptom presentation in males and females. 
Previous research provides evidence that males are more likely to be diagnosed with the 
hyperactive/impulsive ADHD subtype exhibiting more “externalizing symptoms” (i.e., running, 
hitting, and impulsivity), whereas females are more likely to be diagnosed with the inattentive 
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subtype exhibiting more “internalizing symptoms” (e.g., depression, anxiety, and low self-
esteem).124 The externalizing symptoms might be more obvious resulting in screening and 
diagnosis, which may explain the higher proportion of male patients observed in the current 
study. 
With respect to race/ethnicity, the CDC reports that ADHD is more prevalent nationally 
in Whites followed by African Americans and other race/ethnicity groups.125–127 In the current 
study, a majority of the preschoolers diagnosed with ADHD were Hispanic. A higher proportion 
of Hispanic preschoolers was not unexpected, as Hispanics represent the highest proportion of 
enrollees in the Texas Medicaid program. In addition, the proportion of Hispanics diagnosed 
with ADHD was similar to that found in a study conducted by Lawson et al. (2012) using Texas 
Medicaid data from 2006 to 2007 (52.3%).84  
In the current study, ADHD patients were more likely to reside in urban areas as 
compared to rural areas. In a study conducted using the Medical Expenditure Panel Survey 
(MEPS) data, Anderson et al. (2013) reported that children residing in rural areas were more 
likely to be diagnosed with ADHD.128 However, the authors emphasized that the differences did 
not persist after controlling for demographic characteristics.    
ADHD is often associated with comorbid mental health conditions and treatments. In the 
current study, approximately 5% of the patients had other psychotropic medication use. Previous 
studies have also reported psychotropic medication use in preschoolers. In a study conducted to 
determine the prevalence of psychotropic drug use in preschool aged youth using multi-state 
Medicaid program data and salaried group model health maintenance organization (HMO) data, 
Zito et al. (2000) found that 1.23% (n = 1,865) of preschoolers between the ages of 2 and 4 were 
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being prescribed psychotropic medications. Similar trends have been reported in other studies 
conducted on the preschool population using US managed care and MarketScan Research 
datasets.90,129,130 In a study using US managed care claims data, Van Brunt et al. (2005) reported 
the use of bupropion, antidepressants, antipsychotics, antimanics, and anxiolytics in preschool 
patients diagnosed with ADHD.90 In a recent systematic review, Birnbaum et al. (2013) 
concluded that 30.5% of preschoolers treated with antipsychotics were reported to have a 
diagnosis of ADHD.88 In a study examining trends of psychotropic drug utilization of Medicaid 
preschool patients diagnosed with ADHD, Fullerton et al. (2012) reported that the probability of 
filling at least one antipsychotic medication in 2005 was two times that in 1996.131 Further 
exploration of psychotropic drug use in the preschool population will help uncover patterns of 
medication use. In addition to the psychotropic medication use, nearly one-third of the patients 
had other mental health diagnoses, which is in agreement with previous studies.132,133  
Investigation of other factors related to ADHD treatments has been reported in the 
literature. The current study explored the treatment characteristics of preschoolers diagnosed 
with ADHD. A majority of the patients in the current study were taking long-acting (89.0%) 
medications whereas short-acting medications were prescribed in approximately 40% of the 
cases, which is consistent with previous studies conducted by Lawson et al. (2012) and Barner et 
al. (2011) using the Texas Medicaid dataset.83,84 Similar to previous studies, patients in the 
current study also had a higher proportion of stimulant medication use than non-stimulant 
medications.83,84 Studies have shown that simulants are associated with more favorable outcomes 
in alleviating the core symptoms of hyperactivity, impulsivity, inattentiveness, and associated 
aggressiveness exhibited in patients with ADHD. Therefore, stimulants may be a preferred 
choice of treatment even in the preschool population.  
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The mean numbers of pre-index psychiatric visits were similar in both the overall (1.4 ± 
6.7) and the treatment pattern (1.8 ± 7.6) cohorts. The mean numbers of pre-index non-
psychiatric visits were higher than the mean number of pre-index psychiatric visits in both 
cohorts (3.3 ± 4.4 vs. 4.6 ± 5.3). A study by Chan et al. (2002) conducted using Medical 
Expenditure Panel Survey (MEPS) data from 1996 estimated that the average number of 
outpatient visits for patients with ADHD was (5.97 ± 0.60), followed by home health (2.08 ± 
2.04) visits and ED visits (0.23 ± 0.05).134 In another study using a large not-for-profit staff 
model HMO dataset, Guevara et al. (2001) reported a higher number of primary care visits (3.84 
± 3.30), followed by mental health visits (1.35 ± 3.11) and ED visits (0.08 ± 0.33).135 These 
studies, however, were conducted in the school-aged population and may not be directly 
comparable to our results. Although no known study has estimated costs in preschoolers before 
ADHD diagnosis, the current study estimated the mean total pre-index costs at $2,372.16 in the 
overall cohort and at $2,552.42 in the treatment pattern cohort. 
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5.3 Study objectives 
The present study addressed five major objectives covering 33 hypotheses. A discussion 
for each objective is presented in the following sections.   
5.3.1 Objective 1: Prevalence and incidence  
Objective 1a: To determine the prevalence of ADHD in preschoolers <6 years of age enrolled in 
Texas Medicaid 
Objective 1b: To determine the incidence of ADHD in preschoolers <6 years of age enrolled in 
Texas Medicaid 
This part of the study provides insight into the prevalence and incidence of ADHD in 
preschoolers in a state Medicaid pediatric population. To summarize, the treated prevalence of 
ADHD in preschoolers rose steadily from 2008 to 2012; however, the treated incidence estimates 
were stable across those years. ADHD prevalence increased in Texas Medicaid preschoolers 
through the five study years, with an estimated 2.1, 3.9, 5.9, 7.6, and 8.5 cases per 1,000 
preschool enrollees meeting inclusion criteria during 2008, 2009, 2010, 2011, and 2012, 
respectively. These estimates are lower than the most recent national estimates that reported a 
prevalence estimate of 11.0% in the national population and 10.1% in Texas among children and 
adolescents between 4 and 17 years of age.37 A direct comparison seems unwarranted since the 
age range (< 6 years) of the population under consideration in the current study is different from 
the age range (4-17 years) reported by the CDC. Nonetheless, certain factors may help explain 
the differences. The lower prevalence rates found in the present study could be associated with 
challenges in establishing a correct diagnosis of ADHD in preschoolers since they have naturally 
high energy levels and impulsivity. Additionally, the extensive set of inclusion and exclusion 
criteria used in the current study were different from the methodology used by the CDC to 
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estimate prevalence. For instance, we required that the patients should be continuously enrolled 
with at least 2 medication claims for the entire year to be included in the prevalence and 
incidence estimates. This would have excluded those patients who received a diagnosis for 
ADHD and were not continuously enrolled or did not receive any medication for ADHD.    
The incidence was estimated at 2.4, 2.6, 2.7, and 2.1 cases per 1,000 preschoolers (<6 
years of age) for 2009, 2010, 2011, and 2012, respectively. The incidence estimates of ADHD in 
the preschool population were relatively stable and were lower than the incidence estimates 
reported by previous studies. A study assessing the incidence of psychiatric disorders using the 
Teen Health 2000 data revealed that the incidence of ADHD was 1.2%.136 A meta-regression 
analysis of 135 studies by Polanczyk et al. (2014) reported that differences in reported ADHD 
prevalence and incidence estimates could be mostly explained by methodological differences 
characterizing these studies. As discussed earlier, these methodological differences may explain 
the lower incidence estimates in the Texas Medicaid population.137  
Increasing proportions of preschoolers were found to be diagnosed with ADHD each 
year, which could be associated with an actual increase in prevalence or with increasing 
awareness of the condition. Increasing awareness may influence the prevalence rate by 
increasing diagnosis of the previously undiagnosed cases. Additionally, increasing awareness in 
the general population (e.g., teachers, parents, and day care personnel) regarding the symptoms 
of ADHD may have led to higher screening and evaluation rates by healthcare professionals. 
According to Sax et al. (2003), teachers were foremost in suggesting a diagnosis of ADHD 
(46.4%), followed by parents (30.2%), primary care physicians (11.3%), school personnel other 
than teachers (6.0%), consultants such as child psychiatrists or psychologists (3.1%), and other 
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specified categories (3.0%).138 The higher rates of screening and evaluation may have influenced 
the prevalence rates over time. 
In Texas, the STAR Health program was implemented on April 01, 2008;  it covers 
children <18 years of age under the Department of Family and Protective Services (DFPS).139 
STAR Health provides a full-range of Medicaid-covered medical and behavioral health services 
for children in DFPS conservatorship and young adults in DFPS paid placements. A report 
submitted to a subcommittee of the Senate Committee on Homeland Security and Governmental 
Affairs by the National Alliance on Mental Illness (NAMI) highlighted that children in foster 
care settings often experience high rates of mental illness, including ADHD, which may be 
associated with genetic, environmental (i.e., in utero exposure to drugs and alcohol), and social 
determinants (i.e., abuse, neglect, removal from their families and homes, multiple placements, 
poverty, and related experiences).140 Additionally, the AAP implemented a new set of clinical 
practice guidelines for diagnosis and evaluation of ADHD in children and adolescents in 2011. 
The age range of diagnosis was expanded to include patients from 4 to 18 years of age as 
compared to 6 to 12 years of age in the previous guidelines.29 Thus, expanding coverage to 
include foster care children and modifications in the age range for diagnosis of ADHD also may 
have contributed to the increase in prevalence estimates in the latter years of the current study. 
Additionally, coverage of ADHD in the public press and media may have shifted the attention to 
diagnosis of ADHD, thereby resulting in higher prevalence and incidence rates. 
Due to lack of availability of accurate enrollment information for preschoolers enrolled in 
Texas Medicaid, prevalence and incidence estimates were calculated using an estimate of 1.2 
million enrollees (average enrollment from 2012-2013) provided by Texas Medicaid. This may 
have influenced the prevalence and incidence rates in either direction depending on the actual 
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enrollment numbers in each year. Additionally, the increase in estimated prevalence rates despite 
stable incidence estimates could be due to the cross-sectional nature of the data. Although we 
estimated treated prevalence, to our knowledge it is the only study that provides epidemiology 
estimates of preschoolers (<6 years) using the Texas Medicaid population. Considering that 
Medicaid/SCHIP enrolled children provide coverage to nearly 50% of the total children in the 
state of Texas, these estimates could be useful to the Texas state government. 141 
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5.3.2 Objective 2: Comparison of treatment groups with respect to patient demographic, 
clinical, and prior utilization characteristics 
Objective 2a: To determine and compare the baseline demographic, clinical, and prior 
utilization characteristics between the pharmacotherapy only (RX), psychotherapy 
only (PSY), and pharmacotherapy + psychotherapy combined (RX+PSY) groups 
The second objective of the study was to compare the patient demographic, clinical, and 
prior utilization characteristics between the treatment groups. The explanations provided in 
section 5.2 are also applicable to this section.  
In the current study, we identified 10,877 patients between 2 and 6 years of age receiving 
treatment for ADHD. Of these patients, a higher proportion were male, Hispanic, residing in 
urban areas, did not receive psychotropic medications, did not have a mental health diagnosis, 
used long-acting medications, had a higher mean number of pre-index non-psychiatric visits, and 
had a higher mean total pre-index cost in the psychotherapy group. Although the age range in the 
previous studies conducted using Texas Medicaid dataset were different from the present study, 
the proportions were still comparable. In a study using the Texas Medicaid dataset, Lawson et al. 
(2012) reported similar trends in the treatment of school-aged children and adults.84 Furthermore, 
in the current study Hispanics comprised the largest group of preschoolers receiving treatment 
for ADHD. This trend was reflected in the study by Lawson et al. (2012) where the proportion of 
Hispanic patients receiving therapy was higher as compared to the other race/ethnicities.84  
The results of the current study highlight that a higher proportion of patients received 
pharmacotherapy (n = 5,904; 54.3%) followed by combination therapy (n = 4,351; 40.0%) and 
psychotherapy (n = 622; 5.7%). The results of the current study are similar to those found by 
Stein et al. (2012) where a higher proportion of patients received pharmacotherapy compared to 
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combination therapy.80  Conversely, a study by Visser et al. (2015) reported that 25.4% of the 
patients received medication therapy alone, 31.9% received behavior therapy alone, 21.2% 
received combination therapy, and 21.4% received no treatment.142 However, the medication 
only cohort in the Visser et al. study was defined based on data from the past week. In the 
current study, we assessed therapies used over a 1-year timeframe, which may have reduced bias 
associated with short observation periods. Also, Visser et al. included a ‘no treatment’ group 
which would alter the percentages. 
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5.3.3 Objective 3: Time-to-initiation 
Objective 3a: To determine the time to “first pharmacotherapy,” “first psychotherapy,” and 
“first combination therapy” 
Objective 3b: To compare the time to first pharmacotherapy, psychotherapy and combination 
therapy in preschoolers with ADHD and to compare time to pharmacotherapy with 
respect to gender, race/ethnicity, and medication duration of action 
The third objective of the current study was to assess the time-to-initiation of 
pharmacotherapy, psychotherapy, and combination therapy. Results showed that 66.0% of 
preschoolers were initiated on pharmacotherapy (n = 7,184), followed by 32.3% on 
psychotherapy (n = 3,513) and 1.7% on combination therapy (n = 180). The results for average 
time-to-initiation of therapy suggest that preschoolers with ADHD initiated psychotherapy (43.0 
± 89.7 days) relatively early on followed by combination therapy (68.9 ± 92.7 days) and 
pharmacotherapy (107.4± 112.1 days). The median time-to-initiation also revealed a similar 
trend (15.0 vs. 28.0 vs. 67.0 days) in all the treatment groups. This finding is in agreement with 
the recent guidelines, which suggest that a satisfactory trial with psychotherapy should be 
conducted before adding pharmacotherapy.32,53 Also, implementing psychotherapy can reduce 
the need for medication treatment in many preschoolers with ADHD.  
In addition to the aforementioned guidelines, there might be other reasons for not 
prescribing a pharmacologic agent to preschoolers or factors that influence the initiation of 
therapy. First, the preschool population is different from the school-aged population in that 
preschoolers undergo rapid neuronal, emotional, and cognitive developmental changes in a very 
short span of time.106 This phase of high development makes them more vulnerable to 
developmental side effects, which may have long-term consequences. Second, medications in 
preschoolers may show differential therapeutic response and side effect profiles.102,143,144 In 
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addition to a differential therapeutic response, concerns have also been raised about the adverse 
effects associated with use of ADHD medications in preschoolers. Previous studies in 
preschoolers have reported a high rate (30%) of adverse effects associated with ADHD 
medication use including irritability, mood changes, reduced appetite, difficulty falling asleep, 
and a reduction in growth velocity.143,144 These adverse effects were more prominent in the 
preschool population as compared to school-aged children with a similar ADHD profile. Third, 
parents’ preferences for and choice of treatment are also important factors in determining time to 
initiation of therapy. In the PATS study, very few parents opted for the medication treatment arm 
even though the trials with behavioral therapy were not adequate and patients met the strict 
criteria for ADHD diagnosis, which gave the option of treatment with medication.102,143 Lastly, 
most of the ADHD medications are available as tablets/capsules and preschoolers might be 
inexperienced in swallowing pills, thus leading to challenges associated with administration of 
medication. Despite the lack of evidence on prescribing pharmacologic agents to preschoolers, a 
majority of the patients in the current study were initiated on pharmacotherapy. However, 
whether such use is justified still remains a point of contention among experts. Long-term 
population-based studies will help in understanding the outcomes associated with medication use 
in preschoolers with ADHD.  
In accordance with our stated hypothesis, we did not find any difference in the time-to-
pharmacotherapy by gender. Perhaps the differences in pharmacotherapy that have been reported 
in the school-aged population start occurring after the age of 6 years. However, significant 
differences were observed by race/ethnicity which may be related to cultural differences 
regarding perspectives on the condition and its treatment. For instance, previous research has 
shown that Hispanics have delayed acceptance of medication therapies as compared to other 
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race/ethnicities.145,146 Although difference by medication duration of action was significant, it 
was too small to have any meaningful implication.  
5.3.3.2 Predictors of treatment  
Objective 3c: To assess the factors associated with receiving RX, PSY, or RX+PSY, after 
controlling for covariates 
 One of the objectives of the current study was to assess the predictors of treatment 
membership in the overall cohort. With increasing age, patients were less likely to receive 
psychotherapy therapy as compared to pharmacotherapy. In a previous study assessing the 
difference in children receiving behavioral therapy only versus combined treatment for ADHD, 
Pelham et al. (1980) reported that the age of patients receiving combined treatment was higher 
than the age of patients receiving behavioral therapy only.147 Also, as discussed in section 5.3.3, 
an increase in age may have increased prescribers confidence in the safety of medications. In 
addition to the aforementioned explanations, psychotherapy visits impose a significant burden on 
the caregiver and use of medications may help in reducing this burden.133,148,149 Furthermore, 
with increasing age, parents’, teachers’, and children’s performance expectations typically 
increase which may increase the need and intake of medications.150,151  
 The current study found that patients with higher pre-index non-psychiatric visits were 
more likely to undergo psychotherapy as compared to pharmacotherapy. Diagnosis of ADHD 
requires a thorough evaluation of patients’ symptoms. It is even more challenging to determine 
the diagnosis of ADHD in preschoolers who usually have naturally high level of energy, activity, 
and impulsivity.152 This might have resulted in non-psychiatric visits. The presence of pre-index 
non-psychiatric visits may also suggest that parents were visiting healthcare professionals to 
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evaluate and understand the behavioral patterns of their child. This eventually may have led to 
referral and/or diagnosis of ADHD and subsequent initiation of psychotherapy.  
Additionally, patients with other mental health diagnosis were more likely to receive 
psychotherapy as compared to pharmacotherapy. This is similar to the findings published in 
literature.142 In a study assessing the parent-reported prevalence of ADHD treatments among a 
national sample of Children with Special Health Care Needs (CSHCN) dataset, Visser et al. 
(2015) reported that patients with co-occurring conditions were more likely to undergo 
psychotherapy as compared to patients without co-occurring conditions. Additionally, age of the 
patients (Table 4.4) in the psychotherapy group was lower than the age of the patients in the 
pharmacotherapy group. Thus, use of medications in very young preschoolers may not have been 
viewed as the best treatment option by their physician.  
The current study also found that compared to patients not receiving psychotropics, 
patients receiving other psychotropics were more likely to undergo psychotherapy than 
pharmacotherapy. This is contrary to previous research where patients were more likely to 
receive other psychotropic medications if they were being prescribed medications for ADHD. 
However, this observation was based on studies in school-aged children and may not be 
applicable to preschoolers due to concerns about tolerability of medications in this population. 
Thus, patients receiving other psychotropics might actually respond more favorably to 
psychotherapy than to addition of another medication. 
 African American, Hispanic, and other/unknown race/ethnicity groups were more likely 
to receive combination therapy as compared to pharmacotherapy. Previous research shows that 
combination therapy is recommended for patients who are more severe and require intense 
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therapy.153 In addition, patients with other mental disorders were more likely to undergo 
combination therapy than pharmacotherapy as compared to patients without other mental health 
disorders, which is in agreement with previous studies.89,154  
Objective 3d: To compare adherence, persistence, switching, and augmentation of 
pharmacotherapy between the RX and the RX+PSY groups 
5.3.3.3 Medication adherence 
Of the 10,877 preschoolers identified with ADHD, 8,833 patients receiving 
pharmacotherapy were included in the treatment pattern cohort. Of those 8,833 patients, 5,382 
patients were categorized in the pharmacotherapy only group and 3,451 patients were 
categorized in the combination therapy group. Both groups were observed for a 12-month period 
after their index medication claim.  
Overall, medication adherence in the pharmacotherapy and combination therapy groups 
were low. Mean adherence [i.e., proportion of days covered (PDC)] for the entire treatment 
pattern cohort was 0.48 ± 0.30 (i.e., 48%) with a median value of 0.46. Although none of the 
previous studies have estimated medication adherence in a strictly preschooler population, 
adherence estimates of the combined age group (i.e., preschoolers and school-aged children) do 
exist. Adherence estimates of school-aged children varied between 52.0% and 86.1% in a one-
year period.155–158 A study by Barner et al. that (2012) used a cut-off of 80% to measure 
adherence (measured as MPR), reported adherence rates that were similar to the current study. 
Mean adherence (MPR) reported in the study varied between 37.2% (for stimulant users) to 
52.5% (for non-stimulant users).83  
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Unadjusted analysis of the difference in mean medication adherence (i.e., t-test) between 
the pharmacotherapy and combination therapy groups revealed that adherence was higher in the 
combination therapy group as compared to the pharmacotherapy group. The results for 
adherence rate (linear regression) and likelihood of adherence (logistic regression) analysis 
indicate that the difference in adherence between the pharmacotherapy and the combination 
therapy groups were still significant, while controlling for covariates. It is possible that 
differences in patient/parent preferences for prescription drug treatment may explain the results, 
and/or that differences in disease severity might be playing a role. Additionally, it is likely that 
there is a selection effect where by patients who are more severe require a more intensive 
treatment approach including a combination of pharmacotherapy and psychotherapy.159 Thus, 
severe patients may have a greater need to be adherent as compared to patients who might be 
relatively less severe. And patients receiving combination therapy may receive more monitoring 
and encouragement as part of their psychotherapy. Additionally, it is likely that adherence in 
combination therapy was better than in the pharmacotherapy group due to some unobserved 
variables. However, the difference in mean adherence between the pharmacotherapy and 
combination therapy group was too small to have any meaningful clinical implication. 
Covariates that were significantly associated with higher odds of being adherent included 
increasing age and long-acting medication use. Conversely, the covariates significantly 
associated with lower odds of being adherent included female gender, Hispanic, African 
American, and other/unknown race/ethnicity, and stimulant medication user. Previous studies 
have shown that increasing age is one of the main predictors of non-adherence in patients with 
ADHD.157,158 Treatment guideline recommendations regarding medication use in patients > 6 
years of age might have increased prescriber confidence towards medication prescribing as age 
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increased.30,32 The directionality of likelihood of adherence for all other variables is in agreement 
with the existing literature.157,158,160 We could only account for the factors that were available in 
the database. The lack of data for other factors such as adverse events, patient/parent preference, 
and treatment response meant that they could not be accounted for in the model. However, this 
study is based on retrospective observational claims data and no causal inferences can be made. 
5.3.3.4 Medication persistence 
Results showed that the mean persistence was 139.0 ± 127.3 days in the overall treatment 
pattern cohort. Several of the explanations described earlier in Section 5.3.3.2 and 5.3.3.3, also 
apply to the findings from these analyses of persistence. The persistence estimate was within the 
range (95.4 ± 92.6 to 153.3 ± 124.3) reported by Barner et al. using the Texas Medicaid 
dataset.83  In the current study, the mean persistence was lower in the pharmacotherapy group 
(137.1 ± 127.3 days) as compared to the combination therapy group (141.8 ± 127.2 days) which 
is similar to the relationship found for adherence. However, the difference was too small to have 
any meaningful clinical implication. Unadjusted analysis of the difference in mean medication 
persistence (i.e., t-test) between the pharmacotherapy and combination therapy groups showed 
no significant difference. Adjusted analysis, after controlling for covariates, indicated that the 
difference in persistence was still not significant. 
Regarding covariates, female gender, Hispanic, African American, and Other/Unknown 
race/ethnicity, and stimulant medication use were significantly associated with higher hazard 
rates of discontinuation. Conversely, age, rural residence status, and long-acting medication use 
were significantly associated with lower hazard rates of discontinuation. 
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Overall adherence (mean PDC) and persistence in the current study is low and could be 
associated with patient and caregiver/parent-related factors. For instance, adherence in 
preschoolers could be a reflection of parents’/caregivers’ opinions about medication therapy and 
may represent parents’ attitudes towards long-term medication use in preschoolers. Parents may 
be hesitant for their children to receive stimulant medications due to concerns about side effects, 
stigma, and the logistics of administering medications to young children. In addition, Schedule II 
drugs (i.e., methylphenidate and amphetamine) require a new prescription every 30 days which 
could impose a major burden on the caregiver. (In Texas, prescribers can issue multiple 
prescriptions authorizing the patient to receive a total of up to a 90-day supply under certain 
conditions.) 
5.3.3.5 Medication augmentation and switching 
 An examination of the augmentation patterns in the treatment pattern cohort revealed 
medication augmentation in 10.5% of the patients during the study period. In a comparison study 
of commercially insured and Medicaid children ≥ 6 years of age, Molife et al. (2012) 
demonstrated that combination therapy (> 1 ADHD medication class in the same month) was 
used in 10.3% and 24.0% of the commercially and Medicaid insured groups, respectively.161 In 
another study conducted using a large national US health plan, Hodgkins et al. (2012) reported 
an augmentation rate of 8.3%. The augmentation rates were highest for mixed amphetamine 
salts-extended release (11.4%), followed by lisdexamfetamine dimesylate (8.9%), and osmotic-
release oral system methylphenidate (6.0%).162 The estimates in the current study (10.5%) are 
similar to the augmentation rates among school-aged children for the commercial population, but 
lower than the augmentation rates in the Medicaid population as reported by Molife et al. (2012). 
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The augmentation rate observed in the current study is somewhat surprising, considering the 
reservations that exist regarding prescribing medications to preschoolers. However, 
approximately one-third of the preschoolers identified in the current study were also diagnosed 
with comorbid mental health conditions which might be an indication of higher severity and may 
have played a role in the augmentation trends observed.   
Examination of the switching patterns in the treatment pattern cohort revealed that 31.8% 
of the patients switched from their index medication. The rate of switching in our study is similar 
to that found by Lawson et al. (26.9% to 27.8%) and Winterstien et al. (23.9% to 26.8%) 
conducted using the Texas Medicaid and Florida Medicaid datasets, respectively.84,163 The 
results of the current study were not surprising since preschoolers might require more frequent 
dose adjustments or even medication class changes. Switching is usually influenced by drug 
effectiveness, differences and similarities in duration of use, and side-effects. Perhaps in the 
preschool population these effects might be monitored more closely and may be associated with 
switching in cases where potential benefits were judged to outweigh potential risks.  
A multivariate analysis of augmenters and switchers revealed that patients in the 
pharmacotherapy group were less likely to augment or switch as compared to the combination 
therapy group. As discussed earlier, combination therapy users might be more severe and may 
have more frequent opportunities for dose/treatment monitoring. In the case of severe patients, 
sub-optimal response to drug therapy may have encouraged the physician to add another 
medication or to switch to an alternate medication. Also, regular psychotherapy visits along with 
pharmacotherapy visits may allow for closer monitoring of medication use and more frequent 
opportunities for therapy augmentation. 
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5.3.4 Objective 4: Healthcare utilization  
Objective 4a: To determine and compare the healthcare utilization frequencies for all-cause 
office-based, inpatient, outpatient hospital, ED visits, and prescriptions between 
the RX and the RX+PSY groups 
Objective 4b: To determine and compare the healthcare utilization frequencies for ADHD-
related office-based, inpatient, outpatient hospital, ED visits, and prescriptions 
between the RX and RX+PSY groups 
Objective 4c: To determine and compare the healthcare utilization frequencies for other mental 
health-related office-based, inpatient, outpatient hospital, ED visits, and 
prescriptions between the RX and RX+PSY groups 
Texas Medicaid covers nearly 50% of the pediatric population in Texas, which means 
that pediatric expenditures constitute a considerable proportion of Medicaid spending.141 We 
explored the healthcare utilization for preschoolers with ADHD and compared the 
pharmacotherapy and combination therapy groups, to provide estimates of the relative healthcare 
resource utilization burden for the two treatment groups in the state Medicaid program. 
Our findings indicated that preschoolers with ADHD receiving combination therapy had 
significantly higher healthcare utilization compared to preschoolers receiving pharmacotherapy. 
It is likely that the additional psychotherapy component in the combination therapy group 
increased the healthcare utilization in the combination therapy group as compared to medication 
therapy alone. This trend was also reflected in the treatment pattern results (sections 5.3.2.2, 
5.3.2.3, and 5.3.3.4) where the combination therapy group showed better adherence and 
persistence. Consequently, more visits may have allowed for closer treatment monitoring thus, 
leading to increased augmentation and switching in the combination therapy cohort where the 
response might be suboptimal or a more intensive treatment was needed.   
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While utilization patterns for all service use categories (i.e., office-based, outpatient 
hospital, inpatient, emergency department visits, and prescriptions) were different for the 
treatment groups, it is important to note that the utilization was higher in the combination therapy 
group as compared to the pharmacotherapy group in all the categories except for ADHD-related 
prescriptions, other mental health-related office and inpatient visits. Few studies have been 
conducted comparing healthcare utilization in preschoolers with respect to type of therapy (i.e., 
RX, PSY, and RX+PSY).  
In addition to the medical visit resource use categories, all-cause and other mental health-
related prescriptions use were also higher in the combination therapy group. Previous research 
has shown that children with ADHD are more prone to other acute and chronic conditions such 
as asthma, injuries, infections, and mental health comorbidities which may be associated with 
increased healthcare utilization including prescription medications for the treatment of those 
conditions.164–167  
In summary, although the age of the patients in the current study is different from 
reported studies conducted in school-aged children, some of the practice trends may remain 
consistent irrespective of the age group being treated. Additionally, the psychotherapy 




5.3.5 Objective 5: Healthcare costs 
Objective 5a: To determine and compare the all-cause medical (office-based, inpatient, 
outpatient hospital, and ED), prescription, and total costs between the RX and 
RX+PSY groups 
Objective 5b: To determine and compare the ADHD-related medical (office-based, inpatient, 
outpatient hospital, and ED), prescription, and total costs between the RX and 
RX+PSY groups 
Objective 5c: To determine and compare the other mental health-related medical (office-based, 
inpatient, outpatient hospital, and ED), prescription, and total costs between the 
RX and RX+PSY groups 
For objective 5, we explored the healthcare costs for preschoolers with ADHD and 
compared the pharmacotherapy and combination therapy groups to provide estimates of the 
relative economic burden. Healthcare costs were estimated for patients based on the overall 
cohort. Patients in the combination therapy group had higher medical, prescription, and total 
healthcare costs in all the three categories (i.e., ADHD-related, all-cause, and other mental 
health-related). Differences were highest in the all-cause categories, followed by ADHD-related 
and other mental health-related categories. Interestingly, prescription medication costs in the 
ADHD-related category were higher than the ADHD-related medical costs. The prescription 
costs in all other categories (i.e., all-cause and other mental healthcare-related) were lower than 
the medical costs.  
A limited number of studies have been conducted comparing the cost estimates between 
pharmacotherapy and combination therapy groups. Vanoverbeke et al. (2003), estimating costs 
for methylphenidate-IR, methylphenidate-ER, and behavioral therapy over a one-year time 
period, reported that psychotherapy was the most expensive alternative with a cost estimate of 




groups.168 Leinwand et al. (2011) modelled costs of medication and combination therapy with 
respect to gender and comorbidities.169 The authors reported higher costs for combination 
therapy users as compared to medication therapy users for both males and females. Medication 
costs ranged from $832 to $839 whereas costs for the combination therapy group ranged from 
$6,703 to $6,742. Results of these two studies showing that the cost estimate for the 
psychotherapy group was highest are consistent with the findings of the current study showing 
that costs for the combination therapy group (which includes psychotherapy) were higher than 
those for the pharmacotherapy group.  
In a cost-effectiveness analysis comparing methylphenidate (instant release), 
dextroamphetamine, behavioral therapy, combination, and no treatment costs, Zupancic et al. 
(1999) estimated the total cost for the combination therapy group to be $2,510 (based on 2001 
dollars) as compared to $559 with methylphenidate alone.170,171 The cost estimates for 
combination therapy and pharmacotherapy followed a similar trend in the current study with 
higher costs in the combination therapy group as compared to pharmacotherapy group.  
According to the information provided by the American Academy of Pediatrics (2015), 
the average cost of each Medicaid-eligible child in Texas is estimated at $3,045 per year.141 As 
evident from the results of the current study, the medical and total all-cause costs for 
preschoolers with ADHD were higher than the average cost for each Medicaid-eligible child. 
The findings of this study could help identify high spending categories (i.e., medical and/or 
prescription) that could lead to potential cost savings and delivery of more efficient care. Thus, 






The results of this study should be viewed in light of a few limitations. First limitation is 
the use of administrative claims data in identifying ADHD in preschoolers. It is possible that 
some ADHD cases were misclassified either due to misdiagnosis, miscoding, or inaccuracies 
introduced through the inclusion criteria. It is reported that children often present with symptoms 
and risk profile of multiple mental health conditions, which makes it difficult to accurately 
establish an ADHD diagnosis. If children were falsely classified, we cannot reclassify them 
correctly without a chart review or clinical data to confirm the diagnosis. Nevertheless, more 
preschoolers are possibly being diagnosed with ADHD because of the increased attention on 
ADHD in the scientific and lay literature in recent times, which may have an influence on 
diagnosis rate. Similarly, increased awareness of ADHD among clinicians, counselors, parents, 
and other caregivers could have resulted in the diagnosis of formerly undiagnosed pediatric 
patients with the condition, which may explain the high prevalence in the current study.  
A second limitation of the study is that incidence rate may not be representative of new 
cases if diagnoses existed prior to enrollment in Texas Medicaid. Similarly, prevalence rates may 
not be accurate if patients sought care outside of the Medicaid program.172 In addition, the 
incidence and prevalence estimates are based on enrollment estimates provided by Texas 
Medicaid for limited years. These enrollment estimates may have contributed to inaccurate 
prevalence and incidence estimates. 
A third limitation is that the current study only evaluated preschoolers receiving 
treatment for ADHD. It does not include patients who did not receive therapy for ADHD. 




diagnosis of ADHD. This may have underestimated the prevalence, incidence, utilization, and 
costs of the patients. 
A fourth limitation of the study is the small sample size in the psychotherapy group. 
Although these results cannot be extrapolated to the entire preschool population, they provide an 
estimate of spending on preschoolers in Texas Medicaid associated with an ADHD diagnosis.  
Fifth, we could only control for factors that were available in the dataset. Other patient 
characteristics such as education, level of understanding or clinical factors including side-effects 
and adverse events, and physician specialty were not available and thus, could not be controlled 
for in the study. These variables, if present, may provide more insight into the nature of the 
condition in preschoolers.  
Sixth, classification of combination therapy initiators based on having claims for an 
ADHD medication and psychotherapy on the same day may be too restrictive as there might be 




5.4 Conclusions, implications, and future directions 
The prevalence rate of ADHD in preschoolers increased steadily from 2008 to 2012. In 
contrast, the incidence rates were stable for those years. Most of the patients received medication 
therapy followed by combination therapy, and psychotherapy. A comparison of treatments 
revealed that the combination therapy group had a higher healthcare burden (i.e., utilization and 
cost) as compared to the pharmacotherapy group. 
Early treatment intervention during the preschool years may help in reducing the overall 
disease burden. Previous research has shown that patients diagnosed with ADHD early-on may 
have long-term behavioral manifestations. Therefore, the use of combination therapy may 
provide a better management alternative leading to better adherence and persistence with the 
ultimate goal of achieving symptom control and improving daily functioning.173 Additionally, 
the current study also shows that adherence in the Texas Medicaid preschool population is low. 
Further discussion of the desirability of adherence and persistence in the preschool population is 
warranted. Also, future studies could be conducted to identify factors and clinical outcomes 
associated with poor adherence and persistence. The current study also identifies utilization and 
cost categories that could be targeted to avoid the additional long-term healthcare cost to the 
payers such as Medicaid and society at large.  
Additionally, this study has important implications for Texas Medicaid. Stimulant 
medications are among the highest medication expenditure categories for Texas Medicaid. 
Identification and early treatment may avert some of the costs that would be incurred by Texas 
Medicaid if these patients remain untreated. Considering that Texas Medicaid covers 46.3% of 




burden on the healthcare system.141 Economic burden information provided in the current study 
could be useful to Medicaid as decision makers identify and consider cost-effective strategies. 
Findings from the current study add to the limited available research regarding ADHD in 
preschoolers; however, future studies could be conducted to add more information regarding 
treatment in preschoolers. Since this study was conducted using the Texas Medicaid dataset, 
future studies could utilize other data sources to validate the findings and add new information. 
These results would be valuable for stakeholders including, insurance companies, providers, and 
patients to understand the long-term impact of early treatment in preschoolers.  
One of the interesting observations was the cut-off period for adherence and the 
definitions for persistence and adherence. Since preschoolers are vulnerable to ill effects of 
medications, parents often take their children off medications for a certain period. 
Methodological studies could be conducted to determine the impact of drug holidays on the 
outcomes. In this study, we found that even though time-to-initiation of psychotherapy was 
lower, a majority of the patients were represented in the pharmacotherapy only group. 
Longitudinal studies could determine if this pattern of treatment continues or if there is a shift 
from one treatment alternative to another over a period of time.  
In order to get a more in-depth understanding of treatment patterns in preschoolers, a 
thorough evaluation of switching and augmentation by each medication class and duration of 
action could be conducted. This additional information might help tailor medication therapy 
according to the requirements of each patient for a more personalized approach.  
The current study evaluated only patients who received treatment for ADHD. Instead of 




Special Health Care Needs (CSHCN) to include a no-treatment arm so as to provide a more 
holistic evaluation of the treatment and non-treatment trends in preschoolers with ADHD. In 
addition, it is evident from the current research that there are various interactions that could be 
evaluated (e.g., interaction of age and comorbidity). Future research could explore this aspect in 












Types of medications used for the management of Attention Deficit Hyperactivity Disorder in 
patients 
Drug Action Generic Names Brand Names 
Methylphenidates 
Short Acting 
SA Methylphenidate Ritalin, Methylin 
SA Dexmethylphenidate Focalin 
Long Acting 
LA Methylphenidate 
Ritalin LA, Ritalin SR, 
Metadate CD, Metadate 
ER, Methylin ER, 
Daytrana, Concerta 
LA Dexmethylphenidate Focalin XR 
Amphetamines 
Short Acting 
SA Dextroamphetamine Dexedrine, Dextrostat, 
Procentra 
SA Dextroamphetamine 




and Amphetamine Salts 
Adderall XR 
Lisdexamphetamine Vyvanse 
Non-Stimulants Long Acting 
LA Guanfacine Intuniv 
















List of current procedural terminology (CPT) codes used to identify psychotherapy in patients 
with ADHD  
CPT codes Description 
1050X Individual counseling services by LMSW-ACPs and LPCs, per hour 
1052X Family counseling services by LMSW-ACPs and LPCs, per hour 
90805 Individual psychotherapy with E/M, 20-30 min 
90847 Family psychotherapy with patient present 
90806 45-50 minute psychotherapy 
90804 Individual psychotherapy 20-30 min (changed after 2012) 
90837 Individual psychotherapy 53+ minutes (implemented in 2013) (prior to 2013 it 
was coded as 90808  & 90821) 
97150 Group therapy services 
90807 Individual psychotherapy 45-50 min (changed after 2012) 
1152X Family counseling services by LMFT, per hour 
90833 Psychotherapy 30 (16-37*) min (used after 2012) 
90808 Individual psychotherapy (75-80 min) 
1150X Individual counseling services by LMSW-ACP and LPCs, per hour 
90832 Psychotherapy 30 (16-37*) min (used after 2012) 
90834 Psychotherapy 45 (38-52*) min 
90811 Interactive individual psychotherapy with E/M 20-30 min 
90836 Psychotherapy patient&/family with E/M services 45 min 
90812 Interactive individual psychotherapy (45-50 min) 
90853 Group psychotherapy 
1051X Group counseling services by LMSW-ACPs and LPCs, per hour 
90810 Interactive individual psychotherapy 20-30 min 
90817 Individual psychotherapy 20-30 min (changed after 2012) 
90809 Individual psychotherapy with E/M 20-30 min 
90815 Interactive individual psychotherapy with E/M (75-80 min) 
90838 Psychotherapy patient and/family w/E&M services 60 min 
90816 Individual psychotherapy 20-30 min (changed after 2012) 
90818 Individual psychotherapy 45-50 min (changed after 2012) 
90814 Interactive individual psychotherapy (75-80 min) 
90819 Individual psychotherapy 45-50 min (changed after 2012) 







Schoenfeld Residual plots testing the proportional hazards assumption in the Cox proportional 


















Sensitivity analysis for persistence – 60-day gap  
Cox-proportional hazards regression. Determinants of persistence (60-day gap) between 
combination therapy and pharmacotherapy groups in preschoolers diagnosed with ADHD 
Characteristics HR 95% CI  x2 p-value 
Pharmacotherapy  1.041 0.994 – 1.090 2.9 0.09 
Covariates 
Agea 0.921 0.896 – 0.947 34.2 <.0001 
Pre-index psychiatric visitsa 0.999 0.995 – 1.002 0.7 0.40 
Pre-index non-psychiatric visitsa  1.003 0.999 – 1.008 2.1 0.15 
Total pre-index costsa 1.000 1.000 – 1.000 0.7 0.42 
Femaleb 1.087 1.033 – 1.143 10.5 <0.01 
African Americansb  1.269 1.178 – 1.367 39.3 <.0001 
Hispanicsb 1.247 1.171 – 1.329 47.2 <.0001 
Others/Unknownb  1.177 1.080 – 1.282 13.8 <0.01 
Ruralb 0.953 0.903 – 1.006 3.1 0.08 
Other psychotropicsb 1.001 0.932 – 1.075 0.0 0.98 
Other mental health diagnosisb 0.973 0.924 – 1.024 1.1 0.29 
Long-acting medicationsb 0.912 0.856 – 0.971 8.1 <0.01 
Stimulantsb 1.125 1.013 – 1.249 4.8 0.03 
*p < 0.05 (in bold); HR = Hazard Ratio; CI = Confidence Interval; x2= Chi-square; 
a Recorded as a continuous variable in the model;  
b Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other 
mental health diagnosis, no long-acting medication use, no short-acting medication use, and non-stimulant use; 














Sensitivity analysis for persistence – 90-day gap  
Cox-proportional hazards regression. Determinants of persistence (90-day gap) between 
combination therapy and pharmacotherapy groups in preschoolers diagnosed with ADHD 
Parameter HR 95% CI  x2 p-value* 
Pharmacotherapy  1.030 0.984 – 1.079 1.6 0.21 
Covariates 
Agea 0.918 0.893 – 0.944 37.2 <.0001 
Pre-index psychiatric visitsa 0.998 0.995 – 1.001 1.7 0.19 
Pre-index non-psychiatric 
visitsa  
1.002 0.997 – 1.007 0.6 0.43 
Total pre-index costsa 1.000 1.000 – 1.000 1.4 0.23 
Femaleb 1.070 1.017 – 1.125 7.0 0.01 
African Americansb  1.183 1.098 – 1.274 19.6 <.0001 
Hispanicsb 1.205 1.131 – 1.283 33.4 <.0001 
Others/Unknownb  1.139 1.045 – 1.241 8.8 <.01 
Ruralb 0.944 0.894 – 0.996 4.4 0.04 
Other psychotropicsb 0.992 0.924 – 1.066 0.0 0.83 
Other mental health diagnosisb 0.970 0.921 – 1.021 1.4 0.24 
Long-acting medicationsb 0.961 0.902 – 1.024 1.5 0.22 
Stimulantsb 1.105 0.995 – 1.228 3.5 0.06 
*p < 0.05 (in bold); HR = Hazard Ratio; CI = Confidence Interval; x2= Chi-square; 
a Recorded as a continuous variable in the model;  
b Reference categories: combination therapy group, males, whites, urban residents, no psychotropic use, no other 
mental health diagnosis, no long-acting medication use, no short-acting medication use, and non-stimulant use; 










Distribution coefficients for ADHD-related, all-cause, and other mental health-related visits 
Categories Coefficient p-value* 
All-cause 
Office-based visits 1.44 <0.0001 
Inpatient visits 1.26 0.09 
Outpatient hospital visits 1.80 <0.0001 
ER visits 1.26 0.01 
ADHD-related 
Office-based visits 1.30 0.20 
Inpatient visits 1.27 0.44 
Outpatient hospital visits 1.73 0.02 
ER visits 1.89 0.09 
Other mental health related 
Office-based visits 1.51 <0.0001 
Inpatient visits 6.37 0.11 
Outpatient hospital visits 1.72 <0.0001 
ER visits 0.99 1.00 







































Vuong test to identify the best model for ADHD-related, all-cause, and other mental health-related healthcare utilization outcomes 
 
All-cause office ADHD-related office Other mental health-related office 
Vuong Statistic Z Pr>|Z| Model Z Pr>|Z| Model Z Pr>|Z| Model 
Unadjusted 12.20 <.0001 zip 12.20 <.0001 zip 19.62 <.0001 zip 
Akaike Adjusted 12.20 <.0001 zip 12.20 <.0001 zip 19.62 <.0001 zip 
Schwarz Adjusted 12.17 <.0001 zip 12.17 <.0001 zip 19.61 <.0001 zip 
All-cause inpatient ADHD-related inpatient 
Other mental health-related 
inpatient 
Vuong Statistic Z Pr>|Z| Model Z Pr>|Z| Model Z Pr>|Z| Model 
Unadjusted 16.80 <.0001 zip 16.80 <.0001 zip 15.72 <.0001 zip 
Akaike Adjusted 16.80 <.0001 zip 16.80 <.0001 zip 15.72 <.0001 zip 
Schwarz Adjusted 16.78 <.0001 zip 16.78 <.0001 zip 15.73 <.0001 zip 
All-cause outpatient hospital ADHD-related outpatient hospital 
Other mental health-related 
outpatient hospital 
Vuong Statistic Z Pr>|Z| Model Z Pr>|Z| Model Z Pr>|Z| Model 
Unadjusted 29.77 <.0001 zip 29.77 <.0001 zip 29.33 <.0001 zip 
Akaike Adjusted 29.76 <.0001 zip 29.76 <.0001 zip 29.33 <.0001 zip 
Schwarz Adjusted 29.76 <.0001 zip 29.76 <.0001 zip 29.33 <.0001 zip 
All-cause ER ADHD-related ERa Other mental health-related ERa 
Vuong Statistic Z Pr>|Z| Model       
Unadjusted 8.97 <.0001 zip       
Akaike Adjusted 8.94 <.0001 zip       
Schwarz Adjusted 8.84 <.0001 zip       
All-cause prescriptions ADHD-related prescriptions 
Other mental health-related 
prescriptions 
Vuong Statistic Z Pr>|Z| Model Z Pr>|Z| Model Z Pr>|Z| Model 
Unadjusted -0.03 0.98 poi -0.01 1.00 poi 40.14 <.0001 zip 
Akaike Adjusted -29560.20 <.0001 poi -80038.00 <.0001 poi 40.13 <.0001 zip 
Schwarz Adjusted -136502.00 <.0001 poi -369595.00 <.0001 poi 40.12 <.0001 zip 
ZIP = Zero-inflated Poisson regression; poi = Poisson regression; ED = Emergency Department; ADHD= Attention Deficit Hyperactivity Disorder; 







Distribution coefficients for ADHD-related, all-cause, and other mental health-related costs 
 Coefficient p-value 
All-cause 
Medical costs  1.67 <0.0001 
Prescription costs 2.37 0.47 
Total costs 1.97 0.72 
ADHD-related 
Medical costs  -0.41 <0.0001 
Prescription costs 0.66 <0.0001 
Total costs 0.60 0.57 
Other mental health-related 
Medical costs  1.76 <0.0001 
Prescription costs 1.55 <0.0001 
Total costs 1.81 <0.0001 
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